ES2569665T3 - Derivados de imidazol condensados útiles como inhibidores de IDO - Google Patents

Derivados de imidazol condensados útiles como inhibidores de IDO Download PDF

Info

Publication number
ES2569665T3
ES2569665T3 ES12715295.7T ES12715295T ES2569665T3 ES 2569665 T3 ES2569665 T3 ES 2569665T3 ES 12715295 T ES12715295 T ES 12715295T ES 2569665 T3 ES2569665 T3 ES 2569665T3
Authority
ES
Spain
Prior art keywords
imidazo
isoindole
ethanol
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12715295.7T
Other languages
English (en)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
NewLink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewLink Genetics Corp filed Critical NewLink Genetics Corp
Application granted granted Critical
Publication of ES2569665T3 publication Critical patent/ES2569665T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de la fórmula,**Fórmula** o sal del mismo farmacéuticamente aceptable, en donde el enlace ∞ es un enlace doble o sencillo; n es 0, 1, 2, 3, o 4; cada R1 es independientemente halógeno, ciano, nitro, alquilo C1-6, haloalquilo C1-6, -OR, -N(R)2, -SR, -C(O)OR, - C(O)N(R)2, -C(O)R, -S(O)R, -S(O)OR, -S(O)N(R)2, -S(O)2R, -S(O)2OR, -S(O)2N(R)2, -OC(O)R, -OC(O)OR, - OC(O)N(R)2, -N(R)C(O)R, -N(R)C(O)OR, o -N(R)C(O)N(R)2; R2 es -alquilo C1-4-RA o -alquenilo C2-4-R3 cuando el enlace α es un enlace sencillo; y R2 es >=C(H)RA cuando el enlace α es un enlace doble; en donde RA es -CN, -C(O)R3, -C(O)OR3, -C(O)N(R3)(RC), -C(ORB)(R3)(RC), -C(NHRB)(R3)(RC), o -C(>=N-ORC)R3, en donde RB es hidrógeno, alquilo C1-6, haloalquilo C1-6, -alquilo C1-6-RB1, -C(O)R3, -C(O)N(H)R3, o -S(O)2R3, -C(O)(CH2)1- 4COOR, -C(O)(CH2)1-4(NR)COOR, -C(O)CH(NH2)(RD), -S(O)2OR3, -S(O)2N(R3)2, -CH2-OP(O)2(OR)2, o -P(O)(OR3)2, en donde RB1 es ciano, nitro, alquilo C1-6, haloalquilo C1-6, -OR, -N(R)2, -SR, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)R, -S(O)OR, -S(O)N(R)2, -S(O)2R, -S(O)2OR, -S(O)2N(R)2, -OC(O)R, -OC(O)OR, -OC(O)N(R)2, -N(R)C(O)R, -N(R)C(O)OR, o - N(R)C(O)N(R)2; RD es hidrógeno, metilo, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)(CH2CH3), bencilo, 4-hidroxibencilo, -CH2(3- indolil), - CH2SH, -CH2CH2SCH3, -CH2OH, -CH(CH3)OH, -(CH2)4-NH2, -(CH2)3-N(H)C(>=NH)NH2, -CH2(4-imidazolil), - CH2COOH, -CH2CH2COOH, -CH2CONH2, -CH2CH2CONH2; cada R3 es independientemente hidrógeno, alquilo C1-6, haloalquilo C1-6, arilo, heteroarilo, cicloalquilo C3-8, cicloalquenilo C3-8, heterociclilo de 3-10 miembros, arilalquilo C1-6-, heteroarilalquilo C1-6-, cicloalquilo C3-8-alquilo C1- 6-, cicloalquenilo C3-8 alquilo C1-6-, (heterociclilo de 3-10 miembros)alquilo C1-6-, o (heteroarilo)-(heterociclilo de 3-10 miembros)-, en donde el alquilo, cicloalquilo C3-8, cicloalquenilo C3-8, heterociclilo de 3-10 miembros, cicloalquilo C3-8 alquilo C1-6-, cicloalquenilo C3-8 alquilo C1-6-, (heterociclilo de 3-10 miembros)alquilo C1-6-, y (heteroarilo)-(heterociclilo de 3-10 miembros)-, son cada uno opcional e independientemente sustituidos por un grupo >=R32 y cada uno opcional e independientemente sustituidos por uno, dos, tres, o cuatro grupos R31; los grupos arilo, heteroarilo, arilalquilo C1-6-, y heteroarilalquilo C1-6-, son cada uno opcionalmente sustituido por uno, dos, tres, o cuatro grupos R31; en donde cada R31 es independientemente halógeno, ciano, nitro, alquilo C1-6, -alquilo C1-6-R33, haloalquilo C1-6, -OR, -N(R)2, - SR, -C(O)OR, -C(O)N(R)2, -C(O)N(OH)R, -C(O)R, -C(NR11)R, -C(NR11)N(R11)R, -S(O)R, -S(O)OR, -S(O)N(R)2, - S(O)2R, -S(O)2OR, -S(O)2N(R)2, -OC(O)R, -OC(O)OR, -OC(O)N(R)2, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)N(R)2, en donde R33 es ciano, -OR, -N(R)2, -SR, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)R, -S(O)OR, -S(O)N(R)2, -S(O)2R, -S(O)2OR, -S(O)2N(R)2, -OC(O)R, -OC(O)OR, -OC(O)N(R)2, -N(R)C(O)R, -N(R)C(O)OR, o -N(R)C(O)N(R)2; R32 es >=O, >=S, >=N(R), >=N(OR), >=C(R34)2, >=(espiro-cicloalquilo C3-8), o >=(espiro-(heterociclilo de 3-10 miembros)), en donde cada R34 es independientemente hidrógeno, halógeno, ciano, alquilo C1-6, - alquilo C1-6-OR, haloalquilo C1-6, cicloalquilo C3-8, o heterociclilo de 3-10 miembros; o ambos R34 tomados junto con el átomo al que están unidos forman un cicloalquilo C3-8 monocíclico o heterociclilo monocíclico de 3-8 miembros; RC es hidrógeno o alquilo C1-6; y cada R es independientemente hidrógeno o R10, en donde R10 es alquilo C1-6, haloalquilo C1-6, arilo, heteroarilo, cicloalquilo C3-8, cicloalquenilo C3-8, heterociclilo de 3-10 miembros, arilalquilo C1-6, heteroarilalquilo C1-6-, cicloalquilo C3-8 alquilo C1-6-, cicloalquenilo C3-8 alquilo C1-6-, o (heterociclilo de 3-10 miembros) alquilo C1-6-, cada R10 opcionalmente sustituido por uno, dos, tres, o cuatro grupos que son cada uno independientemente halógeno, ciano, nitro, alquilo C1-6, haloalquilo C1-6, -OR11, -N(R11)2, -SR11, - C(O)OR11, -C(O)N(R11)2, -C(O)R11, -S(O)R11, -S(O)OR11, -S(O)N(R11)2, -S(O)2R11, -S(O)2OR11, -S(O)2N(R11)2, - OC(O)R11, -OC(O)OR11, -OC(O)N(R11)2, -N(R11)C(O)R11, -N(R11)C(O)OR11, -N(R11)C(O)N(R11)2, -N(R11)S(O)2R11, o - C(O)-(heterociclilo de 3-10 miembros), en donde cada R11 es independientemente hidrógeno o alquilo C1-6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
5
10
15
20
25
30
en donde
cada R31 es independientemente halógeno, ciano, nitro, alquilo C1–6, –alquilo C1–6–R33, haloalquilo C1–6, –OR, –N(R)2, – SR, –C(O)OR, –C(O)N(R)2, –C(O)R, –S(O)R, –S(O)OR, –S(O)N(R)2, –S(O)2R, –S(O)2OR, –S(O)2N(R)2, –OC(O)R, – OC(O)OR, –OC(O)N(R)2, –N(R)C(O)R, –N(R)C(O)OR, –N(R)C(O)N(R)2, en donde R33 es –OR, –N(R)2, o –SR;
y
R32 es oxo, =C(R34)2, =(espiro–cicloalquilo C3–8), o =(espiro–(heterociclilo de 3–10 miembros)), en donde cada R34 es independientemente hidrógeno, halógeno, alquilo C1–6, o cicloalquilo C3–8.
(6u) R3 es arilo, heteroarilo, cicloalquilo C3–8, cicloalquenilo C3–8, o heterociclilo de 3–10 miembros, en donde el cicloalquilo C3–8, cicloalquenilo C3–8, y heterociclilo de 3–10 miembros son cada uno opcionalmente sustituido por un grupo =R32 y uno, dos, tres, o cuatro grupos R31; y
el arilo y heteroarilo son cada uno opcionalmente sustituido por uno, dos, tres, o cuatro grupos R31.
(6v) R3 es fenilo, ciclopentilo, ciclohexilo, ciclohexenilo, furanilo, tetrahidropiranilo, piperidinilo, imidazolilo, tiazolilo, cada uno opcionalmente sustituido por uno, dos, tres, o cuatro grupos R31, y en donde los grupos ciclopentilo, ciclohexilo, ciclohexenilo, y piperidinilo son cada uno opcionalmente sustituido por un grupo =R32.
(6w) R3 es fenilo, ciclopentilo, ciclohexilo, ciclohex–1–en–1–ilo, ciclohex–3–en–1–ilo, furan–2–ilo, furan–3–ilo, tetrahidropiran– 3–ilo, tetrahidropiran–4–ilo, piperidin–3–ilo, piperidin–4–ilo, imidazol–2–ilo, imidazol–4–ilo, tiazol–2–ilo, tiazol–4–ilo, tiazol–5–ilo, cada uno opcionalmente sustituido por uno o dos grupos R31, y en donde los grupos ciclopentilo, ciclohexilo, ciclohexenilo, y piperidinilo son cada uno opcionalmente sustituido por un grupo =R32.
(6x) Uno cualquiera de los grupos (6a) – (6w), en donde cada R es independientemente hidrógeno, alquilo C1–6, haloalquilo C1–6, arilo, heteroarilo, cicloalquilo C3–8, cicloalquenilo C3–8, heterociclilo de 3–10 miembros, arilalquilo C1–6, heteroarilalquilo C1–6–, cicloalquilo C3–8– alquilo C1–6–, cicloalquenilo C3–8–alquilo C1–6–, o (heterociclilo de 3–10 miembros)alquilo C1–6–.
(6y) Uno cualquiera de los grupos (6a) – (6w), en donde cada R es independientemente hidrógeno, alquilo C1–6, haloalquilo C1–6, fenilo, heteroarilo de 5– o 6–miembros, cicloalquilo C3–8, cicloalquenilo C3–8, heterociclilo de 3–8 miembros, bencilo, (heteroarilo de 5– o 6–miembros)alquilo C1–6–, cicloalquilo C3–8 alquilo C1–6–, cicloalquenilo C3–8– alquilo C1–6–, o (heterociclilo de 3–6 miembros)alquilo C1–6–.
(6z) Uno cualquiera de los grupos (6a) – (6w), en donde cada R es independientemente hidrógeno o alquilo C1–6.
Las realizaciones particulares de este aspecto de la invención incluyen compuestos de una cualquiera de las fórmulas (I), (I'), y (Ia) – (Id), cada uno como se define en cada una de las siguientes filas, en donde cada entrada es un número de grupo como se definió anteriormente (por ejemplo, (1s) se refiere a n es 1 y cada R1 es halógeno), y un guion "–" indica que la variable es como se define para la fórmula (I) o (I’) o definido de acuerdo con una cualquiera de las definiciones de las variables pertinentes (1a) – (6z) [por ejemplo, cuando RC es un guion, que puede ser ya sea tal como se define para la Fórmula (I) o (I’) o una cualquiera de las definiciones (5a)–(5 g)]:
imagen11
imagen12
imagen13
imagen14
imagen15
En otro aspecto, la invención provee el compuesto de acuerdo con fórmula (II),
imagen16
o sal del mismo farmacéuticamente aceptable, en donde
5 n es 0 o 1;
cada R1 es independientemente halógeno, –OR, –N(R)2, o –SR;
cada R3 es independientemente hidrógeno, alquilo C1–6, arilo, heteroarilo, cicloalquilo C3–8, cicloalquenilo C3–8,
heterociclilo de 3–10 miembros, o cicloalquilo C3–8–alquilo C1–6–, en donde el alquilo C1–6, cicloalquilo C3–8, cicloalquenilo C3–8, heterociclilo de 3–10 miembros, y cicloalquilo C3–8–alquilo C1–6–, son cada uno opcional e independientemente 10 sustituidos por un grupo =R32 y cada uno opcional e independientemente sustituido por uno o dos grupos R31; los grupos arilo y heteroarilo, son cada uno opcionalmente sustituido por uno o dos grupos R31; en donde
imagen17
5
10
15
20
25
30
imagen18
(IIe): en donde la configuración estereoisomérica de carbono–1 (C–1) y carbono–3 (C–3) de fórmula (II) son respectivamente (R, R). (IIf): en donde la configuración estereoisomérica de carbono–1 y carbono–3 de fórmula (II) son respectivamente (R, S). (IIg): en donde la configuración estereoisomérica de carbono–1 y carbono–3 de fórmula (II) son respectivamente (S, R). (IIh): en donde la configuración estereoisomérica de carbono–1 y carbono–3 de fórmula (II) son respectivamente (S, S).
n y R1 se seleccionan de uno de los siguientes grupos (7a) – (7i): (7a) n es 0 o 1 y R1 es halógeno, –OR0, –N(R0)2, o –SR0; en donde cada R0 es independientemente hidrógeno o alquilo C1–6.
(7b) n es 0 o 1 y R1 es fluoro, cloro, hidroxi, o metoxi. (7c) n es 0 o 1 y R1 es halógeno. (7d) n es 0 o 1 y R1 es fluoro ocloro. (7e) n es 1 y R1 es halógeno, –OR0, –N(R0)2, o –SR0; en donde cada R0 es independientemente hidrógeno o alquilo C1–
6. (7f) n es 1 y R1 es fluoro, cloro, hidroxi, o metoxi. (7g) n es 1 y R1 es halógeno. (7h) n es 1 y R1 es fluoro o cloro. (7i) n es 0. RC se selecciona de uno de los siguientes grupos (8a) – (8g): (8a) RC es hidrógeno o alquilo C1–4. (8b) RC es hidrógeno o alquilo C1–2 . (8c) RC es hidrógeno o metilo. (8d) RC es hidrógeno. (8e) RC es alquilo C1–6. (8f) RC es alquilo C1–4. (8g) RC es metilo. R3 se selecciona de uno de los siguientes grupos (9a) – (9x): (9a) R3 es arilo, heteroarilo, cicloalquilo C3–8, cicloalquenilo C3–8, heterociclilo de 3–10 miembros, o cicloalquilo C3–8–
alquilo C1–6–, en donde el cicloalquilo C3–8, cicloalquenilo C3–8, heterociclilo de 3–10 miembros, y cicloalquilo C3–8–alquilo C1–6–, son cada uno opcional e independientemente sustituidos por un grupo =R32 y cada uno opcional e independientemente sustituido por uno o dos grupos R31; y los grupos arilo y heteroarilo, son cada uno opcionalmente sustituido por uno o dos grupos R31.
imagen19
imagen20
La realizaciones particulares de este aspecto de la invención incluyen compuestos de una cualquiera de las fórmulas (II), (II’), y (IIa) – (IId), cada una como se define en cada una de las siguientes filas, en donde cada entrada es un número de grupo como se define anteriormente y un guion "–" indica que la variable es como se define para la fórmula (II), o (II’), o definida de acuerdo con una cualquiera de las definiciones de las variables pertinentes (7a)–(9t) [por ejemplo, cuando RC es un guion, puede ser ya sea como se define para la Fórmula (II), o (II’), o cualquiera de las definiciones (8a)–(8g)]:
imagen21
imagen22
imagen23
imagen24
1256
etil 2–(5H–imidazo[5,1–a]isoindol–5–il)acetato
1258
ácido 2–(5H–imidazo[5,1–a]isoindol–5–il)acético
1259
2–(5H–imidazo[5,1–a]isoindol–5–il)–N–metilacetamida
1273
(E)–5–(2–bromostiril)–5H–imidazo[5,1–a]isoindol
1286
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1– ciclohexiletanol
1287
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1– ciclohexiletanona
1288
2–(5H–imidazo[5,1–a]isoindol–5–il)etil 2–(((1R,2R,5S)–2– isopropil–5–metilciclohexil)oxi)acetato
1300
tert–butil (4–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)fenil)carbamato
1301
1–(4–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona
1302
tert–butil (4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)fenil)carbamato
1303
1–(4–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1304
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1306
imagen25 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3–nitrofenil)etanona
1307
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3–nitrofenil)etanol
1326
imagen26 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2–nitrofenil)etanona
1327
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2–nitrofenil)etanol
1328
tert–butil (2–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)fenil)carbamato
1329
tert–butil (2–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)fenil)carbamato
1330
1–(2–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona
1331
1–(2–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1334
1–(2–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona
1335
1–(5H–imidazo[5,1–a]isoindol–5–il)–2–metilpropan–2–ol
1336
1–(2–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1343
imagen27 1–(3–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1348
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–feniletanona
1349
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–feniletanol
1352
1–(2,4–dimetilfuran–3–il)–2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanol;
1353
1–(3–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona
1356
1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)etanona
1357
1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)etanol
1358
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tetrahidro–2Hpiran–4– il)etanol
1359
2–(7–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1– ciclohexiletanol
1360
(Z)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona oxima
1362
1–ciclopentil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1363
tert–butil 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidina–1–carboxilato
1364
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanamina
1367
tert–butil (3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)fenil)carbamato
1369
1–(3–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1370
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piperidin–4–il)etanol
1371
4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol;
1372
1–ciclohexil–2–(9–metoxi–5H–imidazo[5,1–a]isoindol–5– il)etanol
1373
5–(2–ciclohexil–2–hidroxietil)–5H–imidazo[5,1–a] isoindol–9– ol
1374
2–(8–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1– ciclohexiletanol;
1375
1–(ciclohex–1–en–1–il)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol;
1376
1–ciclohexil–2–(8–fluoro–5H–imidazo[5,1–a]isoindol–5– il)etanol;
1378
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1,4– dioxaspiro[4.5]decan–8–il)etanol;
1379
4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanona;
1381
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilenociclohexil)etanol;
1382
1–(ciclohex–3–en–1–il)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol;
1383
1–(4–(hidroximatil)ciclohexil)–2–(5H–imidazo[5,1–a] isoindol– 5–il)etanol;
1384
(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)(tiofen–2–il)metanona;
1385
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)etanona;
1386
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilenociclohexil)etanol;
1387
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilciclohexil)etanol;
1389
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1–metil–1Himidazol– 4–il)etanol;
1390
imagen28 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol–4–il)etanol;
1391
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol–5–il)etanol;
1392
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2,2–dimetilpropan–1–ona;
1393
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(furan–2– il)etanol;
1394
imagen29 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1–metil–1H– imidazol–2–il)etanol;
1396
(1S)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol;
1397
(1R)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol;
1398
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4– (yodometileno)ciclohexil)etanol;
1400
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)propan–1–ol;
1402
2–(5H–imidazo[5,1–a]isoindol–5–il)acetonitrilo;
1403
imagen30 1–ciclohexil–3–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)propan–2–ol;
1404
1–ciclohexil–3–(5H–imidazo[5,1–a]isoindol–5–il)propan–2–ol;
1405
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–feniletanona;
1406
1–(4,4–difluorociclohexil)–2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanol;
1407
1–(4,4–difluorociclohexil)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol;
1409
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1–metil–1H– imidazol–5–il)etanol;
1410
1–(4–(ciclopropilmetileno)ciclohexil)–2–(6–fluoro– 5Himidazo[5,1–a]isoindol–5–il)etanol;
1411
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(propan– 2–ilideno)ciclohexil)etanol;
1412
(E)–5–(2–ciclohexilvinil)–5H–imidazo[5,1–a]isoindol;
1413
2–(9–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilciclohexil)etanol;
1414
1–(ciclohex–3–en–1–il)–2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanol;
1415
(R)–1–ciclohexil–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etanol
1416
(S)–1–ciclohexil–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etanol
1417
imagen31 (S)–1–ciclohexil–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etanol
1418
(R)–1–ciclohexil–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etanol
1419
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–ilideno)etanol
1420
imagen32 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etilacetato
1421
1–(4–(2–(benciloxi)etilideno)ciclohexil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanol
1422
1–(1–(bencilsulfonil)piperidin–4–il)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol
1423
imagen33 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(pirimidin–5–il)etanona
1424
2–(3,4–difluorofenil)–1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)etanona
1425
ciclohexil(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)metanona
1426
metil 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexanocarboxilato
1427
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etil fenilcarbamato
1428
ácido 4–(1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etoxi)–4–oxobutanoico
1429
imagen34 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexanol
1431
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etil benzoato
1432
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–(2– (metilsulfonamido)etil) ciclohexanocarboxamina
1433
(2S)–1–(1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etoxi)–3–metil–1–oxobutan–2–aminio cloruro
1434
sodio 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etil fosfato
1436
ácido 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexanocarboxílico
1437
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(piridin–4–il)etanona
1438
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(espiro[2.5]octan–6– il)etanol
1439
2–(4–fluorofenil)–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)piperidin–1–il)etanona
1440
imagen35 (2S)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etil 2– aminopropanoato
1441
1–(4–(2–hidroxietilideno)ciclohexil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol
1442
imagen36 (2S)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etil pirrolidina–2–carboxilato
1443
(2S)–5–(1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etil) 1–metil 2–aminopentanodioato
1447
1–(4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–feniletanona
1448
(3–fluoro–2–hidroxifenil)(4–(1–hidroxi–2–(5Himidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)metanona
1449
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)– Nfenilpiperidina–1–carboxamina
1450
(4–fluorofenil)(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5– il)etil)piperidin–1–il)metanona
1451
(2S)–2–amino–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)piperidin–1–il)–3–fenilpropan–1–ona
1454
(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)((S)–pirrolidin–2–il)metanona
1455
(1R,4s)–4–(2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–hidroxietil)ciclohexil benzoato
1456
(1R,4s)–4–(2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–hidroxietil)ciclohexanol
1458
imagen37 1–(3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)azetidin–1–il)–2–feniletanona
1459
3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)– Nfenilazetidina– 1–carboxamina
1460
tert–butil 3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)azetidina–1–carboxilato
1461
1–(azetidin–3–il)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
1469
tert–butil 4–((S)–1–hidroxi–2–((R)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxilato
1470
tert–butil 4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxilato
1471
tert–butil 4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxilato
1472
imagen38 tert–butil 4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxilato
1473
imagen39 1–((1s,4s)–4–(benciloxi)ciclohexil)–2–(6–fluoro– 5Himidazo[5,1–a]isoindol–5–il)etanol
1474
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piridin–3–il)etanol
1475
imagen40 (1r,4r)–4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol
1476
4–((S)–1–hidroxi–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–fenilpiperidina–1–carboxamina
1477
4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–fenilpiperidina–1–carboxamina
1478
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–fenilpiperidina–1–carboxamina
1479
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5–il)etil)– N–fenilpiperidina–1–carboxamina
1480
1–(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–feniletanona
1482
(1R,4s)–4–((S)–2–((R)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1483
(1S,4s)–4–((R)–2–((R)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1484
(1S,4s)–4–((R)–2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1485
(1R,4s)–4–((S)–2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1486
(1S,4r)–4–((S)–2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1487
(1S,4r)–4–((S)–2–((R)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1488
imagen41 (1R,4r)–4–((R)–2–((S)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1489
(1R,4r)–4–((R)–2–((R)–6–fluoro–5H–imidazo[5,1–a]isoindol– 5–il)–1–hidroxietil)ciclohexanol
1490
1–(4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(tetrahidro–2H–piran–4–il)etanona
1491
1–(4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–feniletanona
1492
N–((1s,4s)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)benzamida
1493
1–(4–((S)–1–hidroxi–2–((R)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–feniletanona
1494
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– (fenilcarbamoil)piperidin–4–il)etil fenilcarbamato
1495
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–((1r,4R)–4–hidroxiciclohexil)piperidina–1– carboxamina
1496
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5–il)etil)– N–(tetrahidro–2H–piran–4–il)piperidina–1–carboxamina
1497
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5–il)etil)– N–((1r,4S)–4–hidroxiciclohexil)piperidina–1–carboxamina
1498
1–((1r,4r)–4–(benciloxi)ciclohexil)–2–(5H–imidazo[5,1–a] isoindol–5–il)etanol
1499
1–((1r,4r)–4–(benciloxi)ciclohexil)–2–(6–fluoro– 5Himidazo[5,1–a]isoindol–5–il)etanol
1500
1–(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(tetrahidro–2H–piran–4–il)etanona
1501
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piridin–4–il)etanol
1502
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piridin–2–il)etanol
1503
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–(tetrahidro–2H–piran–4–il)piperidina–1–carboxamina
1504
N–ciclohexil–4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxamina
1505
N–((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)benzamida
1507
N–ciclopentil–4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxamina
1508
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4– (trifluorometil)ciclohexil)etanol
1509
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– (trifluorometil)ciclohexil)etanol
1511
2–(4–fluorofenil)–1–(4–((R)–1–hidroxi–2–((S)–5Himidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)etanona
1512
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)–N–(4–(trifluorometil)fenil)piperidina–1–carboxamina
1513
(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)(1H–imidazol–1–il)metanona
1–(5H–imidazo[5,1–a]isoindol–5–il)–3–metilbutan–2–ol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tetrahidro–2Hpiran– 3–il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piperidin–3– il)etanol
imagen42
1–ciclohexil–2–((R)–5H–imidazo[5,1–a]isoindol–5–il)etanol
1–ciclohexil–2–((S)–5H–imidazo[5,1–a]isoindol–5–il)etanol
1–ciclohexil–3–(5H–imidazo[5,1–a]isoindol–5–il)propan–1–ol
1–ciclohexil–2–(9–fluoro–5H–imidazo[5,1–a]isoindol–5– il)etanol
N–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)fenil)– 2–(tetrahidro–2H–piran–4–il)acetamida
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1H–imidazol–2– il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1H–imidazol–4– il)etanol
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol–2– il)etanol
(5S)–5–(2–ciclohexil–2–hidroxietil)–5H–imidazo[5,1–a] isoindol–6–ol
1–(2–aminociclohexil)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol
N–(1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)acetamida
N–(2–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)acetamida
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)– Nmetiletanamina
imagen43
2–(1–ciclohexil–2–((S)–5H–imidazo[5,1–a]isoindol–5– il)etil)amino)etanosulfonamida
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1– metilpiperidin–4–il)etanol
1–(4–aminociclohexil)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol
N–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)acetamida
1–(4–(aminometil)ciclohexil)–2–(5H–imidazo[5,1–a] isoindol– 5–il)etanol
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexanocarboxamina
1–(3–aminociclohexil)–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(piridin–2– ilmetoxi)ciclohexil)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(piridin–3– ilmetoxi)ciclohexil)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(piridin–4– ilmetoxi)ciclohexil)etanol
imagen44
1–((1r,4r)–4–((2–aminopiridin–4–il)metoxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(pyrazin–2– ilmetoxi)ciclohexil)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(pirimidin– 5–ilmetoxi)ciclohexil)etanol
1–((1r,4r)–4–((6–aminopiridin–2–il)metoxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol
1–((1r,4r)–4–((6–aminopiridin–3–il)metoxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol
1–((1r,4r)–4–((3–aminopiridin–2–il)metoxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol
1–((1r,4r)–4–((2–aminopirimidin–5–il)metoxi) ciclohexil)–2– (5H–imidazo[5,1–a]isoindol–5–il)etanol
imagen45
1–((1r,4r)–4–((4–aminopirimidin–5–il)metoxi) ciclohexil)–2– (5H–imidazo[5,1–a]isoindol–5–il)etanol
1–((1r,4r)–4–((5–aminopiridin–2–il)metoxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol
imagen46
4–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)–N,N–dimetilbenzamida
3–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)–N,N–dimetilbenzamida
2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)–N,N–dimetilbenzamida
imagen47
4–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil) bencenosulfonamida
imagen48
3–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil) bencenosulfonamida
2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil) bencenosulfonamida
4–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)benzamida
3–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)benzamida
2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)benzamida
imagen49
metil 4–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato
metil 3–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato
metil 2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4– metoxiciclohexil)etanol
1–((1r,4r)–4–etoxiciclohexil)–2–(5H–imidazo[5,1–a] isoindol– 5–il)etanol
imagen50
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4– isopropoxiciclohexil)etanol
1–((1r,4r)–4–(ciclopropilmetoxi)ciclohexil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanol
imagen51
1–((1r,4r)–4–(ciclopentilmetoxi)ciclohexil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(tiofen–2– ilmetoxi)ciclohexil)etanol
1–((1r,4r)–4–((1H–indol–3–il)oxi)ciclohexil)–2– (5Himidazo[5,1–a]isoindol–5–il)etanol
1–((1r,4r)–4–((1H–indol–5–il)oxi)ciclohexil)–2– (5Himidazo[5,1–a]isoindol–5–il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–((tetrahidro– 2Hpiran–4–il)metoxi)ciclohexil)etanol
imagen52
4–(((4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexil)oxi)metil)bencenosulfonamida
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(oxazol–2– ilmetoxi)ciclohexil)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(tiazol–2– ilmetoxi)ciclohexil)etanol
imagen53
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1–(1–imino–2– feniletil)piperidin–4–il)etanol
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)– Nfenilpiperidina–1–carboximidamida
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N– (piridin–4–il)piperidina–1–carboximidamida
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N– (tetrahidro–2H–piran–4–il)piperidina–1–carboximidamida
N–(4–cianofenil)–4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)piperidina–1–carboxamina
N–(tert–butil)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidina–1–carboxamina
imagen54
N–(tert–butil)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidina–1–sulfonamida
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(3–hidroxifenil)etanona
2–(1–(azetidina–1–carbonil)piperidin–4–il)–2–hidroxi– 1–(4– (1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)etanona
2–ciclopentil–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol– 5–il)etil)piperidin–1–il)etanona
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(2–metiltiazol–5–il)etanona
N–ciclohexil–N–hidroxi–4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidina–1–carboxamina
N–(4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–oxoetil)fenil) metanosulfonamida
N–ciclopropil–N–hidroxi–4–(1–hidroxi–2–(5Himidazo[5,1– a]isoindol–5–il)etil)piperidina–1–carboxamina
3,3–difluoro–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)piperidin–1–il)butan–1–ona
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(p–tolil)etanona
1–(11–(4–aminopirimidin–2–il)piperidin–4–il)–2– (5Himidazo[5,1–a]isoindol–5–il)etanol
1–(1–(2–aminopirimidin–4–il)piperidin–4–il)–2– (5Himidazo[5,1–a]isoindol–5–il)etanol
N–ciclopropil–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidina–1–carboxamina
2–ciclopropil–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol– 5–il)etil)piperidin–1–il)etanona
2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)ciclohexilideno)acetonitrilo
imagen55
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–(4– (trifluorometil)tiazol–2–il)piperidina–1–carboxamina
imagen56
4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–oxoetil)benzamida
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–(4–(metilsulfonil)fenil)etanona
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N– ((1r,4r)–4–metilciclohexil)piperidina–1–carboxamina
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–3,3–dimetilbutan–1–ona
4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–oxoetil)bencenosulfonamida
N–(tert–butil)–4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– oxoetil)bencenosulfonamida
ácido 4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–1–il)–2–oxoetil)benzoico
1–(4–(difluorometileno)ciclohexil)–2–(5H–imidazo[5,1–a] isoindol–5–il)etanol
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(2,2,2– trifluoroetilideno)ciclohexil)etanol
N–bencil–4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanocarboxamina
4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)–N–fenilciclohexanocarboxamina
N–(4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexil)benzamida
1–(4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexil)–3–fenilurea
N–(4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexil)–2–fenilacetamida
y las sales farmacéuticamente aceptables de los mismos.
En otro aspecto, la presente divulgación provee compuestos y composiciones farmacéuticas que comprenden los compuestos de acuerdo con uno cualquiera de los aspectos precedentes de la invención o cualquier realización de la misma, junto con un excipiente, diluyente, o portador farmacéuticamente aceptable.
En otro aspecto de la divulgación, se describen los métodos para tratar inmunosupresión mediada por indolamina 2,3– dioxigenasa (IDO) en un sujeto en necesidad del mismo, que comprende la administración de una cantidad eficaz de
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
#
Compuesto Nombre Rendimiento (%)
1
(E)–3–(2–cloro–6–yodofenil)–1– ciclohexilprop–2–en–1–ona 63
1H RMN 1.22–1.45 (m, 5 H), 1.70–174 (m, 1H), 1.79–1.85 (m, 2H), 1.93–1.99 (m, 2H), 2.61–2.65 (m, 1H), 6.67 (d, 1H, J = 16 Hz), 6.93 (t, 1H, J = 8 Hz), 7.42 (d, 1H, J = 8 Hz), 7.48 (d, 1H, J = 16 Hz), 7.82 (d, 1H, J = 8 Hz)
2
imagen69 (E)–3–(2–yodofenil)–1–(3– nitrofenil)prop–2–en–1–ona 53
1H RMN 7.10–7.16 (m, 1H), 7.34 (d, 1H, J = 15.6 Hz), 7.41–7.46 (m, 1H), 7.71–7.76 (m, 2H), 7.94–7.97 (m, 1H), 8.05 (d, 1H, J = 15.6 Hz), 8.34–8.48 (m, 2H), 8.81 (s, 1H)
Ejemplo 2 Procedimiento general para la síntesis de 2–(5H–imidazo[5,1–a]isoindol–5–il)etanonas por acoplamiento cruzado Negishi catalizado con paladio de yoduro de arilos 1 y 2 con 4–yodo–1–tritil–1H–imidazol.
imagen70
5 A una solución agitada de 4–yodo–1–tritil–1H–imidazol (218 mg, 0.5 mmol) en THF anhidro (4 mL) a rt se le adicionó gota a gota EtMgBr (1.0 M en THF, 0.5 mmol, 0.5 mL), con una atmósfera de N2. La solución resultante se dejó agitar, durante 90 min y se le adicionó ZnCl2 anhidro (0.5 mmol, 68.2 mg). La suspensión de color blanco resultante se dejó agitar, durante 90 min y una solución del yoduro de arilo apropiado 1, 2 o 86 (0.5 mmol) en THF (1 mL) se le adicionó seguido de la adición inmediata de Pd(PPh3)4 (56 mg, 0.05 mmol). La mezcla de reacción se dejó agitar a 70 °C,
10 durante 12 h con una atmósfera de N2. Después de enfriar a temperatura ambiente, la solución se diluyó con CH2Cl2 (20 mL) y la capa orgánica se lavó con una solución reguladora EDTA (acuosa) (pH = 9) (2 x 5 mL) y salmuera. La capa orgánica se secó (Na2SO4) y se concentró a presión reducida. El residuo en bruto se utilizó en la siguiente etapa sin purificación adicional. A una solución del producto en bruto imidazol a partir de la etapa anterior se le adicionó ácido acético (1.0 mL) y MeOH (4.0 mL). La solución se agitó a 90 °C, durante 3 h. La mezcla de reacción se dejó enfriar a
15 temperatura ambiente y el pH se ajustó a 10 con K2CO3 saturado (acuoso). La fase acuosa se extrajo con EtOAc (3 x 20 mL). Las capas orgánicas combinadas se lavaron con agua, salmuera y se secaron. El solvente se eliminó a vacío para proporcionar el residuo en bruto, que se purificó por cromatografía en columna instantánea en sílica gel para proporcionar los siguientes compuestos.
20
#
Compuesto Nombre Rendimiento (%)
1287
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5– il)–1–ciclohexiletanona 25
1H RMN 1.18–1.36 (m, 5H), 1.68–1.88 (m, 5H), 2.37–2.40 (m, 1H), 2.64 (dd, 1H, J = 20.0 Hz, 10.0 Hz), 3.79 (dd, 1H, J = 16.0 Hz, 4.0 Hz), 5.70 (d, 1H, J = 8.0 Hz), 7.17–7.20 (m, 2H), 7.32 (t, 1H, J = 8.0 Hz), 7.43 (d, 1H, J = 8.0 Hz), 7.61 (s, 1H)
1256
etil 2–(5H–imidazo[5,1–a]isoindol–5– il)acetato 23
1H RMN 1.31 (t, 3H, J = 7.5 Hz), 2.67 (dd, 1H, J = 20.0 Hz, 12.0 Hz), 3.07 (dd, 1H, J = 20.0 Hz, 4.0 Hz), 4.25 (q, 2H, J = 6.0 Hz), 5.53 (dd, 1H, J = 12.0 Hz, 4.0 Hz), 7.16 (s, 1H), 7.21–7.37 (m, 3H), 7.51 (d, 1H, J = 6.0 Hz), 7.75 (s, 1H)
1306
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3– nitrofenil)etanona 15
1H RMN 3.49 (dd, 1H, J = 18.6 Hz, 9.6 Hz), 3.80 (dd, 2H, J = 18.3 Hz, 3.3 Hz), 5.84 (dd, 1H, J = 3 Hz, 9.3 Hz), 7.26–7.32 (m, 1H), 7.38–7.49 (m, 2H), 7.55–7.59 (m, 1H), 7.70–7.76 (m, 2H), 8.32 (d, 1H, J = 6 Hz), 8.46–8.50 (m, 1H), 8.78 (s, 1H)
Ejemplo 3 acoplamiento cruzado Suzuki de 4–yodo–1–tritil–1H–imidazol con ácidos fenilborónicos
imagen71
Una suspensión de 4–yodo–1–tritil–1H–imidazol (6.88 mmol), el derivado ácido 2–formil borónico apropiado (10.31 mmol) y K3PO4 (20.63 mmol) en N,N–dimetilformamida (30 mL) y agua (6 mL) se purgó con nitrógeno, durante 5 minutos, seguido por la adición de Pd(PPh3)4 y la mezcla se purgó con nitrógeno, durante otros 5 minutos. La mezcla de reacción se agitó a 90 °C, durante 16 h con una atmósfera de N2. La solución se dejó enfriar y se filtró a través de un tapón de celite. La mezcla se diluyó con agua (50 mL) y EtOAc (25 mL). La capa orgánica se recolectó y la capa acuosa se extrajo con EtOAc (2 x 25 mL). Los extractos orgánicos combinados se lavaron con agua (2 x 25 mL), salmuera y se secaron (Na2SO4). La solución se filtró y el solvente se eliminó a presión reducida para proporcionar el producto en bruto que se purificó por cromatografía en columna instantánea en sílica gel para proporcionar los siguientes compuestos.
#
Compuesto Nombre Rendimiento (%)
3
2–(1–tritil–1H–imidazol–4–il)benzaldehido 52
1H RMN 7.03 (s, 1H), 7.18–7.20 (m, 6 H), 7.36–7.39 (m, 10H), 7.53–7.58 (m, 3H), 7.64 (d, 1H, J = 7.78 Hz), 7.93 (d, 1H, J = 7.87 Hz)
4
2–fluoro–6–(1–tritil–1H–imidazol–4– il)benzaldehido 46
1H RMN 7.02–7.07 (m, 1H), 7.10 (d, 1H, J = 1.6 Hz), 7.16–7.18 (m, 6H), 7.36–7.39 (m, 9H), 7.46–7.52 (m, 2H), 7.57 (s, 1H), 10.27 (s, 1H)
5
5–cloro–2–(1–tritil–1H–imidazol–4– il)benzaldehido 48
1H RMN 7.04 (d, 1H, J = 1.2 Hz), 7.10–7.19 (m, 5H), 7.32–7.38 (m, 12H), 7.58 (dd, 1H, J = 2.4, 8.4 Hz), 7.57–7.59 (m, 2H), 7.89 (d, 1H, J = 2.0 Hz), 10.34 (s, 1H)
6
4–cloro–2–(1–tritil–1H–imidazol–4–il)benzaldehido 55
1H RMN 7.08–7.38 (m, 18 H), 7.60 (s, 1H), 7.88 (d, 1H, J = 8.4 Hz), 10.41 (s, 1H)
7
4–fluoro–2–(1–tritil–1H–imidazol–4– il)benzaldehido 89
1H RMN (MeOH–d4) 7.16–7.27 (m, 6H), 7.29–7.47 (m, 3H), 7.60–7.70 (m, 9H), 7.85–7.90 (m, 2H), 10.26 (s, 1H)
Ejemplo 4 3–Metoxi–2–(1–tritil–1H–imidazol–4–il)benzaldehido
77
imagen72
1H RMN 3.19 (dd, 1H, J = 20.0 Hz, 8.0 Hz), 3.65 (dd, 1H, J = 20.0 Hz, 4.0 Hz), 5.81 (dd, 1H, J = 8.0 Hz, 4.0 Hz), 7.19 (s, 1H), 7.22–7.28 (m, 1H), 7.36 (m, 3H), 7.54 (d, 1H, J = 8.0 Hz), 7.61–7.65 (m, 1H), 7.70–7.74 (m, 1H), 7.85 (s, 1H), 8.16 (d, 1H, J = 8.0 Hz).
1328
tert–butil (2–(2–(5H–imidazo[5,1–a] isoindol–5–il)acetil)fenil)carbamato 44
1H RMN 1.50 (s, 9H), 3.47 (dd, 1H, J = 18.0 Hz, 9.6 Hz), 3.77 (dd, 1H, 18.0 Hz, 3.3 Hz), 5.77–5.81 (m, 1H), 6.98 (t, 1H, J = 8.0 Hz), 7.19 (s, 1H), 7.28 (d, 1H, J = 7.6 Hz), 7.37 (d, 1H, J = 8.0 Hz), 7.41 (d, 1H, J = 8.0 Hz), 7.52–7.56 (m, 2H), 7.72 (d, 1H, J = 8.0 Hz), 7.77 (s, 1H), 8.54 (d, 1H, J = 8.4 Hz)
1300
tert–butil (4–(2–(5H–imidazo[5,1–a] isoindol–5– il)acetil)fenil)carbamato 39
1H RMN 1.52 (s, 9H), 3.39 (dd, 1H, J = 18.6 Hz, 9.6 Hz), 3.68 (dd, 1H, J = 18.3 Hz, 3.3 Hz), 5.83 (dd, 1H, J = 3 Hz, 9.3 Hz), 6.88 (s, 1H), 7.14–7.58 (m, 7H), 7.75 (s, 1H), 7.92 (d, 2H, J = 9 Hz)
1348
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– feniletanona 45
1H RMN 3.44 (dd, 1H, J = 20.0 Hz, 8.0 Hz), 3.72 (dd, 1H, J = 20.0 Hz, 4.0 Hz), 5.83 (d, 1H, J = 8.0 Hz), 7.18 (s, 1H), 7.25–7.29 (m, 1H), 7.40 (t, 2H, J = 10 Hz), 7.47 (t, 2H, J = 8.0 Hz), 7.57 (d, 1H, J = 8.0 Hz), 7.61 (t, 1H, J = 6.0 Hz), 7.74 (s, 1H), 7.97 (d, 2H, J = 8 Hz)
9
tert–butil 4–(2–(5H–imidazo[5,1–a] isoindol–5–il)acetil)piperidina–1– carboxilato 19
1H RMN 1.44 (s, 9H), 1.50–1.82 (m, 4H), 2.72–2.76 (m, 2H), 2.90 (dd, 1H, J = 18.5 Hz, 9.4 Hz), 3.21 (dd, 1H, J = 18.57 Hz, 3.6 Hz), 5.63 (dd, 1H, J = 9.6 Hz, 3.6 Hz), 7.16 (s, 1H), 7.23 (m, 2H), 7.35–7.39 (m, 1H), 7.53 (d, 1H, J = 7.5 Hz), 7.59 (s, 1H)
10
imagen73 2–(6–fluoro–5H–imidazo[5,1–a] isoindol–5– il)–1–(1,4–dioxaspiro[4.5] decan–8– il)etanona 18
1H RMN (MeOH–d4) 1.50–1.90 (m, 6H), 2.35–2.60 (m, 2H), 2.98 (dd, 1H, J = 18.9 Hz, 10.2 Hz), 3.61 (dd, 1H, J = 18.9 Hz, 2.7 Hz), 5.78–5.82 (m, 1H), 7.01–7.07 (m, 1H), 7.16 (s, 1H), 7.42–7.45 (m, 2H), 7.66 (s, 1H)
11
2–(8–cloro–5H–imidazo[5,1–a] isoindol–5– il)–1–ciclohexiletanona 21
1H RMN (MeOH–d4) 1.10–1.90 (m, 10H), 2.42–2.48 (m, 1H), 2.99 (dd, 1H, J = 18.9 Hz, 9 Hz), 3.40 (dd, 1H, J = 18.9 Hz, 3.6 Hz), 5.58–5.62 (m, 1H), 6.95–7.08 (m, 1H), 7.16–7.88 (m, 4H)
12
2–(7–cloro–5H–imidazo[5,1–a] isoindol–5– il)–1–ciclohexiletanona 43
1H RMN 1.19–1.46 (m, 5H), 1.68–1.70 (m, 1H), 1.78–1.91 (m, 5H), 2.35–2.43 (m, 1H), 2.91 (dd, 1H, J = 10.0, 20.0 Hz), 3.18 (dd, 1H, J = 4.0, 20.0 Hz), 5.611 (dd, 1H, J = 4.0, 8.0 Hz), 7.15 (s, 1H), 7.28 (s, 1H), 7.35 (d, 1H, J = 8.0 Hz), 7.45 (d, 1H, J = 8.0 Hz), 7.60 (s, 1H)
13
1–ciclohexil–2–(6–fluoro–5Himidazo[5,1– a]isoindol–5–il)etanona 50
1H RMN 1.20–1.48 (m, 5H), 1.66–1.69 (m, 1H)1.78–1.92 (m, 5H), 2.36–2.44 (m, 1H), 2.79 (dd, J = 12.0, 20.0 Hz), 3.50 (dd, 1H, J = 4.0, 20.0 Hz), 5.77 (d, 1H, J = 8.0 Hz), 6.94 (t, 1H, J = 8.0 Hz), 7.18 (s, 1H), 7.31–7.37 (m, 2H), 7.62 (s, 1H)
14
1–ciclohexil–2–(9–metoxi–5H imidazo[5,1– a]isoindol–5–il)etanona 41
1H RMN 1.32–1.42 (m, 2H), 1.66–1.69 (m, 1H), 1.78–1.90 (m, 4H), 2.35–2.38 (m, 1H), 2.88 (dd, 1H, J = 18.4 Hz, 10 Hz), 3.17 (dd, 1H, J = 13.8 Hz, 3.2 Hz), 3.96 (s, 3H), 5.60–5.64 (m, 1H), 6.88 (d, 2H, J = 8 Hz), 7.15 (s, 1H), 7.21 (t, 1H, J = 8 Hz), 7.59 (s, 1H),
15
2–(5H–imidazo[5,1–a]isoindol–5–il)– 1– (tetrahidro–2H–piran–4– il)etanona 61
1H RMN 1.75–1.84 (m, 4H), 2.58–2.62 (m, 1H), 2.90 (dd, 1H, J = 18.4 Hz, 9.6 Hz), 3.21 (dd, 1H, J = 18.4 Hz, 3.6 Hz), 3.38–3.45 (m, 2H), 3.99–4.01 (m, 2H), 5.65 (dd, 1H, J = 9.6 Hz, 3.6 Hz), 7.17 (s, 1H), 7.22–7.30 (m, 2H), 7.38 (dt, 1H, J = 7.2 Hz, 0.8 Hz), 7.54 (d, 1H, J = 7.6 Hz), 7.61 (s, 1H)
16
1–ciclohexil–2–(8–fluoro–5Himidazo [5,1– a]isoindol–5–il)etanona 58
1H RMN a
17
tert–butil (3–(2–(5H–imidazo[5,1–a] isoindol–5– il)acetil)fenil)carbamato 80
1H RMN a
18
1–ciclopentil–2–(5H–imidazo[5,1–a] isoindol–5–il)etanona 11
1H RMN a
1334
1–(2–clorofenil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanona 15
1H RMN 3.30–3.50 (m, 1H), 3.65–3.85 (m, 1H), 5.50–5.70 (m, 1H), 7.17 (s, 1H), 7.20–7.60 (m, 8H), 7.75 (s, 1H)
imagen74
imagen75
imagen76
imagen77
destilación y el producto en bruto se disolvió en EtOAc (40 mL) y la solución se lavó con solución saturada de NaHCO3 (25 mL). La capa orgánica se separó y la capa acuosa se extrajo con EtOAc (2 x 20 mL). Los extractos orgánicos combinados se secaron sobre Na2SO4 y se concentró a presión reducida para proporcionar 120 (4.90 g, 89%).1H RMN : 1.62–2.01 (m, 8H), 2.34–2.38 (m, 1H), 3.64 (s, 3H), 3.82–3.88 (m, 1H).
imagen78
A una solución de metil cis–4–hidroxiciclohexanocarboxilato (4.80 g, 30.3 mmol) en hexano/CHCl3 2:1 (60 mL) se le adicionó bencil tricloroacetimidato (9.19 g, 36.4 mmol) y ácido trifluorometanosulfónico (683 mg, 4.55 mmol) a 23 °C. La mezcla de reacción se agitó durante 18 h y se diluyó con EtOAc (300 mL). La mezcla se lavó con NaHCO3 saturado
10 acuoso, agua y salmuera. La capa orgánica se secó sobre Na2SO4 anhidro y se concentró a presión reducida. El residuo en bruto se purificó por cromatografía en columna en sílica gel para proporcionar 121 (4.60 g, 18.5 mmol).
Ejemplo 18 Procedimiento general para la reacción de metil piperidina–4–carboxilato clorhidrato con cloruros ácidos
imagen79
A una suspensión de metil piperidina–4–carboxilato clorhidrato (5.6 mmol) en CH2Cl2 (20 mL) a 0 °C se le adicionó
15 diisopropiletil amina (16.7 mmol) y la suspensión se agitó durante 10 minutos. Se le adicionó gota a gota cloruro ácido apropiado (8.4 mmol) y la solución se dejó calentar a rt y se agitó durante la noche. La reacción se diluyó con agua (15 mL) y CH2Cl2 (15 mL). La capa orgánica se recolectó y la capa acuosa se extrajo con CH2Cl2 (2 x 20 mL). Los extractos orgánicos combinados se secaron (Na2SO4) y se concentró bajo presión reducida para proporcionar los siguientes compuestos.
#
Compuesto Nombre Rendimiento (%)
24
metil 1–pivaloilpiperidina–4–carboxilato 77
1H RMN 1.21 (s, 9H) 1.65–1.53 (m, 2H), 1.87–1.92 (m, 2H), 2.48–2.52 (m, 1H), 2.89–2.93 (m, 2H), 3.63 (s, 3H), 4.18–4.22 (m, 1H), 4.24–4.27 (m, 1H)
25
metil 1–(tiofeno–2–carbonil)piperidina–4– carboxilato 91
1H RMN 1.69–1.79 (m, 2H), 1.89–1.95 (m, 2H), 2.56–2.63 (m, 1H), 3.12 (t, 2H, J= 12.0 Hz), 3.68 (s, 3H), 4.28– 4.31 (m, 2H), 7.0–7.02 (m, 1H), 7.24–7.26 (m, 1H), 7.40–7.42 (m, 1H)
imagen80
A una solución de metil 3–fluoro–2–(1–tritil–1H–imidazol–4–il)benzoato (62 mg, 0.134 mmol) en tolueno (4 mL) a –78 °C se le adicionó gota a gota una solución de DIBAH (1 M, 0.161 mL, 0.161 mmol). La agitación se continuó, durante 10 min. A esta temperatura, se adicionó metanol seco. La mezcla se vertió en NH4Cl acuoso saturado (5 mL), se diluyó con EtOAc (15 mL), se agitó vigorosamente, durante 3 min, se adicionó salmuera (5 mL), se agitó de nuevo, las fases se separaron y la capa orgánica se secó sobre Na2SO4, se filtró y evaporó para proporcionar el aldehído deseado que se utilizó sin purificación adicional.
Ejemplo 22 Procedimiento general para la síntesis de Dimetil (2–oxo)fosfonatos
imagen81
A una solución agitada de dimetil metilfosfonato (3.14 g, 25.3 mmol) en 20 mL de tetrahidrofurano anhidro a –78 °C se le
10 adicionó gota a gota una solución de n–butil litio (10.13 mL, 25.3 mmol, 2.5 M en hexanos) con una atmósfera de N2, y la mezcla se agitó durante 30 minutos. A esta mezcla de reacción se le adicionó gota a gota una solución del éter metílico o etílico apropiado disponible comercialmente o 19–26, 91 o 115–121 (12.7 mmol) como una solución en THF (5 mL). Después de ser agitado durante 30 minutos, la mezcla de reacción se dejó calentar a 0 °C, y se agitó durante 1
h. El solvente se separó por destilación y el producto en bruto se diluyó con NH4Cl saturada (10 mL) y 10 mL de agua.
15 La mezcla se extrajo con acetato de etilo (2 x 40 mL). Las capas de acetato de etilo combinadas se lavaron con agua (1 x 20 mL), salmuera (1 x 20 mL) y se secaron sobre sulfato de sodio anhidro. La solución se filtró y se concentró a presión reducida para proporcionar el producto en bruto. El producto en bruto se purificó por cromatografía en columna para proporcionar los siguientes compuestos.
#
Compuesto Nombre Rendimiento (%)
27
dimetil (2–(2,5–dimetilfuran–3–il)–2– oxoetil)fosfonato 52
1H RMN 2.23 (s, 3H), 2.53 (s, 3H), 3.31 (d, 2H, J = 22.5 Hz), 3.75 (s, 3H), 3.79 (s, 3H), 6.24 (s, 1H)
28
dimetil (2–(furan–2–il)–2–oxoetil)fosfonato 63
1H RMN 3.52 (d, 2H, J = 22.6 Hz), 3.75 (s, 3H), 3.78 (s, 3H), 6.56 (d, 1H, J = 1.6 Hz), 7.29 (s, 1H), 7.62 (s, 1H)
29
dimetil (2–(1–metil–1H–imidazol–2–il)–2– oxoetil)fosfonato 45
1H RMN 3.80 (s, 3H), 3.83 (s, 3H), 3.88 (d, 2H, J = 22.2 Hz), 4.01 (s, 3H), 7.07 (s, 1H), 7.18 (s, 1H)
30
dimetil (2–oxo–2–(tiazol–4–il)etil)fosfonato 91
1H RMN 3.76 (s, 3H), 3.79 (s, 3H), 3.90 (d, 2H, J = 22.8 Hz), 8.32 (s, 1H), 8.85 (s, 1H)
31
dimetil2–(4,4–difluorociclohexil)–2– oxoetilfosfonato 82
1H RMN 1.72–1.81 (m, 4H), 1.96–1.98 (m, 2H), 2.11–2.13 (m, 2H), 2.68–2.70 (m, 1H), 3.14 (d, 2H, J = 22.4 Hz), 3.79 (d, 6H, J = 11.2 Hz)
32
dimetil 2–(4–metilenociclohexil)–2– oxoetilfosfonato 67
1H RMN 1.43–1.53 (m, 2H), 1.95–2.13 (m, 4H), 2.37–2.41 (m, 2H), 2.72–2.78 (m, 1H), 3.18 (d, 2H, J = 22.5 Hz), 3.82 (d, 6H, J = 11.3 Hz), 4.68 (s, 2H)
33
dimetil 2–oxo–2–(1,4–dioxaspiro [4.5]decan– 8–il)etilfosfonato 72
1H RMN 1.31–1.39 (m, 2H), 1.70–1.85 (m, 5H), 1.85–1.98 (m, 2H), 3.15 (d, 2H, J = 11.2 Hz), 3.77 (d, J = 18 Hz, 6H), 3.92 (m, 4H)
34
dimetil 2–(4–metilciclohexil)–2– oxoetilfosfonato 60
1H RMN 0.88–0.90 (m, 3H), 1.20–1.50 (m, 2H), 1.50–1.65 (m, 5H), 1.80–1.95 (m, 2H), 2.62–2.71 (m, 2H), 3.13 (d, J = 22.8 Hz, 2H), 3.73 y 3.80 (dos s, 6H)
35
dimetil 2–(4–(yodometileno)ciclohexil)–2– oxoetilfosfonato 47
1H RMN 1.20–1.52 (m, 2H), 1.93–2.10 (m, 4H), 2.30–2.36 (m, 1H), 2.49–2.58 (m, 4H), 3.07–3.10 (m, 2H), 3.73– 3.76 (m, 6H), 4.60 (s, 1H)
36
dimetil (2–oxo–2–(4–(propan–2– ilideno)ciclohexil)etil)fosfonato 70
1H RMN 1.28–1.42 (m, 2H), 1.63 (s, 6H), 1.72–1.96 (m, 4H), 2.65–2.75 (m, 3H), 3.12 (d, 1H, J = 21.0 Hz), 3.75 (d, 6H, J = 12.0 Hz)
37
dimetil (2–(4–(ciclopropilmetileno)ciclohexil)– 2–oxoetil)fosfonato 68
1H RMN 0.24 (s, 2H), 0.67 (d, 2H, J = 7.8 Hz), 1.39–1.43 (m, 3H), 1.86–2.07 (m, 4H), 2.17–2.21 (m, 1H), 2.71– 2.79 (m, 2H), 3.13 (d, 2H, J = 22.5 Hz), 3.77 (d, 6H, J = 11.2 Hz), 4.50 (d, 1H, J = 9.3 Hz)
38
dimetil (2–oxo–2–(1–pivaloilpiperidin–4– il)etil)fosfonato 68
1H RMN 1.23 (s, 9H), 1.51 (m, 1H, 1.87 (m, 3H), 2.85 (m, 3H), 3.02 (s, 1H), 3.14 (s, 1H), 3.75 (d, 6H, J = 11.2 Hz), 4.34 (m, 1H), 4.37 (m, 1H)
39
dimetil (2–(1–metil–1H–imidazol–5–il)–2– oxoetil)fosfonato 36
1H RMN 3.35 (d, 2H, J = 22.8 Hz), 3.74 (d, 6H, J = 11.2 Hz), 3.86 (s, 3H), 7.54 (s, 1H), 7.78 (s, 1H)
40
dimetil (2–(1–metil–1H–imidazol–4–il)–2– oxoetil)fosfonato 29
1H RMN 3.66–3.74 (s, 3H condensado con d, 2H, J = 22.5 Hz), 3.78 (d, 6H, J = 11.2 Hz), 7.44 (s, 1H), 7.63 (s, 1H)
41
dimetil (2–oxo–2–(tiazol–5–il)etil)fosfonato 18
1H RMN 3.53 (s, 1H), 3.61 (s, 1H), 3.73 (d, 6H, J = 11.2 Hz), 8.52 (s, 1H), 9.04 (s, 1H)
42
dimetil (2–(1–acetilpiperidin–4–il)–2– oxoetil)fosfonato 64
1H RMN 1.44–1.69 (m, 2H), 1.83–1.89 (m, 2H), 2.07 (s, 3H), 2.66–2.73 (m, 1H), 2.79–2.85 (m, 1H), 3.03–3.22 (m, 3H), 3.72–3.83 (m, 1H superpuesto con d, 6H, J = 11.2 Hz), 4.53 (d, 1H, J = 13.4 Hz)
43
dimetil (2–oxo–2–(1–(tiofeno–2– carbonil)piperidin–4–il)etil)fosfonato 59
1H RMN 1.63 (m, 2H), 1.95 (m, 2H), 2.89 (s, 1H), 3.07 (m, 2H), 3.10 (s, 1H), 3.18 (s, 1H), 3.77 (d, 6H, J = 11.2 Hz), 4.38 (m, 2H), 7.02 (dd, 1H, J = 5.0 Hz, 3.7 Hz), 7.25 (dd, 1H, J = 3.7 Hz, 1.1 Hz), 7.42 (dd, 1H, J = 5.1 Hz,
1.2 Hz)
44
dimetil 2–oxo–2–(1–(2–fenilacetil)piperidin– 4–il)etilfosfonato 39
1H RMN 1.20–1.90 (m, 4H), 1.67 (d, 1H, J = 10.2 Hz), 1.84 (d, 1H, J = 9.6 Hz), 2.55–2.75 (m, 2H), 2.90–3.15 (m, 2H), 3.65(s, 2H), 3.70 (d, 6H, J = 11.2 Hz), 3.90 (d, 1H, J = 10.2 Hz), 4.48 (d, 1H, J = 9.9 Hz), 7.10–7.30 (m, 5H)
45
imagen82 dimetil 3–ciclohexil–2–oxopropilfosfonato 70
1H RMN 0.60–1.15 (m, 5H), 1.35–1.71 (m, 5H), 2.28 (d, 2H, J = 8.8 Hz), 2.83 (s, 1H), 2.91 (s, 1H), 3.55 (s, 3H), 3.59 (s, 1H)
46
dimetil (2–oxo–2–(4–(tritiloxi) ciclohexil)etil)fosfonato 79
1H RMN (mezcla de isómeros cis y trans) 1.08–1.36 (m, 5H), 1.59–1.91 (m, 3H), 2.41–2.52 (m, 1H), 3.03 y 3.13 (dos d, 2H, J = 20.0 Hz), 3.35–3.79 (m, 1H), 3.73–3.79 (m, 6H), 7.22–7.29 (m, 9H), 7.49–7.51 (m, 6H)
122
(trans)–metil 4–(2–(dimetoxifosforil) acetil)ciclo hexanocarboxilato 70
1H RMN 1.31–1.53 (m, 4H), 2.00–2.20 (m, 4H), 2.23–2.31 (m, 1H), 2.53–2.61 (m, 1H), 3.13 (d, 2H, J = 22.6 Hz), 3.67 (s, 3H), 3.79 (d, 6H, J = 11.2 Hz)
124
dimetil (2–oxo–2–(4–(propan–2– ilideno)ciclohexil)etil)fosfonato 70
1H RMN 1.28–1.42 (m, 2H), 1.63 (s, 6H), 1.72–1.96 (m, 4H), 2.65–2.75 (m, 3H), 3.12 (d, 1H, J = 21.0 Hz), 3.75 (d, 6H, J = 12.0 Hz)
125
dimetil (2–oxo–2–(espiro[2.5]octan–6– il)etil)fosfonato 77
1H RMN 0.13–0.27 (m, 4H), 0.91–0.95 (m, 2H), 1.40–2.06 (m, 6H), 2.52–2.58 (m, 1H), 3.11 (d, 2H, J = 24.0 Hz), 3.75 (d, 6H, J = 12.0 Hz)
126
dimetil (2–((trans)–4–((tertbutildimetilsilil) oxi)ciclohexil)–2–oxoetil) fosfonato 96
1H RMN 0.11 (s, 6H), 0.82 (s, 9H), 1.19–1.32 (m, 4H), 1.85–1.88 (m, 4H), 2.41–2.47 (m, 1H), 3.08 (d, 2H, J = 24.0 Hz), 3.72 (s, 3H), 3.74 (s, 3H)
127
dimetil (2–((trans)–4–(benciloxi) ciclohexil)– 2–oxoetil) fosfonato 16
1H RMN 1.13–1.41 (m, 4H), 1.93–2.02 (m, 2H), 2.12–2.15 (m, 2H), 2.51–2.56 (m, 1H), 3.11 (d, 2H, J = 24 Hz), 3.27–3.32 (m, 1H), 3.75 (d, 6H, J = 12 Hz), 7.22–7.32 (m, 5H)
128
dimetil (2–(cis–4–benzamidociclohexil) –2– oxoetil)fosfonato 83
1H RMN 1.76–1.85 (m, 8H), 2.78–2.79 (m, 1H), 3.18 (d, 2H, J = 22.8 Hz), 3.82 (d, 6H, J = 11.2 Hz), 4.21–4.25 (m, 1H), 7.40–7.52 (m, 3H), 7.76–7.78 (m, 2H)
129
dimetil (2–(trans–4–benzamidociclohexil) –2– oxoetil)fosfonato 54
1H RMN 1.29 (dq, 2H, J = 3.1, 12.1 Hz), 1.54 (dq, 2H, J = 3.0, 11.5 Hz), 2.04 (d, 2H, J = 12.9 Hz), 2.12 (dd, 2H, J = 3.0, 12.6 Hz), 2.60 (tt, 1H, J = 3.4, 12.0 Hz), 3.15 (d, 2H, J = 22.6 Hz), 3.79 (d, 6H, J = 11.2 Hz), 3.93–3.99 (m, 1H), 5.98 (d, 1H, J = 7.7 Hz), 7.41–7.45 (m, 2H), 7.48–7.52 (m, 2H), 7.74 (d, 2H, J = 7.1 Hz)
130
dimetil (2–oxo–2–(4–(2– (tritiloxi)etilideno)ciclohexil)etil) fosfonito 42
1H RMN 1.26–1.60 (m, 2H), 1.35–1.37 (m, 1H), 1.80–2.30 (m, 3H), 2.25–2.40 (m, 2H), 2.70–2.76 (m, 1H), 3.05 (d, J = 27 Hz, 2H), 3.57–3.61 (m, 2H), 3.71–3.75 (d, J = 12 Hz, 2H), 7.19–7.32 (m, 9H), 7.44–7.51 (m, 6H)
131
tert–butil 3–(2– (dimetoxifosforil)acetil)azetidina–1– carboxilato 99
1H RMN 1.43 (s, 9H), 3.11 (d, J = 24 Hz, 2H), 3.68–3.82 (m, 7H), 3.81–4.12 (m, 4H)
132
dimetil (2–oxo–2–(piridin–2–il)etil)fosfonato 56
1H RMN 3.69–3.77 (m, 6H), 3.96–4.04 (m, 2H), 7.45–7.48 (m, 1H), 7.80–7.85 (m, 1H), 8.03–8.09 (m, 1H), 8.66– 8.69 (m, 1H)
133
dimetil (2–oxo–2–(piridin–3–il)etil)fosfonato 65
1H RMN 3.60–3.80 (m, 8H), 7,41–7.45 (m, 1H), 8.26–8.29 (m, 1H), 8.78–8.79 (m, 1H), 9.18 (m, 1H)
134
dimetil (2–oxo–2–(4– (trifluorometil)ciclohexil)etil)fosfonato 30
1H RMN 1.55–1.64 (m, 4H), 1.75–1.77 (m, 2H), 204–2.16 (m, 3H), 2.83–2.84 (m, 1H), 3.14 (d, J = 22.4 Hz, 2H), 3.78 (d, J = 11.2 Hz, 6H)
135
dimetil (2–((1s,4s)–4–(benciloxi)ciclohexil)– 2–oxoetil)fosfonato 17
1H RMN 1.47–1.55 (m, 2H), 1.66–1.71 (m, 2H), 1.78–1.85 (m, 2H), 1.95–1.99 (m, 2H), 2.58–2.62 (m, 1H), 3.14 (d, 2H, J = 22.4 Hz), 3.60–3.63 (m, 1H), 3.78 (d, 6H, J = 11.2 Hz), 4.48 (s, 2H), 7.24–7.33 (m, 5H)

Ejemplo 23 Procedimiento general para la síntesis de 2–(5H–imidazo[5,1–a]isoindol–5–il)etanonas mediante reacción de Horner–Wadsworth– Emmons seguido por ciclación.
imagen83
A una suspensión de NaH al 95% (17.4 mg, 0.7 mmol) en THF (3 mL) a 0 °C se le adicionó el reactivo fosfonato apropiado 27–46, 89, 90 o 122–135 (0.75 mmol) como una solución en THF (2 mL) y la mezcla se agitó durante 40 min. El 2–(1–tritil–1H–imidazol–4–il)benzaldehido apropiado se le adicionó como una solución en THF (3 mL) gota a gota 5 durante un periodo de 3 min. La reacción se dejó calentar a rt y se agitó durante la noche. El solvente se eliminó a presión reducida y el producto en bruto se diluyó con NH4Cl saturada (10 mL) y agua (10 mL). La capa acuosa se extrajo con CH2Cl2 (2 x 20 mL) y las fracciones orgánicas combinadas se lavaron con salmuera (15 mL), se secaron sobre Na2SO4 y se concentraron a presión reducida para proporcionar el producto en bruto. Al residuo en bruto se le adicionó AcOH (1 mL) y MeOH (3 mL) y la solución se agitó a 90 °C, durante 2 h. Después de enfriar a rt, el solvente se
10 separó por destilación y el producto en bruto se agitó en una mezcla de K2CO3 saturada (5 mL) y EtOAc (5 mL). La capa orgánica se separó y la capa acuosa se extrajo con EtOAc (2 x 10 mL). Las capas orgánicas combinadas se lavaron con agua, salmuera y se secaron (Na2SO4) y el solvente se evaporó a presión reducida. El residuo en bruto se purificó por cromatografía en columna instantánea en sílica gel para proporcionar los siguientes compuestos.
#
Compuesto Nombre Rendimiento (%)
47
imagen84 1–(ciclohex–1–en–1–il)–2–(5H–imidazo[5,1– a] isoindol–5–il)etanona 54
1H RMN 1.64–1.68 (m, 4H), 2.23–2.33 (m, 4H), 3.12 (dd, 1H, J = 9.8, 17.8 Hz), 3.36 (dd, 1H, J = 3.2, 18.0 Hz), 5.72 (dd, 1H, J = 3.6, 7.6 Hz), 6.86–6.88 (m, 1H), 7.17 (s, 1H), 7.32 (d, 1H, J = 7.6 Hz), 7.38 (t, 1H, J = 7.4 Hz), 7.55 (d, 1H, J = 7.2 Hz), 7.65 (s, 1H)
48
imagen85 1–(2,5–dimetilfuran–3–il)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanona 93
1H RMN 2.22 (s, 3H), 2.60 (s, 3H), 2.97 (dd, 1H, J = 10.8, 18.4 Hz), 3.72 (d, 1H, J = 18.2Hz), 5.86 (d, 1H, J = 10.7 Hz), 6.11 (s, 1H), 6.93 (t, 1H, J = 8.5 Hz), 7.16 (s, 1H), 7.30–7.37 (m, 2H). 7.74 (s, 1H)
49
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(furan–2–il)etanona 65
1H RMN 3.16 (dd, 1H, J = 10.5, 18.4 Hz), 3.85 (d, 1H, J = 18.4 Hz), 5.86 (d, 1H, J = 10.5 Hz), 6.54 (s, 1H), 6.92 (t, 1H, J = 8.9 Hz), 7.14 (s, 1H), 7.24–7.35 (m, 3H), 7.57 (s, 1H), 7.74 (s, 1H)
50
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1–metil–1H–imidazo 1–2–il)etanona 39
1H RMN 3.56 (dd, 1H, J = 12.0, 20.0 Hz), 4.07 (s, 3H), 4.13 (d, 1H, J= 20.0 Hz), 5.86 (d, 1H, J = 12.0 Hz), 6.92 (t, 1H, J = 8.0 Hz), 7.09 (d, 1H, J = 8.0 Hz), 7.15 (s, 1H), 7.31–7.34 (m, 3H), 7.71 (s, 1H)
51
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazo 1–4–il)etanona 58
1H RMN 3.62 (dd, 1H, J = 9.7, 18.8 Hz), 3.92 (dd, 1H, J = 3.0, 18.9 Hz), 5.79 (d, 1H, 9.5 Hz), 7.18 (s, 1H), 7.26– 7.28 (m, 1H superpuesto con CHCl3), 7.36–7.40 (m, 2H), 7.55 (d, 1H, J = 7.4 Hz), 7.75 (s, 1H), 8.38 (s, 1H), 8.82 (s, 1H)
52
1–(4,4–difluorociclohexil)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanona 81
1H RMN 1.65–1.82 (m, 4H), 1.90–2.01 (m, 2H), 2.11–2.16 (m, 2H), 2.44–2.48 (m, 1H), 2.79 (dd, 1H, J = 10.4 Hz, 18.4 Hz), 3.52 (dd, 1H, J = 2 Hz, 18.4 Hz), 5.72 (d, 1H, J = 10.4 Hz), 6.92 (t, 1H, J = 8.8 Hz), 7.15 (s, 1H), 7.28–7.35 (m, 2H), 7.58 (s, 1H)
53
1–(4,4–difluorociclohexil)–2–(5H– imidazo[5,1–a] isoindol–5–il)etanona 96
1H RMN 1.73–1.80 (m, 4H), 1.91–1.95 (m, 2H), 2.10–2.14 (m, 2H), 2.41–2.47 (m, 1H), 2.90 (dd, 1H, J = 9.4 Hz, 18.8 Hz), 3.21 (dd, 1H, J = 3.6 Hz, 18.4 Hz), 5.60 (dd, 1H, J = 3.4 Hz, 9.4 Hz), 7.13 (s, 1H), 7.22–7.28 (m, 2H), 7.36 (t, 1H, J = 7.2 Hz), 7.51 (d, 1H, J = 7.6 Hz), 7.57 (s, 1H)
54
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilenociclohexil)etanona 93
1H RMN 1.30–1.50 (m, 2H), 1.80–2.05 (m, 3H), 2.20–2.32 (m, 2H), 2.40–2.50 (m, 1H), 2.58–2.67 (m, 1H), 2.78– 2.88 (m, 1H), 3.16–3.17 (m, 1H), 5.50–5.54 (m, 1H), 7.13–7.17 (m, 1H), 7.20–7.30 (m, 2H), 7.43–7.45 (m, 1H), 7.52 (s, 1H)
55
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–metilenociclohexil)etanona 64
1H RMN 1.30–1.60 (m, 2H), 1.90–2.10 (m, 3H), 2.32–2.35 (m, 2H), 2.50–2.60 (m, 1H), 2.60–2.72 (m, 1H), 2.76– 2.84 (m, 1H), 3.52 (d, J = 18.4 Hz, 1H), 4.63 (s, 2H), 5.73 (d, J = 10.4 Hz, 1H), 6.91–6.96 (m, 1H), 7.20–7.30 (m, 2H), 7.43–7.45 (m, 1H), 7.52 (s, 1H)
56
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1,4–dioxaspiro [4.5]decan–8– il)etanona 84
1H RMN (CD3OD) 1.48–1.91 (m, 6H), 2.35–2.65 (m, 2H), 3.58–3.65 (m, 1H), 3.91 (s, 4H), 5.79–5.82 (m, 1H), 7.01–7.07 (m, 1H), 7.16 (m, 1H), 7.42–7.45 (m, 2H), 7.70 (s, 1H)
57
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–metilciclohexil)etanona 87
1H RMN 0.80–0.95 (m, 3H), 1.24–1.40 (m, 2H), 1.40–1.68 (m, 5H), 1.70–2.00 (m, 2H), 2.40–2.55 (m, 1H), 2.72– 2.84 (m, 1H), 3.48 (d, J = 18.4 Hz, 1H), 5.75 (d, J = 10.4 Hz, 1H), 6.89–6.95 (m, 1H), 7.15 (s, 1H), 7.26–7.38 (m, 2H), 7.62 (s, 1H)
58
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)– 1–(4–(yodometileno)ciclohexil)etanona 46
1H RMN (CD3OD) 1.20–1.52 (m, 2H), 1.80–2.20 (m, 4H), 2.30–2.36 (m, 1H), 2.45–2.80 (m, 3H), 2.90–3.02 (m, 1H), 3.59–3.64 (m, 1H), 4.63 (s, 1H), 5.75–5.80 (m, 1H), 7.02–7.08 (m, 1H), 7.15 (s, 1H), 7.42–7.47 (m, 2H), 7.65 (s, 1H).
59
2–(9–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–metilciclohexil)etanona 55
1H RMN (CD3OD) 0.80–0.95 (m, 3H), 1.24–1.40 (m, 2H), 1.40–1.68 (m, 5H), 1.70–2.00 (m, 2H), 2.40–2.55 (m, 1H), 2.72–2.84 (m, 1H), 3.48 (d, J = 18.4 Hz, 1H), 5.49–5.59 (m, 1H), 7.10–7.18 (m, 2H), 7.60–8.00 (m, 1H)
60
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–(propan–2– ilideno)ciclohexil)etanona 36
1H RMN 1.30–1.52 (m, 2H), 1.64 (s, 6H), 1.70–1.81 (m, 2H), 1.85–1.98 (m, 2H), 2.52–2.62 (m, 1H), 2.68–2.74 (m, 2H), 2.80 (dd, 1H, J = 18.5 Hz, 10.6 Hz), 3.50 (dd, 1H, J = 18.5 Hz, 2.2 Hz), 5.75 (d, 1H, J = 9.27 Hz), 6.90– 6.96 (m, 1H), 7.17 (s, 1H), 7.32–7.36 (m, 2H), 7.59 (s, 1H)
61
1–(4–(ciclopropilmetileno)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]iso indo 1–5– il)etanona 49
1H RMN 0.24 (s, 2H), 0.67 (d, 2H, J = 7.8 Hz), 1.43–1.49 (m, 3H), 1.82–2.15 (m, 3H), 2.12–2.28 (m, 1H), 2.50– 2.62 (m, 1H), 2.75–2.85 (m, 2H), 3.52 (d, 1H,J = 18.6 Hz), 4.52 (d, 1H, J = 9.3 Hz), 5.75 (d, 1H J = 10.2 Hz), 6.89–6.95 (m, 1H), 7.16 (s, 1H), 7.25–7.36 (m, 3H), 7.59 (s, 1H)
62
1–(4–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)piperidin–1–il)–2,2–dimetilpropan–1– ona 42
1H RMN 1.26 (s, 9H), 1.60 (m, 2H), 1.88 (m, 2H), 2.61 (m, 1H), 2.84 (m, 2H), 2.89 (dd, 1H, J = 9.39 Hz, 18.6 Hz), 3.22 (dd, 1H, J = 3.6 Hz, 18.3 Hz), 4.41 (m, 2H), 5.62 (dd, 1H, J = 3.54 Hz, 9.45 Hz), 7.16 (s, 1H), 7.24 (m, 2H), 7.37 (m, 1H), 7.53 (d, 1H, J = 7.56 Hz), 7.59 (s, 1H)
63
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1–metil–1H–imidazol–5–il)etanona 62
1H RMN 3.13–3.20 (m, 1H), 3.85–3.89 (m, 1H), 4.0 (s, 3H), 5.79 y 5.89 (dos d, 1H, J = 10.4 Hz), 6.96 (t, 1H, J = 8.8 Hz), 7.20 (s, 1H), 7.33–7.38 (m, 2H), 7.62 (s, 1H), 7.74 y 7.81 (dos s, 3H)
64
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– metil–1H–imidazol–4–il)etanona 24
1H RMN 3.42 (d, 1H, J = 9.9 Hz), 3.48 (d, 1H, J = 8.7 Hz), 3.75 (s, 3H), 5.75 (dd, 1H, J = 3.4 Hz, 9.8 Hz), 7.26– 7.19 (m, 1H), 7.14 (s, 1H), 7.35 (m, 2H), 7.41 (d, 1H, J = 1.0 Hz), 7.52 (dd, 1H, J = 1.2 Hz, 7.35 Hz), 7.71 (s,
1H), 7.67 (d, 1H, J = 1.2 Hz),
65
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (tiazol–5–il)etanona 30
1H RMN 3.40 (dd, 1H, J = 9.6 Hz, 18.4 Hz), 3.71 (dd, 1H, J = 3.2 Hz, 18.0 Hz), 5.80 (dd, 1H, J = 2.8 Hz, 9.2 Hz), 7.21 (s, 1H), 7.29 (d, 1H, J = 7.2 Hz), 7.36–7.41 (m, 2H), 7.57 (d, 1H, J = 8.0 Hz), 8.41 (s, 1H), 7.73 (s, 1H), 9.0 (s, 1H),
66
1–(1–acetilpiperidin–4–il)–2–(5H– imidazo[5,1–a] isoindol–5–il)etanona 74
1H RMN 1.57 (m, 2H), 1.90 (m, 2H), 2.09 (s, 3H), 2.60 (m, 2H), 2.91 (m, 1H), 3.07–3.26 (m, 2H), 3.82 (m, 1H), 4.58 (m, 1H), 5.62 (m, 1H), 7.16 (s, 1H) 7.29 (m, 2H), 7.37 (m, 1H), 7.53 (d, 1H, J= 10.4 Hz), 7.58 (d, 1H, J=4.8 Hz)
67
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– (tiofeno–2–carbonil)piperidin–4–il)etanona
1H RMN a
68
1–(4–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)piperidin–1–il)–2–feniletanona 49
1H RMN 1.20–1.90 (m, 4H), 2.40–3.33(m, 5H), 3.73(s, 2H), 3.89 (d, 1H, J = 13.5 Hz), 4.59 (d, 1H, J = 13.5 Hz), 5.50–5.70 (m, 1H), 7.15–7.45 (m, 9H), 7.53 (d, 1H, J = 7.5 Hz), 7.68 (d, 1H, J = 7.8 Hz)
69
1–ciclohexil–3–(5H–imidazo[5,1–a]isoindol– 5–il)propan–2–ona 82
1H RMN 0.85–1.35 (m, 5H), 1.55–1.175 (m, 5H), 1.80–1.95 (m, 1H), 2.25–2.38 (m, 2H), 2.70–2.80 (m, 1H), 3.16 (dd, 1H, J = 2.4, 14.8 Hz), 5.50–5.60 (m, 1H), 7.16 (s, 1H), 7.20–7.30 (m, 3H), 7.35 (t, 1H, J = 5.4 Hz), 7.41 (d, 1H, J = 5.4 Hz), 7.73 (s, 1H)
70
1–ciclohexil–3–(6–fluoro–5H–imidazo [5,1–a] isoindol–5–il)propan–2–ona 78
1H RMN 0.80–1.40 (m, 5H), 1.45–2.00 (m, 6H), 2.32 (t, 2H, J = 9.3Hz), 2.80–2.60 (m, 1H), 3.46 (d, 1H, J = 18.6 Hz), 5.72 (d, 1H, J = 10.5 Hz), 6.92 (t, 1H, J = 9.3 Hz), 7.18 (s, 1H), 7.25–7.40 (m, 2H), 7.71 (s, 1H)
71
2–(6–fluoro–5H–imidazo[5,1–a]isoindol –5– il)–1–(4–hidroxiciclohexil)etanona 89
1H RMN (mezcla de isómeros cis y trans) 1.25–1.77 (m, 6H), 1.90–2.06 (m, 3H), 2.34–2.42 (m, 1H), 2.80 (dd, 1H, J = 10.8 Hz, 18.8 Hz), 3.51 (d, 1H, J = 18.8 Hz), 3.60–3.62 y 3.97–4.01 (m, 1H), 5.73–5.76 (m, 1H), 6.93 (t, 1H, J = 8.4 Hz), 7.17 (s, 1H), 7.30–7.37 (m, 2H), 7.59 y 7.62 (dos s, 1H)
72
1–ciclohexil–2–(5H–imidazo[5,1–a]iso indo 1–5–il)etanona 86
1H RMN 1.25 (m, 5H), 1.79 (m, 5H), 2.38 (m, 1H), 2.89 (dd, 1H, J = 18.0 Hz, 9.0 Hz), 3.18 (dd, 1H, J = 18 Hz, 3.0 Hz), 5.63 (m, 1H), 7.16 (s, 1H), 7.21–7.28 (m, 2H), 7.37 (t, 1H, J = 7.5 Hz), 7.53 (d, 1H, J = 6 Hz), 7.60 (s, 1H)
aEl compuesto no se caracterizó y se utilizó como tal para la siguiente etapa de síntesis
136
1–ciclohexil–2–(5H–imidazo[5,1–a]iso indo 1–5– ilideno)etanona 62
1H RMN indistinguible mezcla de isómeros E/Z 1.26–1.48 (m, 8.9H), 1.63–1.94 (m, 13.7H), 2.58–2.62 (m, 0.6H), 3.33–3.38 (m, 1H), 6.40 (s, 0.4H), 6.60 (s, 0.53H), 7.15 (d, 0.8 Hz, J = 6.0 Hz), 7.25–7.28 (m condensado con CHCl3, 0.8H), 7.43–7.49 (m, 3H), 7.63–7.67 (m, 2H), 7.74–7.77 (m, 3H), 7.93 (s, 1H), 8.06 (d, 1H, J = 8.0 Hz), 9.25 (s, 0.4H), 9.43 (s, 0.8 H)
137
(trans)–metil 4–(2–(5H–imidazo[5,1– a]isoindol–5–il)acetil)ciclohexanocarboxilato 90
1H RMN 1.38–1.49 (m, 4H), 1.95–2.11 (m, 4H), 2.27–2.32 (m, 1H), 2.27–2.42 (m, 1H), 2.91 (dd, J = 9.5, 18.5 Hz, 1H), 3.21 (dd, J = 3.5, 18.5 Hz, 1H), 3.67 (s, 3H), 5.63 (dd, J = 3.3, 9.5 Hz), 7.17 (s, 1H), 7.22–7.29 (m, 2H),
7.38 (t, 1H, J = 7.5 Hz), 7.54 (d, 1H, J = 7.6 Hz), 7.60 (s, 1H)
139
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–(propan–2– ilideno)ciclohexil)etanona 36
1H RMN 1.30–1.52 (m, 2H), 1.64 (s, 6H), 1.70–1.81 (m, 2H), 1.85–1.98 (m, 2H), 2.52–2.62 (m, 1H), 2.68–2.74 (m, 2H), 2.80 (dd, 1H, J = 18.5 Hz, 10.6), 3.50 (dd, 1H, J = 18.5 Hz, 2.2 Hz), 5.75 (d, 1H, J = 9.27 Hz), 6.90– 6.96 (m, 1H), 7.17 (s, 1H), 7.32–7.36 (m, 2H), 7.59 (s, 1H)
140
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (espiro[2.5] octan–6–il)etanona 59
1H RMN 0.18–0.30 (m, 4H), 0.90–0.98 (m, 2H), 1.52–1.87 (m, 6H), 2.38–2.53 (m, 1H), 2.91 (dd, 1H, J = 18.4, 9.60 Hz), 3.20 (dd, 1H, J = 18.47, 3.6 Hz), 5.58–5.65 (m, 1H), 7.15 (s, 1H), 7.21–7.27 (m, 2H), 7.36 (t, 1H, J = 7.60 Hz), 7.52 (d, 1H, J = 7.60 Hz), 7.61 (s, 1H)
141
1–((trans)–4– ((tertbutildimetilsilil)oxi)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]iso indo 1–5– il)etanona 79
1H RMN 0.028 (s, 6H), 0.88 (s, 9H), 11.27–1.96 (m, 8H), 2.32–2.38 (m, 1H), 2.80 (dd, 1H, J = 18.8, 10.6 Hz), 3.48–3.57 (m, 2H), 5.75 (d, J = 9.3 Hz), 6.91–6.95 (m, 1H), 7.17 (s, 1H), 7.23–7.39 (m, 2H), 7.59 y 7.64 (dos s, 1H)
142
1–((trans)–4–(benciloxi)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]iso indo 1–5– il)etanona 72
1H RMN 1.15–1.54 (m, 4H), 1.91–2.20 (m, 4H), 2.37–2.43 (m, 1H), 2.80 (dd, 1H, J = 18.5, 10.5 Hz), 3.31–3.36 (m, 1H), 3.51 (d, 1H, J = 18.6 Hz), 4.55 (s, 2H), 5.74 (d, 1H, J = 10.3 Hz), 6.93 (t, 1H, J = 8.0 Hz), 7.17 (s, 1H), 7.29–7.39 (m, 7H), 7.59 y 7.78 (dos s, 1H)
143
1–((trans)–4–(benciloxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanona 81
1H RMN 1.14–1.50 (m, 4H), 1.92–2.01 (m, 2H), 2.15–2.19 (m, 2H), 2.34–2.43 (m, 1H), 2.90 (dd, 1H, J = 18, 9 Hz), 3.19 (dd, 1H, J = 24, 6 Hz), 3.30–3.37 (m, 1H), 4.49 y 4.55 (dos s, 2H), 5.61 (dd, 1H, J = 10.5, 4.5 Hz), 7.16–7.39 (m, 9H), 7.53 (d, 1H, J = 9 Hz), 7.62 (s, 1H)
144
N–((cis)–4–(2–(5H–imidazo[5,1–a]isoindol– 5–il)acetil)ciclohexil)benzamida 53
1H RMN 1.25–1.34 (m, 2H), 1.53–1.63 (m, 2H), 1.98–2.08 (m, 2H), 2.20 (t, 2H, J = 11.6 Hz), 2.36 (t, 1H, J =12.2 Hz), 2.90 (dd, 1H, J = 9.4, 18.6 Hz), 3.25 (dd, 1H, J = 3.2, 18.4 Hz), 3.93–4.00 (m, 1H), 5.63 (dd, 1H, J = 3.2, 9.2 Hz), 6.32 (d, 1H, J = 6.8 Hz), 7.19 (s, 1H), 7.26–7.35 (m, 2H, condensado con cloroformo), 7.38–7.43 (m, 3H), 7.48 (d, 1H, J = 7.2 Hz), 7.55 (d, 1H, J = 7.6 Hz), 7.71 (s, 1H), 7.76 (d, 2H, J = 7.6 Hz)
145
N–((trans)–4–(2–(5H–imidazo[5,1– a]isoindol–5– il)acetil)ciclohexil)benzamida 69
1H RMN 1.19–1.36 (m, 2H), 1.48–1.65 (m, 2H), 1.93–2.07 (m, 2H), 2.18–2.23 (m, 2H), 2.35 (tt, 1H, J = 3.2, 12.2 Hz), 2.90 (dd, 1H, J = 9.5, 18.4 Hz), 3.22 (dd, 1H, J = 3.6, 18.4 Hz), 3.92–3.99 (m, 1H), 5.62 (dd, 1H, J = 3.4, 9.4 Hz), 6.23 (d, 1H, J = 7.6 Hz), 7.23–7.32 (m, 3H, condensado con cloroformo), 7.34–7.42 (m, 3H), 7.46–7.50 (m, 1H), 7.54 (d, 1H, J = 7.6 Hz), 7.63 (s, 1H), 7.76 (d, 2H, J = 7.6 Hz)
146
1–(4–(2–hidroxietilideno)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanona 85
1H RMN 1.26–1.50_(m, 2H), 1.70–2.30 (m, 4H), 2.31–2.40 (m, 1H), 2.41–2.75 (m, 2H), 2.76–2.90 (m, 1H), 3.15–3.25 (m, 1H), 4.08–4.13 (m, 1H), 5.25–5.40 (m, 1H), 5.51–5.60 (m, 1H), 7.12 (s, 1H), 7.13–7.40 (m, 2H), 7.48–7.60 (m, 3H)
147
tert–butil 3–(2–(5H–imidazo[5,1–a]isoindol– 5–il)acetil)azetidina–1–carboxilato 77
1H RMN 1.38 (s, 9H), 2.85–2.92 (m, 1H), 3.20–3.25 (m, 1H), 3.44–3.48 (m, 1H), 3.65–3.70 (m, 2H), 4.01–4.28 (m, 2H), 5.63–5.66 (m, 1H), 7.16 (s, 1H), 7.21–7.31 (m, 2H), 7.36–7.40 (m, 1H), 7.53–7.55 (m, 1H), 7.66 (s, 1H)
148
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–2–il)etanona 75
1H RMN 3.60 (dd, J = 10, 19.2Hz, 1H), 3.91 (dd, J = 3.2, 19.2Hz, 1H), 5.65 (dd, J = 3.2, 10 Hz, 1H), 7.08 (s, 1H), 7.13–7.17 (m, 1H), 7.25–7.30 (m, 2H), 7.38–7.45 (m, 2H), 7.66 (s, 1H), 7.78–7.80 (m, 1H), 8.05 (d, J = 8
Hz, 1H), 8.51–8.53 (m, 1H)
149
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–3–il)etanona 89
1H RMN 3.57–3.67 (m, 1H), 3.80–3.95 (m, 1H), 6.01–6.05 (m, 1H), 7.27–7.73 (m, 6H), 8.29–8.36 (m, 1H), 8.61(s, 1H), 8.86 (d, J = 3 Hz, 1H), 9.18 (s, 1H)
150
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–4–il)etanona 21
1H RMN 3.42–3.49 (dd, J = 9.2, 18.8 Hz, 1H), 3.76 (dd, J = 3.6, 18.8Hz, 1H), 5.83 (dd, J = 3.2, 9.2 Hz, 1H), 7.20 (s, 1H), 7.28–7.32 (m, 1H), 7.38–7.45 (m, 2H), 7.58–7.60 (m, 1H), 7.74–7.75(m, 2H), 7.81 (s, 1H), 8.84–8.86 (m, 2H)
151
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– (trifluorometil)ciclohexil)etanona 50
1H RMN 1.55–1.81 (m, 5H),_2.08–2.29 (m, 4H), 2.58–2.62 (m, 1H), 2.94 (dd, J = 9, 18 Hz, 1H), 3.22 (dd, J = 6, 18 Hz, 1H), 5.68 (dd, J = 6, 9 Hz, 1H), 7.18–7.57 (m, 5 H), 7.81 y 7.83 (dos s, 1H)
152
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)– 1–(4–(trifluorometil)ciclohexil)etanona 53
1H RMN 1.51–1.83 (m, 6H), 1.95–2.21 (m, 3H), 2.58–2.62 (m, 1H), 2.79 (dd, J = 9, 18 Hz, 1H), 3.46–3.55 (m, 1H), 5.73–5.79 (m, 1H), 6.89–6.98 (m, 1H), 7.20–7.38 (m, 4H), 7.71 (s, 1H)
153
1–((cis)–4–(benciloxi)ciclohexil)–2–(6–fluoro– 5H–imidazo[5,1–a]isoindol–5–il)etanona 77
1H RMN 1.67–2.04 (m, 8H), 2.39–2.45 (m, 1H), 2.79 (dd, 1H, J = 18.6, 10.6 Hz), 3.50 (dd, 1H, J = 16.4, 2.4 Hz), 3.60–3.65 (m, 1H), 4.49 y 4.55 (dos s , 1H), 5.76 (d, 1H, J = 8.8 Hz), 6.91–6.95 (m, 1H), 7.17 (s, 1H), 7.26–7.35 (m, 7H), 7.63 (s, 1H)
imagen86
1304
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindo1– 5–il)etanol 79
1H RMN (una mezcla de diastereómeros) 1.10–1.37 (m, 6H), 1.66–1.80 (m, 5H), 2.05 (m, 2H), 2.15 (m, 1H), 3.72 (m, 1H), 5.36 y 5.46 (dos m, 1H), 7.16 (s, 1H), 7.25 (m,1H), 7.34 (m, 1H), 7.43 (d, 1H, J= 7.6 Hz), 7.54 (d, 1H, J= 7.6 Hz), 7.80 (s, 1H)
1327
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2– nitrofenil)etanol 73
1H RMN (una mezcla de diastereómeros) 2.29 (m, 1H), 2.61 (m, 1H), 5.44 (m, 1H), 5.71 (dd, 1H, J = 9.0 Hz, 4.5 Hz), 7.08 (s, 1H), 7.27 (m, 2H), 7.34 (m,1H), 7.45–7.53 (m, 3H), 7.68 (m, 1H), 7.95 (m, 2H)
1307
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3– nitrofenil)etanol 39
1H RMN (una mezcla de diastereómeros) 2.32–2.40 (m, 1H), 2.48–2.58 (m, 1H), 5.06–5.11 (m, 1H), 5.41 y 5.61 (dos m, 1H), 7.09 (s, 1H), 7.30–7.43 (m, 2H), 7.48–7.57 (m, 3H), 7.64–7.72 (m, 2H), 8.12–8.19 (m, 2H)
1329
tert–butil (2–(1–hidroxi–2–(5H–imidazo[5,1– a] isoindol–5–il)etil)fenil)carbamato 50
1H RMN (una mezcla de diastereómeros) 1.50 y 1.55 (dos s, 9H), 2.50 y 2.78 (dos m, 2H), 5.02 y 5.07 (dos m, 1H), 5.19 y 5.56 (dos m, 1H), 6.93–7.02 (m, 2H), 7.12 (d, 1H, J = 8.0 Hz), 7.24 (m, 2H), 7.36 (m, 2H), 7.49 (d, 1H, J = 7.6 Hz), 7.71 (br s, 1H), 7.80 y 7.85 (dos s, 1H, J = 8.0 Hz), 8.12 y 8.45 (dos s, 1H)
1302
tert–butil (4–(1–hidroxi–2–(5H –imidazo[5,1– a] isoindol–5–il)etil)fenil)carbamato 81
1H RMN (una mezcla de diastereómeros) 1.50 (s, 9H), 2.28–2.41 (m, 2H), 4.98–5.03 (m, 1H), 5.25 y 5.55 (dos m, 1H), 6.55 y 6.61 (dos s, 1H), 7.12–7.54 (m, 7H), 7.66 y 7.78 (dos s, 1H)
1367
tert–butil (3–(1–hidroxi–2–(5H–imidazo [5,1– a] isoindol–5–il)etil)fenil) carbamato 52
1H RMN (una mezcla de diastereómeros) (MeOH–d4) 1.51 (s, 9H), 2.33–2.57 (m, 2H), 4.93–4.96 (m, 1H), 5.36 y 5.49 (dos m, 1H), 7.00–7.06 (m, 2H), 7.19–7.40 (m, 4H), 7.48 (s, 1H), 7.53–7.57 (m, 2H), 7.72 (s, 1H)
1349
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– feniletanol 73
1H RMN (una mezcla de diastereómeros) 2.30 (m, 1H), 2.41 (m, 1H), 5.08 (m, 1H), 5.31 (m, 1H), 7.08 (m, 1H), 7.20–7.51 (m, 9 H), 7.63 (s, 1H).
1363
tert–butil 4–(1–hidroxi–2–(5H–imidazo [5,1– a] isoindol–5–il)etil) piperidina–1–carboxilato 83
1H RMN (una mezcla de diastereómeros) 1.26 (m, 2H), 1.44 (s, 9 H), 1.47–1.59 (m, 2H), 1.76 (m, 1H), 206– 2.11 (m, 1H), 2.14–2.20 (m, 1H), 2.64 (m, 2H), 3.73 y 3.80 (dos m, 1H), 4.16 (m, 2H), 5.37 y 5.51 (dos m, 1H), 7.16 (s, 1H), 7.22 (m, 1H), 7.32–7.41 (m, 2H), 7.54 (d, 1H, J = 4.0 Hz), 7.79 y 7.81 (dos s, 1H)
1357
1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1–a] isoindol–5–il)etanol 96
1H RMN (una mezcla de diastereómeros) 0.98–1.39 (m, 6H), 1.65–1.79 (m, 5H), 2.03–2.07 (m, 1H) 2.34– 2.50 (m, 2H), 3.54–3.73 (m, 1H), 5.46 y 5.67 (dos dd, 1H, J1 =, 3.0, 8.0 Hz, J2 =3.0, 10.4 Hz), 6.93 (t, 1H, J = 8.0 Hz), 7.17 (d, 1H, J = 7.17 Hz), 7.30–7.37 (m, 2H), 7.82, 7.88 (dos s, 1H)
1359
2–(7–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol 98
1H RMN (una mezcla de diastereómeros)1.00–1.28 (m, 5H), 1.37–1.40 (m, 1H), 1.66–2.01 (m, 5H), 1.91– 2.0 (m, 1H) 2.12–2.23 (m, 1H), 3.71–3.75 (m, 1H), 7.15 (s, 1H), 7.33 (d, 1H, J = 8.0 Hz), 7.45 (d, 1H, J = 8.0
Hz), 7.79, 7.82 (dos s, 1H)
1362
1–ciclopentil–2–(5H–imidazo[5,1 – a]isoindol–5–il)etanol 91
1H RMN (una mezcla de diastereómeros) 1.11–1.41 (m, 2H), 1.55–1.70 (m, 4H), 1.83–2.17 (m, 4H), 3.74– 3.79 (m, 1H), 5.38, 5.49 (una t y una d, 1H, J1 = 6.0 Hz, J2 = 6.0 Hz), 7.18 (s, 1H), 7.25 (d condensado con CHCl3, 1H), 7.38 (t, 1H, J = 7.2 Hz), 7.46 (d, 1H, J = 7.6 Hz), 7.55 (d, 1H, J= 7.6 Hz), 7.84 (s, 1H)
1375
1–(ciclohex–1–en–1–il)–2–(5H–imidazo[5,1– a] isoindol–5–il)etanol 92
1H RMN (una mezcla de diastereómeros) 1.47–1.68 (m, 3H), 1.73–1.82 (m, 1H), 1.93–2.14 (m, 4H), 2.18– 2.22 (m, 1H), 2.33–2.40 (m, 2H), 4.36 (t, 1H, J = 7.0 Hz), 5.26, 5.44 (una t y (una dd, 1H, J1 = 6.0 Hz, J2 = 10.0 Hz), 5.71, 5.72 (dos s, 1H), 7.15, 7.18 (dos, s, 1H), 7.2–7.26 (m, 1H), 7.34, 7.3 (dos d, 1H, J1 = 6.8 Hz, J2 =7.27 Hz), 7.43 (d, 1H, J = 7.6 Hz), 7.54 (d, 1H, J = 7.6 Hz), 7.81, 7.86 (dos s, 1H)
1343
1–(3–clorofenil)–2–(5H–imidazo[5,1–a]iso indo 1–5–il)etanol 59
1H RMN (una mezcla de diastereómeros) 2.18–2.52 (m, 2H), 5.25–5.40 (m, 1H), 5.46–5.60 (m, 1H), 7.07 (s, 1H), 7.15–7.55 (m, 7H), 7.69 (d, 1H, J= 8.0 Hz), 7.79 (s, 1H)
1336
1–(2–clorofenil)–2–(5H–imidazo[5,1–a]iso indo 1–5–il)etanol 45
1H RMN (una mezcla de diastereómeros) 2.20–2.50 (m, 2H), 5.0–5.08 (m, 1H), 5.26–5.38 (m, 1H), 7.05 (s, 1H), 7.20–7.45 (m, 7H), 7.45 (d, 1H, J = 7.6 Hz), 7.52 (d, 1H, J = 7.6 Hz) 7.68 (s, 1H)
1374
2–(8–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol 41
1H RMN (una mezcla de diastereómeros) (MeOH–d4) 1.00–2.30 (m, 13H), 3.60–3.70 (m, 1H), 5.35 y 5.50
(dos m, 1H), 6.95–7.08 (m, 1H), 7.16–7.88 (m, 4H)
1376
1–ciclohexil–2–(8–fluoro–5H–imidazo[5,1–a] isoindol–5–il)etanol 15
1H RMN (una mezcla de diastereómeros) (MeOH–d4) 1.00–2.30 (m, 13H), 3.50–3.57 (m, 1H), 5.35 y 5.50 (m, 1H), 7.18–7.50 (m, 3H), 7.60–7.65 (m, 1H), 7.92 y 7.98 (dos s, 1H)
1378
2–(6–fluoro–5H–imidazo[5,1–a]isoindo1–5– il)– 1–(1,4–dioxaspiro[4.5]decan–8–il)etanol 90
1H RMN (una mezcla de diastereómeros) (MeOH–d4) 1.31–1.52 (m, 5H), 1.60–1.63 (m, 1H), 1.71–1.78 (m, 3H), 1.86–2.07 (m, 1H), 2.43–2.48 (m, 1H), 3.48–3.64 (m, 1H), 3.90 (s, 4H), 5.57 y 5.69 (dos m, 1H), 7.00– 7.06 (m, 1H), 7.18 (d, 1H, J = 11.6 Hz), 7.41–7.44 (m, 2H), 7.94–8.00 (m, 2H)
1358
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (tetrahidro–2H–piran–4–il)etanol 92
1H RMN (una mezcla de diastereómeros)1.39–1.51 (m, 2H), 1.59–1.65 (m, 1H), 1.71–1.75 (m, 1H), 2.11– 2.17 (m, 1H), 3.32–3.39 (m, 3H), 3.69–3.73 (m, 1H), 3.96–4.05 (m, 3H), 5.39 y 5.49 (dos m, 1H), 7.17 (s, 1H), 7.23–7.28 (m, 1H), 7.33–7.44 (m, 2H), 7.55 (d, 1H, J = 8 Hz), 7.84 (s, 1H)
1372
1–ciclohexil–2–(9–metoxi–5H –imidazo[5,1– a] isoindol–5–il)etanol 83
1H RMN (una mezcla de diastereómeros) (CD3OD) 1.05–1.11 (m, 1H), 1.13–1.33 (m, 4H), 1.58–1.81 (m, 5H), 2.01–2.08 (m, 1H), 3.57 y 3.67 (dos m, 1H), 3.95 (s, 3H), 5.40 y 5.47 (dos m, 1H), 6.81 y 6.83 (dos d, 1H, J = 8 Hz), 6.90 y 6.97 (dos d, 1H, J = 7.6 Hz), 7.04 y 7.05 (dos s, 1H), 7.12–7.17 (m, 1H), 7.92 y 7.99 (dos s, 1H).
1352
1–(2,5–dimetilfuran–3–il)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanol 81
1H RMN (una mezcla de diastereómeros)1.89–1.96, 2.37–2.45, 2.53–2.59, 2.77–2.83 (cuatro m, 2H), 2.11, 2.17 (s, 3H), 2.20, 2.22 (dos s, 3H), 4.79–4.88 (m, 1H), 5.36–5.68, 5.63–5.64 (dos m, 1H), 5.94, 5.97 (dos s, 1H), 6.87–6.97 (m, 1H), 7.15, 7.21 (dos s, 1H), 7.32–7.38 (m, 2H), 7.74, 7.88 (dos s, 1H)
1393
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)– 1–(furan–2–il)etanol 88
1H RMN (una mezcla de diastereómeros 2.36–2.43 (dos m, 1H), 2.77–2.80, 2.92– 2.98 (dos m, 1H), 3.72 (d, 1H, J = 11.0 Hz), 5.02–5.08 (m, 1H), 5.39–5.40, 5.67–5.69 (dos m, 1H), 6.27 (t, 1H, J = 6.4 Hz), 6.31 (s, 1H), 6.93 (s, 1H, J = 9.2 Hz), 7.08 (d, 1H, J = 12.2 Hz), 7.26–7.36 (m, 2H), 7.77, 7.86 7.86 (dos s, 1H)
1394
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1–metil–1H–imidazol–2–il)etanol 81
1H RMN (una mezcla de diastereómeros 2.81–2.85, 2.99–3.15 (tres m,2H), 3.69 (s, 3H), 5.00–5.08 (m, 1H), 5.38–5.40 5.67–5.69 (dos m, 1H), 6.77 (s, 1H), 6.79 (s, 1H), 6.91 (t, 1H, J = 8.9 Hz), 7.07 (s, 1H), 7.28–7.33 (m, 2H), 7.79 (s, 1H)
1390
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazo 1–4–il)etanol 34
1H RMN (una mezcla de diastereómeros 2.49–2.58, 2.68–2.82 (m, 2H),5.23–5.53 (m, 2H), 7.11 (s, 1H), 7.21 (s, 1H), 7.25–7.28 (m, 1H, superpuesto con CHCl3), 7.37(t, 1H, J = 7.5 Hz), 7.47–7.54 (m, 2H), 7.74 (s, 1H), 8.79 (s, 1H)
1407
imagen87 1–(4,4–difluorociclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol 61
1H RMN (una mezcla de diastereómeros )1.26–1.36 (m, 3H), 1.63–1.97 (m, 5H), 2.02–2.08 (m, 3H), 3.69– 3.72 (m, 1H), 5.02 y 5.12 (dos d, 1H, J = 6.0 Hz), 5.34–5.53 y 5.41– 5.43 (dos m, 1H), 7.10 y 7.12 (dos s, 1H), 7.25 (t, 1H, J = 7.4 Hz), 7.36 (t, 1H, J = 7.4 Hz), 7.54–7.58 (m, 2H), 7.91 y 7.93 (dos s, 1H
1406
1–(4,4–difluorociclohexil)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanol 78
1H RMN (una mezcla de diastereómeros) (DMSO–d6): 1.21–1.29 (m, 3H), 1.56–1.72 (m, 4H), 1.88–1.96 (m, 3H), 2.28 y 2.32 (dos t, 1H, J = 5Hz), 3.41–3.44 y 3.62–3.65 (dos m, 1H), 4.73 y 5.17 (dos d, 1H, J = 8.2 Hz), 5.56–5.59 y 5.61–5.64 (dos m, 1H), 7.03–7.17 (m, 2H), 7.39–7.44 (m, 2H), 7.91 y 7.95 (dos s, 1H)
1414
1–(ciclohex–3–enil)–2–(6–fluoro– 5Himidazo[5,1–a]isoindol–5–il)etanol 74
1H RMN (una mezcla de diastereómeros)1.21–1.42 (m, 2H), 1.62–1.83 (m, 4H), 1.93–2.15 (m, 7H), 2.30– 2.44 (m, 1H), 2.6 (br s , 1H), 3.67–3.72 (m, 1H), 3.77–3.82 (m, 1H), 5.49 (q, 1H, J= 5.3 Hz), 5.64–5.70 (m, 3H), 6.92–6.96 (m, 2H), 7.16–7.19 (m, 2H), 7.31–7.38 (m, 3H), 7.77–7.79 (m, 1H), 7.88 (d, 1H, J = 3.6 Hz), 7.91 (s, 1H)
1386
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilenociclohexil)etanol 70
1H RMN (una mezcla de diastereómeros)1.11–1.20 (m, 2H), 1.49–1.55 (m, 1H), 1.74–1.78 (m, 1H), 1.90– 2.10 (m, 4H), 2.16–2.23 (m, 1H), 2.31–2.38 (m, 2H), 3.74–3.77 y 3.80–3.85 (dos m, 1H), 4.62 (d, 2H, J = 0.8 Hz), 5.37 y 5.48(t y dd, 1H, J = 6 Hz y J = 3 Hz, 10.4 Hz), 7.18 (s, 1H), 7.23 (dd, 1H, J= 1.2 Hz, 7.6 Hz), 7.37 (t, 1H, J = 7.6 Hz), 7.43 (d, 1H, J = 7.6 Hz), 7.55 (d, 1H, J = 7.6 Hz), 7.77 y 7.79 (dos s, 1H)
1381
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1,4–dioxaspiro[4.5]decan–8–il)etanol 90
1H RMN (una mezcla de diastereómeros) (CD3OD) 1.20–2.00 (m, 2H), 1.38–1.60 (m, 1H), 1.70–1.80 (m, 1H), 1.87–2.09 (m, 6H), 3.30–3.34 y 3.53–3.78 (dos m, 1H), 5.56–5.58 y 5.69–5.71 (dos m, 1H), 7.00–7.04 (m, 1H), 7.42 y 7.62 (m y s, 2H), 7.93 y 8.00 (dos s, 1H)
1387
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–metilciclohexil)etanol 68
1H RMN (una mezcla de diastereómeros)0.81–0.95 (m, 3H), 1.20–1.83 (m, 10H), 1.85–2.03 (m, 1H), 2.35–
2.52 (m, 1H), 3.45–3.80 (m, 1H), 5.50–5.60 y 5.65–5.71 (dos m, 1H), 6.98–7.06 (m, 1H), 7.14 y 7.18 (dos s, 1H), 7.30–7.42 (m, 2H), 7.93 y 7.98 (dos s, 1H)
1398
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–(yodometileno)ciclohexil)etanol 77
1H RMN (una mezcla de diastereómeros)0.92–1.45 (m, 2H), 1.54–1.76 (m, 2H), 1.80–2.11 (m, 3H), 2.33– 3.10 (m, 4H), 3.59–3.90 (m, 1H), 4.60 (s, 1H), 5.45–5.81 (m, 1H), 6.91–6.95 (m, 1H), 7.16 (s, 1H), 7.26–7.31 (m, 2H), 7.81–7.83 (m, 1H)
1413
2–(9–fluoro–5H–imidazo[5,1–a]isoindol–5– il)– 1–(4–metilciclohexil)etanol 35
1H RMN (una mezcla de diastereómeros) (CD3OD) 0.75–0.96 (m, 3H), 1.00–1.25 (m, 1H), 1.28–1.74 (m, 9H), 2.01–2.14 (m, 2H), 3.67–3.80 (m, 1H), 5.49–5.59 (m, 1H), 7.10–7.18 (m, 2H), 7.60–8.00 (m, 1H)
1411
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(4–(propan–2–ilideno)ciclohexil )etanol 77
1H RMN (una mezcla de diastereómeros)1.01–1.06 (m, 2H), 1.46–1.57 (m, 2H), 1.63 (s, 6H), 1.68–1.75 (m, 2H), 1.82–1.96 (dos m, 1H), 2.03–2.11 (m, 1H), 2.32–2.39 (dos m , 1H), 2.45–2.51 y 2.66–2.75 (dos m, 2H), 3.65–3.75 (m, 1H), 5.44–5.65 (dos m, 1H), 6.91 (t, 1H, J = 8.7 Hz),7.16 y 7.17 (dos s, 1H), 7.28–7.36 (m, 2H), 7.80 y 7.87 (dos s, 1H)
1410
1–(4–(ciclopropilmetileno)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol 75
1H RMN (una mezcla de diastereómeros)0.24 (s, 2H), 0.65 (d, 2H, J = 7.4 Hz), 1.12–1.20 (m, 2H), 1.44–1.54 (m, 2H), 1.71–2.03 (m, 6H), 2.34–2.54 (dos m ,1H), 2.72–2.84 (m, 1H), 3.63–3.80 (m, 1H), 4.48 (d, 1H, J = 9.0 Hz), 5.43–5.67 (dos m, 1H), 6.81–6.94 (m, 1H), 7.15 (s, 1H), 7.15–7.30 (m, 3H), 7.80 y 7.88 (dos s, 1H)
1392
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2,2– dimetilpropan–1–ona 77
1H RMN (una mezcla de diastereómeros)1.24 (s, 9H), 1.28 (m, 2H), 1.60 (m, 2H), 2.13–1.86 (m, 3H), 2.70 (m, 2H), 3.78 (m, 1H), 4.46 (m, 2H), 5.53 y 5.38 (dos m, 1H), 7.12 (s, 1H), 7.21 (m, 1H), 7.33 (m, 1H), 7.42 (d, 1H, J = 7.5 Hz), 7.52 (d, 1H, J = 7.5 Hz), 7.81 y 7.79 (dos s, 1H),
1409
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–(1–metil–1H–imidazo 1–5–il)etanol 44
1H RMN (una mezcla de diastereómeros)1.92–2.42 (tres m, 1H), 2.72–3.10 (tres m, 1H), 3.72 (s, 3H), 4.90– 5.10 (tres m, 1H), 5.42–5.76 (tres m, 1H), 6.77–6.92 (m, 2H), 7.07 y 7.13 (dos s, 1H), 7.25–7.37 (m, 3H), 7.82, 7.88 y 7.94 (tres s, 1H)
1389
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– metil–1H–imidazol–4–il)etanol 94
1H RMN (una mezcla de diastereómeros)2.01, 2.51, 2.67 (tres m, 2H), 3.61 (s, 3H), 5.09 y 5.00 (dos m, 1H), 5.53 y 5.33 (dos m, 1H), 6.75 y 6.70 (dos s , 1H), 7.11 (s, 1H), 7.25–7.16 (m, 2H), 7.32 (m, 1H), 7.37 (s, 1H), 7.49 (t, 1H, J = 7.80 Hz), 7.88 y 7.67 (dos s, 1H),
1391
imagen88 2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (tiazol–5–il)etanol 75
1H RMN (una mezcla de diastereómeros)1.84, 2.03, 2.45, 2.51, 2.66, (cinco m, 2H), 5.29 5.41, 5.55 (tres m, 2H), 7.06–7.28 (m, 2H), 7.37 (t, 1H, J = 7.5 Hz), 7.41 (d, 1H, J = 7. 5Hz), 7.52 (d, 1H, J = 7.5 Hz), 7.71, 7.73 (dos s, 1H), 7.83 (s, 1H), 8.70, 8.71 (dos s, 1H),
1385
imagen89 1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)etanona 93
1H RMN (una mezcla de diastereómeros) 1.28 (m, 2H), 1.62 (m, 2H), 1.83 (m, 1H), 2.04 y 2.06 (dos s, 3H), 2.19 (m, 1H), 2.47 (t, 1H, J = 12.4 Hz), 3.00 (t, 1H, J = 13.1 Hz), 3.74 (m, 1H), 3.84 (t, 1H, J = 15.5 Hz), 4.68
(d, 1H, J = 14.6 Hz), 5.37 y 5.51 (dos m, 1H), 7.15 (s, 1H), 7.23 (m, 1H), 7.39 (m, 2H), 7.54 (d, 1H, J = 7.5 Hz), 7.80 (s, 1H)
1384
(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)piperidin–1–il)(tiofen–2–il)metanona 72
1H RMN (una mezcla de diastereómeros)1.39 (m, 2H), 1.66 (m, 2H), 2.07 (m, 1H), 2.17 (m, 1H), 2.89 (m, 2H), 3.76 (m, 1H), 5.37 y 5.51 (m, 1H), 7.01 (t, 1H, J= 4.3 Hz), 7.16 (s, 1H), 7.24 (m, 2H), 7.31–7.40 (m, 3H), 7.54 (d, 1H, J = 7.6 Hz), 7.81 (s, 1H)
1405
1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindo1–5–il)etil)piperidin–1–il)–2– feniletanona 68
1H RMN (una mezcla de diastereómeros)1.00–2.25 (m, 6H), 2.47 (t, 1H, J = 9.8 Hz), 2.47 (t, 1H, J = 9.8 Hz), 2.89 (t, 1H, J = 12.0 Hz), 3.70 (m, 3H), 3.90 (t, 1H, J = 12.6 Hz), 3.90 (t, 1H, J = 12.3 Hz), 5.25–5.50 (m, 1H), 7.10–7.30 (m, 9H), 7.36 (t, 1H, J = 9.6 Hz), 7.53 (d, 1H, J = 7.8 Hz)
1404
1–ciclohexil–3–(5H–imidazo[5,1–a]iso indo 1–5–il)propan–2–ol 85
1H RMN (una mezcla de diastereómeros)0.80–1–85 (m, 14H), 2.00–2.20 (m, 1H), 4.20–4.50 (m, 1H), 5.30– 5.60 (m, 1H), 7.14 (s, 1H), 7.20–7.39 (m, 2H), 7.43 (d, 1H, J = 7.2 Hz), 7.43 (d, 1H, J = 7.2 Hz), 7.91 (s, 1H)
1403
1–ciclohexil–3–(6–fluoro–5H–imidazo[5,1–a] isoindo1–5–il)propan–2–ol 55
1H RMN (una mezcla de diastereómeros)0.55–1.75 (m, 13H), 2.00–2.50 (m, 2H), 3.75–4.10 (m, 1H), 5.30– 5.75 (m, 1H), 6.85–7.00 (m, 1H), 7.10–7.25 (m, 2H), 7.25–7.40 (m, 2H), 7.93 (s, 1H)
1419
imagen90 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol– 5–ilideno)etanol 72
1H RMN mezcla de isómeros E/Z: 1.15–1.30 (m, 10H), 1.66–1.83 (m, 10H), 2.00–2.12 (m, 2H), 4.56 (t, 1H, J = 6.4 Hz), 4.66 (d, 1H, J = 7.4 Hz), 6.02 (d, 1H, J = 8.3 Hz), 6.76 (s, 1H), 7.07 (s, 1H), 7.33–7.48 (m, 4H),
7.56 (d, 2H, J = 7.8 Hz), 7.82 (s, 1H), 7.98 (d, 1H, J = 7.9 Hz), 8.04 (s, 1H), 8.42 (s, 1H).
1426
(trans)–metil 4–((1R)–1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5– il)etil)ciclohexanocarboxilato 87
1H RMN (una mezcla de diastereómeros) 1.05 – 1.20 (m, 2H), 1.42 (qt, J = 12.7, 4.0 Hz, 3H), 1.63 – 1.82 (m, 1H), 1.92 – 2.10 (m, 4H), 2.11 – 2.31 (m, 2H), 3.65 (s, 3H), 3.72 – 3.83 (m, 1H), 5.36 (t, J= 6.2 Hz, 0.7H), 5.52 (dd, J = 10.8, 3.1 Hz, 0.3H), 7.14 (s, 1H), 7.23 (t, J = 7.4 Hz, 1H), 7.31 – 7.40 (m, 1H), 7.42 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.83 (s, 1H)
1438
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (espiro[2.5]octan–6–il)etanol 46
1H RMN (una mezcla de diastereómeros) 0.14–0.28 (m, 4H), 0.89 (t, 2H, J = 12.0 Hz), 1.19–2.938(m, 9H), 2.81 (br s, 1H), 3.80–3.82 (m, 1H), 5.36–5.39 y 5.50–5.53 (dos m, 1H), 7.16 (s, 1H), 7.21–7.25 (m, 1H), 7.33 (t, 1H, J = 7.6 Hz), 7.44 (d, 1H, J = 7.6 Hz), 7.53 (d, 1H, J = 7.6 Hz), 7.80 y 7.81 (dos s, 1H)
1475
(trans)–4–(2–(6–fluoro–5H–imidazo[5,1–a] isoindol–5–il)–1–hidroxietil)ciclohexanol 92
1H RMN (una mezcla de diastereómeros) 1.07–2.52 (m, 11H), 3.48–3.68 (dos m, 2H), 5.45 (t, 1H, J = 6.0 Hz), 5.65 (dd, 1H, J = 9.0, 3.0 Hz), 6.89–6.96 (m, 1H), 7.16 (s, 1H), 7.29–7.38 (m, 2H), 7.80 y 7.88 (dos s, 1H)
1499
(1R)–1–((trans)–4–(benciloxi)ciclohexil)–2– (6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)etanol 65
1H RMN (una mezcla de diastereómeros) 1.04–1.33 (m, 5H), 1.71–2.32 (m, 5H), 2.75–2.51 (dos m, 1H), 3.24–3.29 (m, 1H), 3.65–3.69 (m, 1H), 4.54 (s, 2H), 5.43 (t, 1H, J =4.7 Hz, isómero), 5.65 (dd, 1H, J = 10.4, 2.4 Hz, isómero), 6.92 (t, 1H, J = 8.8 Hz), 7.14 (s, 1H), 7.26–7.33 (m, 7H), 7.79 y 7.88 (dos s, 1H)
1498
(1R)–1–((trans)–4–(benciloxi)ciclohexil)–2– (5H–imidazo[5,1–a]isoindol–5–il)etanol 78
1H RMN (una mezcla de diastereómeros) 1.15–2.20 (m, 11H), 3.22–3.31 (m, 1H), 3.65–3.75 (m, 1H), 4.48 y 4.54 (dos s, 2H), 5.35 (t, 1H, J = 8.0 Hz, isómero), 5.48 (dd, 1H, J = 16.0, 4.0 Hz, isómero), 7.15–7.55 (m,
10H), 7.77 y 7.79 y 7.81 (tres s, 1H)
1492
N–((cis)–4–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)ciclohexil)benzamida 63
1H RMN (una mezcla de diastereómeros) (CD3OD) 1.27–1.46 (m, 5H), 1.79 (d, 1H, J = 12.0 Hz), 2.04–2.22 (m, 5H), 3.78–3.88 (m, 2H), 5.47–5.49 y 5.53–5.54 (dos m, 1H), 7.16 y 7.19 (dos s, 1H), 7.35 (t, 1H, J = 7.4 Hz), 7.42–7.49 (m, 3H), 7.53 (d, 1H, J = 7.2 Hz), 7.59 (d, 1H, J = 7.6 Hz), 7.64 (d, 1H, J = 7.6 Hz), 7.82 (d, 2H, J = 7.6 Hz), 7.97 y 8.01 (dos s, 1H)
1505
N–((trans)–4–(1–hidroxi–2–(5H–imidazo[5,1– a] isoindol–5–il)etil)ciclohexil)benzamida 57
1H RMN (una mezcla de diastereómeros) 1.14–1.45 (m, 4H), 1.74 (d, 1H, J = 10.6 Hz), 1.97 (d, 1H, J = 10.6 Hz), 2.09–2.20 (m, 4H), 3.71–3.82 (m, 1H), 3.85–3.95 (m, 1H), 5.3–5.40 y 5.48–5.59 (dos m, 1H), 6.03 (d, 1H, J = 7.6 Hz), 7.17 (s, 1H), 7.21–7.30 (m, 1H, condensado con cloroformo), 7.31–7.51 (m, 5H), 7.55 (d, 1H, J = 7.4 Hz), 7.74 (d, 2H, J = 7.6 Hz), 7.83 (s, 1H)
1441
1–(4–(2–hidroxietilideno)ciclohexil)–2– (5Himidazo[5,1–a]isoindol–5–il)etanol 59
1H RMN (una mezcla de diastereómeros) 1.00–1.30 (m, 2H), 1.40–1.60 (m, 1H), 1.62–1.81 (m, 2H), 1.82– 2.13 (m, 3H), 2.60–2.75 (m, 1H), 3.60–3.75 (m, 1H), 3.90–4.10 (m, 2H), 5.25–5.31 (m, 1H), 5.33–5.48 (m, 1H), 7.13 (s, 1H), 7.20–7.43 (m, 2H), 7.46–7.60 (m, 2H), 7.97 (s, 1H)
1460
tert–butil 3–(1–hidroxi–2–(5H–imidazo[5,1–a] isoindol–5–il)etil)azetidina–1–carboxilato 43
1H RMN (una mezcla de diastereómeros) 1.42 (s, 9H), 1.92–2.23 (m, 2H), 2.50–2.63 (m, 1H), 3.61–3.80 (m, 2H), 3.90–4.02 (m, 3H), 4.20–4.58 (br, 1H), 5.33–5.41 y 5.52–5.58 (dos m, 1H), 7.13 (s, 1H), 7.21–7.28 (m, 1.58H), 7.30–7.39 (m, 1.33H), 7.41–7.48 (m, 0.8H), 7.58 (d, J = 14.3 Hz, 1H), 7.93 y 7.99 (dos s, 1H)
1502
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–2–il)etanol 82
1H RMN (una mezcla de diastereómeros) 2.25–2.33 (m, 2H), 5.06–5.07 (m, 1H), 5.09 (br s, 1H), 5.35–5.38 y 5.46–5.49 (dos m, 1H), 7.02 (s, 1H), 7.13–7.24 (m, 4H), 7.44–7.48 (m, 2H), 7.57–7.62 (m, 2H), 8.46–8.47
(m, 1H)
1474
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–3–il)etanol 69
1H RMN (una mezcla de diastereómeros) 1.75–2.43 (m, 2H), 5.07–5.12 (m, 1H), 5.38–5.40 y 5.56–5.58 (dos m, 2H), 6.98 y 7.11 (dos s, 1H), 7.19–7.33 (m, 3H), 7.43–7.49 (m, 2H), 7.43–7.79 (m, 2H), 8.3–8.51 (m, 2H)
1501
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–4–il)etanol 30
1H RMN (una mezcla de diastereómeros) 1.98–2.32 (m, 2H), 3.59 (br, 1H), 5.03–5.06 (m, 1H), 5.42–5.45 y 5.56–5.58 (dos m, 1H), 7.20–7.23 (m, 1H), 7.24–7.25 (m, 4H), 7.34 (t, J = 7.0 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 8.44–8.46 (m, 2H)
1509
2–(5H–imidazo[5,1–a]isoindol–5–il)– 1–(4– (trifluorometil)ciclohexil)etanol 69
1H RMN (una mezcla de diastereómeros) 1.53–2.22 (m, 12H), 3.92–3.98 (m, 1H), 4.12 (br s, 1H), 5.39–5.43 y 5.50–5.60 (dos m, 1H), 7.14 (s, 1H), 7.23–7.54 (m, 5H), 7.94 (s, 1H)
1508
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)– 1–(4–(trifluorometil)ciclohexil)etanol 61
1H RMN (una mezcla de diastereómeros) 1.40–1.70 (m, 7H), 1.70–1.90 (m, 2H), 1.91–2.04 (m, 1H), 2.09– 2.28 (m, 1H), 2.38–2.48 (m, 1H), 3.80–3.98 (br, 2H), 5.43–5.71 (dos m, 1H), 6.91–6.94 (m, 1H), 7.14 (s, 1H), 7.29–7.38 (m, 2H), 7.93 y 7.97 (dos s, 1H)
1473
1–((cis)–4–(benciloxi)ciclohexil)–2–(6–fluoro– 5H–imidazo[5,1–a]isoindol–5–il)etanol 87
1H RMN (una mezcla de diastereómeros) 1.39–2.42 (m, 12 H), 3.39–3.78 (m, 2H), 4.47 y 4.48 (dos s, 2H), 5.44 (t, 1H, J = 5.1 Hz), 5.67 (dd, 1H, J = 10.2, 2.8 Hz), 6.88–6.94 (m, 1H), 7.25–7.36 (m, 8H), 7.80, 7.82, 7.88 y 7.90 (cuatro s, 1H)
imagen91
imagen92
A un vial que contiene sal de amina apropiada obtenida del Ejemplo 27 (0.25 mmol) en DMF (4 mL) se le adicionó el correspondiente ácido carboxílico (0.26 mmol), DIPEA (1.5 mmol) y HATU (0.28 mmol). La mezcla de reacción se agitó a rt, durante 18 h y se vertió en agua (10 mL) y la capa acuosa se extrajo con diclorometano (2 x 20 mL). Las capas orgánicas combinadas se lavaron con agua (2 x 10 mL), se secaron sobre Na2SO4, y se concentró. El producto en bruto se purificó por cromatografía en columna instantánea para proporcionar 1423, 1424, 1425, 1437, 1439, 1448, 1450, 1458, 1480, 1481, 1490, 1493 o 1500.
imagen93
10 A un vial que contiene sal de amina apropiada obtenida del Ejemplo 19 (0.25 mmol) en diclorometano (4 mL) se le adicionó DIPEA (1.0 mmol) y fenilisocianato (0.25 mmol). La mezcla de reacción se agitó a rt, durante 30 min y se concentró. El residuo se disolvió en diclorometano (30 mL) y se lavó con agua (3 x 10 mL). La capa orgánica se secó sobre Na2SO4 y se concentró. El producto en bruto se purificó por cromatografía en columna instantánea para proporcionar ureas 1449, 1459, 1476, 1477, 1478 y 1479.
15 Ejemplo 30 Procedimiento general para la síntesis de 1495, 1496, 1497, 1503, 1504, 1507, 1512.
imagen94
A una solución de la amina (0.3 mmol) apropiada en CH2Cl2 (3 mL) se le adicionó carbonildiimidazol (0.35 mmol) y etil diisopropilamina (2.0 mmol) a 0 °C con una atmósfera de N2 y la mezcla se agitó durante 1 h. La sal de amina apropiada obtenida del Ejemplo 19 (0.25 mmol) se le adicionó y la mezcla se dejó agitar durante la noche. La solución se sometió
20 a partición con agua en un embudo de separación y la capa orgánica se recolectó. La capa acuosa se extrajo con diclorometano (3 x 10 mL) y las fracciones orgánicas combinadas se secaron (Na2SO4). El producto en bruto se purificó por cromatografía en columna instantánea para proporcionar 1495, 1496, 1497, 1503, 1504 o 1507.
imagen95
1423
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– (pirimidin–5–il)etanona 76
1H RMN (una mezcla de diastereómeros) 1.30–1.41 (m, 3H), 1.63–1.72 (m, 2H), 1.87–2.22 (m, 2H), 2.56 (t, 1H, J = 12.4 Hz), 3.01–3.15 (m, 2H), 3.67 (d, 1H, J = 6.0 Hz), 3.83–3.85 (m, 1H), 3.96 (t, 1H, J = 14.6 Hz), 4.66 (t, 1H, J = 14.6 Hz), 5.44–5.46 y 5.62–5.65 (dos m, 1H), 7.17 y 7.19 (dos s, 1H), 7.26–7.30 (m, 1H, condensado con cloroformo), 7.39 (t, 1H, J = 7.4 Hz), 7.46 (d, 1H, J = 7.6 Hz), 7.56 (d, 1H, J = 7.2 Hz), 8.14 (d, 1H, J = 13.2 Hz), 8.63 (d, 2H, J = 4.4 Hz), 9.08–9.10 (m, 1H)
1424
2–(3,4–difluorofenil)–1–(4–(1–hidroxi–2–(5H– imidazo[5,1–a] isoindol–5–il)etil)piperidin–1– il)etanona 71
1H RMN (una mezcla de diastereómeros) 1.16–1.33 (m, 2H), 1.61–1.64 (m, 3H), 1.84–1.92 (m, 1H), 2.09– 2.15 (m, 1H), 2.53 (t, 1H, J = 12.8 Hz), 2.98 (t, 1H, J = 12.8 Hz), 3.67 (d, 2H, J = 4.0 Hz), 3.76–3.78 (m, 1H), 3.90 (t, 1H, J = 13.6 Hz), 4.19 (br s, 1H), 4.70 (t, 1H, J = 13.6 Hz), 5.32–5.36 y 5.49–5.53 (dos m, 1H), 6.94 (s, 1H), 7.06–7.13 (m, 2H), 7.14 (s, 1H), 7.24–7.30 (m, 1H), 7.34–7.42 (m, 2H), 7.56 (d, 1H, J = 6.8 Hz), 7.81–7.85 (m, 1H)
1425
ciclohexil(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)metanona 44
1H RMN (una mezcla de diastereómeros) 1.20–1.34 (m, 6H), 1.49–1.77 (m, 10H), 1.87–1.97 (m, 1H), 2.03– 2.08 (m, 1H), 2.16–2.20 (m, 1H), 2.46 (t, 2H, J = 12.0 Hz), 3.76–3.79 (m, 1H), 3.97 (t, 1H, J = 16.2 Hz), 4.70 (t, 1H, J = 14.2 Hz), 5.38–5.41 y 5.51–5.56 (dos m, 1H), 7.15 (s, 1H), 7.23–7.27 (m, 1H, condensado con cloroformo), 7.37 (t, 1H, J = 7.8 Hz), 7.44 (d, 1H, J = 7.6 Hz), 7.54 (d, 1H, J = 7.6 Hz), 7.79 y 7.82 (dos s, 1H)
1437
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– (136piridin–4–il)etanona 49
1H RMN (una mezcla de diastereómeros) 1.08–1.16 (m, 1H), 1.23–1.33 (m, 1H), 1.57–1.65 (m, 2H), 1.86 (t, 1H, J = 14.0 Hz), 1.99–2.17 (m, 2H), 2.52 (dt, 1H, J = 2.4, 12.8 Hz), 2.97 (dt, 1H, J = 4.0, 12.8 Hz), 3.70 (d, 2H, J = 7.2 Hz), 3.70–3.76 (m, 1H, condensado con doblete a 3.70), 3.83 (t, 1H, J = 13.8 Hz), 4.30 (br s, 1H), 4.69 (t, 1H, J = 14.0 Hz), 5.32–5.36 y 5.51–5.53 (dos m, 1H), 7.10 y 7.12 (dos s, 1H), 7.16–7.25 (m, 3H), 7.35–7.41 (m, 2H), 7.54 (d, 1H, J = 7.6 Hz), 7.76 (d, 1H, J = 4.4 Hz), 8.49–8.52 (m, 2H)
1439
imagen96 2–(4–fluorofenil)–1–(4–(1–hidroxi–2–(5H– imidazo[5,1–a] isoindol–5–il)etil)piperidin–1– il)etanona 80
1H RMN (una mezcla de diastereómeros) 1.08–1.13 (m, 1H), 1.23–1.30 (m, 1H), 1.54–1.63 (m, 2H), 1.78 y 1.86 (dos d, 1H, J = 13.0 Hz), 1.99–2.12 (m, 2H), 2.49 (dt, 1H, J = 2.4, 12.8 Hz), 2.93 (dt, 1H, J = 3.0, 12.8
Hz), 3.66 (d, 2H, J = 4.4 Hz), 3.71–3.73 (m, 2H, condensado con singlete amplio de OH), 3.90 (t, 1H, J = 15.2 Hz), 4.68 (t, 1H, J = 13.6 Hz), 5.30–5.37 y 5.47–5.50 (dos m, 1H), 6.94–7.00 (m, 2H), 7.13 (s, 1H), 7.15–7.20 (m, 2H), 7.22–7.31 (m, 1H, condensado con cloroformo), 7.35–7.41 (m, 2H), 7.54 (d, 1H, J = 7.6 Hz), 7.84 (d, 1H, J = 5.2 Hz)
1448
(3–fluoro–2–hidroxifenil)(4–(1–hidroxi–2– (5H–imidazo[5,1–a] isoindol–5– il)etil)piperidin–1–il)metanona 26
1H RMN 1.35–1.47 (m, 2H), 1.66–1.70 (m, 2H), 1.86–2.15 (m, 7H), 2.89 (m, 1H), 4.31 (br s, 1H), 5.43–5.47 y 5.53–5.59 (dos m, 1H), 6.78–6.84 (m, 1H), 6.99 (d, 1H, J = 7.6 Hz), 7.11 (t, 1H, J = 9.4 Hz), 7.19 (s, 1H), 7.33 (d, 1H, J = 7.2 Hz), 7.37–7.47 (m, 2H), 7.58 (d, 1H, J = 7.2 Hz), 8.03 y 8.13 (dos s, 1H)
1449
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)–Nfenilpiperidina–1–carboxamina 62
1H RMN (CD3OD) 1.33–1.43 (m, 2H), 1.59–1.71 (m, 2H), 1.92–1.95 (m, 1H), 2.10–2.22 (m, 2H), 2.87 (t, 2H, J = 11.8 Hz), 3.79–3.83 (m, 1H), 4.25 (t, 2H, J = 15.2 Hz), 5.48 y 5.52–5.55 (t, J = 6.0 Hz y m, 1H), 7.03 (t, 1H, J = 7.4 Hz), 7.16 y 7.19 (dos s, 1H), 7.28 (t, 2H, J = 8.0 Hz), 7.33–7.37 (m, 3H), 7.43 (t, 1H, J = 7.4 Hz), 7.62 (dd, 2H, J = 7.6, 21.6 Hz), 7.94 y 7.97 (dos s, 1H), 8.01 (s, 1H)
1450
(4–fluorofenil)(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)metanona 29
1H RMN 1.29–1.37 (m, 3H), 1.57–1.87 (m, 3H), 2.18–2.36 (m, 2H), 3.73–3.86 (m, 4H), 4.74 (br s, 1H), 5.44–5.49 y 5.58–5.63 (dos m, 1H), 7.08 (t, 2H, J = 7.2 Hz), 7.23 (s, 1H), 7.31–7.48 (m, 5H), 7.59 (d, 1H, J = 7.2 Hz), 8.20 y 8.27 (dos s , 1H)
1458
1–(3–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5– il)etil)azetidin–1–il)–2– feniletanona 55
1H RMN (una mezcla de diastereómeros)1.79–2.13 (m, 2H), 2.44–2.48 (m, 1H), 3.33–3.42 (m, 2H), 3.67– 3.93 (m, 2H), 3.97–4.04 (m, 2H), 4.12–4.19 (m, 1H), 5.23–5.31 y 5.34–5.42 (dos m, 1H), 7.08–7.37 (m, 9H), 7.46–7.48 (m, 1 H), 7.93 y 8.07 (dos d, J = 7.6 Hz, 1H)
1459
3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)–Nfenilazetidina–1–carboxamina 19
1H RMN (una mezcla de diastereómeros) 1.95–2.20 (m, 2H), 2.64–2.68 (m, 1H), 3.76–3.81 (m, 1H), 3.98– 4.10 (m, 4H), 5.43–5.46 y 5.51–5.57 (dos m, 1H), 6.97–7.14 (m, 1H), 7.22 y 7.24 (dos s, 1H), 7.26–7.38 (m, 3.3H), 7.40–7.42 (m, 3H), 7.57–7.62 (m, 1.7H), 7.99 y 8.00 (dos s, 1H)
1476
4–((S)–1–hidroxi–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina 67
1H RMN 1.32–1.41 (m, 2H), 1.51–1.57 (m, 1H), 1.61 (d, 1H, J = 12.4 Hz), 1.83 (d, 1H, J = 12.4 Hz), 2.00– 2.14 (m, 2H), 2.78 (t, 2H, J = 12.0 Hz), 3.74–3.76 (m, 1H), 4.15–4.18 (m, 2H), 4.42 (br s, 1H), 5.32 (t,1H, J = 6.0 Hz), 6.98 (t, 1H, J = 7.4 Hz), 7.15 (d, 2H, J = 14.4 Hz), 7.20–7.25 (m, 3H), 7.35–7.37 (m, 3H), 7.40 (d, 1H, J = 7.6 Hz), 7.52 (d, 1H, J = 7.6 Hz), 7.86 (s, 1H)
1477
4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1– a]isoindol–5– il)etil)–N–fenilpiperidina–1– carboxamina 78
1H RMN 1.15–1.61 (m, 6 H), 1.86 (d, 1H, J = 12.8 Hz), 2.17–2.22 (t, 1H, J = 11.2 Hz), 2.66–2.75 (m, 2H), 3.68–3.76 (m, 1H), 4.04–4.08 (m, 2H), 4.60 (br,2H), 5.47 (d, 1H, J = 8.8 Hz), 6.86–6.90 (t, 1H, J = 11.2 Hz), 6.94 (s, 1H), 7.09–7.31 (m, 7H), 7.45 (d, 1H, J = 7.2 Hz), 8.24 (s, 1H)
1478
imagen97 4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina 74
1H RMN 1.32–1.61 (m, 4H), 1.81 (d, 1H, J =12.5 Hz), 2.01–2.15 (m, 2H), 2.77 (t, 2H, J = 12.4 Hz), 3.68– 3.73 (m, 1H), 4.08–4.14 (m, 2H), 5.31 (t, 1H, J = 4.0 Hz), 6.92 (s, 1H), 6.97 (t, 1H, J = 6.0 Hz), 7.12 (s, 1H), 7.21–7.38 (m, 6H), 7.51 (d, 1H, J = 7.4 Hz), 7.87 (s, 1H)
1479
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5– il)etil)–N–fenilpiperidina–1– carboxamina 78
1H RMN 1.15–1.61 (m, 6 H), 1.86 (d, 1H, J = 12.8 Hz), 2.17–2.22 (t, 1H, J = 11.2 Hz), 2.66–2.75 (m, 2H), 3.68–3.76 (m, 1H), 4.04–4.08 (m, 2H), 4.60 (br,2H), 5.47 (d, 1H, J = 8.8 Hz), 6.86–6.90 (t, 1H, J = 11.2 Hz), 6.94 (s, 1H), 7.09–7.31 (m, 7H), 7.45 (d, 1H, J = 7.2 Hz), 8.24 (s, 1H)
1480
1–(4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)–2–feniletanona 82
1H RMN 1.0–2.14 (m, 8H), 2.46 (t, 1H, J = 12 Hz), 2.91 (t, 1H, J =12 Hz), 3.65–3.72 (m, 3H), 3.91 (t, 1H, J = 16 Hz), 4.71 (t, 1H, J = 12 Hz), 7.15–7.56 (m, 9H), 7.55 (d, 1H, J = 7.51 Hz), 7.91 (d, 1H, J = 7.7 Hz)
1481
1–(4–((S)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)–2–feniletanona 85
1H RMN 1.04–1.27 (m, 2H), 1.51–1.67 (m, 3H), 1.81–1.89 (m, 1H), 2.19–2.25 (m, 1H), 2.46–2.52 (m, 1H),
2.90 (t, 1H, J = 12.8 Hz), 3.66–3.74 (m, 3H), 3.90 (t, 1H, J = 16.0 Hz), 4.62–4.70 (m, 1H), 5.23 (br s, 1H), 5.49 (dd, 1H, J = 2.2, 10.2 Hz), 7.12 (s, 1H), 7.18–7.37 (m, 8H), 7.53 (d, 1H, J = 7.5 Hz), 7.92 (d, 1H, J = 3.0 Hz)
1490
1–(4–((S)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)–2–(tetrahidro–2H–piran–4–il)etanona 77
1H RMN (CD3OD) 1.06 –1.46 (m, 4H), 1.56 – 1.73 (m, 3H), 1.82 – 2.08 (m, 3H), 2.32 (t, J = 6.4 Hz, 2H), 2.39 (dd, J = 18.4, 7.2 Hz, 1H), 2.54 (t, J = 13.0 Hz, 1H), 3.03 (t, J = 12.9 Hz, 1H), 3.40 (t, J = 11.7 Hz, 2H), 3.48– 3.59 (m, 1H), 3.90 (d, J = 11.5 Hz, 2H), 3.94 – 4.06 (m, 1H), 4.57 (t, J = 14.8 Hz, 1H), 5.71 (d, J = 6.5 Hz, 1H), 7.41 –7.52 (m, 2H), 7.55 (d, J = 7.3 Hz, 1H), 7.73 (d, J = 7.1 Hz, 1H), 7.90 (s, 1H), 8.57 (s, 1H)
1493
1–(4–((S)–1–hidroxi–2–((R)–5H– imidazo[5,1–a]isoindol–5– il)etil)piperidin–1– il)–2–feniletanona 63
1H RMN 0.49–1.21 (m, 4H), 1.44–1.56 (m, 1H), 1.96–2.05 (m, 2H), 2.38–2.47 (m, 1H), 2.80–2.86 (m, 1H), 3.58–3.64 (m, 2H), 3.83 (t, J = 13.2 Hz, 1H), 4.62 (t, J = 13.2 Hz, 1H), 5.25–5.30 (m, 1H), 7.13–7.24 (m, 7H), 7.29–7.34 (m, 2H), 7.48 (d, J = 7.6 Hz, 1H), 7.94 (br s, 1H)
1495
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–((trans)–4– hidroxiciclohexil)piperidina–1–carboxamina 56
1H RMN (CD3OD) 1.21–1.43 (m, 7H), 1.48–1.66 (m, 2H), 1.81–2.01 (m, 5H), 2.14 (ddd, 2H, J = 4.4, 8.4, 10.4 Hz), 2.71 (t, 2H, J = 11.7 Hz), 3.49–3.55 (m, 2H), 3.74–3.79 (m, 1H), 4.08 (t, 1H, J = 13.6 Hz), 5.46 (t, 1H, J = 6.2 Hz), 7.16 (s, 1H), 7.34 (t, 1H, J = 7.5 Hz), 7.43 (t, 1H, J = 7.3 Hz), 7.57 (d, 1H, J = 7.6 Hz), 7.64 (d, 1H, J = 7.6 Hz), 8.00 (s, 1H)
1496
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5– il)etil)–N–(tetrahidro–2H–piran– 4–il)piperidina–1– carboxamina 84
1H RMN 1.16–1.74 (m, 6H), 1.78– 2.00 (m, 2H), 2.18 – 2.37 (m, 1H), 2.70 (t, J = 12.7 Hz, 2H), 3.33 – 3.51 (m, 2H), 3.71– 4.13 (m, 5H), 4.76 (d, J = 7.4 Hz, 1H), 5.54 (dd condensado con br s, J = 10.6, 2.3 Hz, 3H), 7.13 (s, 1H), 7.20 – 7.38 (m, 3H), 7.51 (d, J = 7.5 Hz, 1H), 7.90 (s, 1H)
1497
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–((trans)–4– hidroxiciclohexil)piperidina–1– carboxamina 65
1H RMN 1.08 – 1.44 (m, 6H), 1.57 (t, J = 12.5 Hz, 2H), 1.67 – 1.80 (m, 1H), 1.90 (dd, J = 24.8, 9.8 Hz, 4H), 2.29 (ddd, J = 14.3, 11.0, 3.1 Hz, 1H), 2.69 (t, J = 12.8 Hz, 2H), 3.35 (s, 1H), 3.49 (d, J = 4.4 Hz, 2H), 3.63– 3.77 (m, 1H), 3.95– 4.19 (m, 2H), 5.50 (dd, J = 9.7, 3.0 Hz, 1H), 6.05 (d, J = 7.8 Hz, 1H), 7.15 (s, 1H), 7.31 (td, J = 7.5, 1.0 Hz, 1H), 7.39 (t, J = 7.4 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.60 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H)
1500
1–(4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)–2–(tetrahidro–2H–piran–4–il)etanona 46
1H RMN 1.19–1.42 (m, 4H), 1.54–1.67 (m, 4H), 1.86–1.90 (m, 1H), 2.08–2.25 (m, 4H), 2.43–2.51 (m, 1H), 2.92–3.01 (m, 1H), 3.39 (t, 2H, J = 11.8 Hz), 3.72–3.76 (m, 1H), 3.90–3.99 (m, 3H), 4.70 (m, 1H, J = 9.75 Hz), 5.35–5.40 (m, 1H), 7.13 (s, 1H), 7.24–7.27 (m, 1H), 7.35–7.43 (m, 2H), 7.54 (d, 1H, J = 7.4 Hz), 7.80 (s, 1H)
1503
imagen98 4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5– il)etil)–N–(tetrahidro–2H–piran– 4–il)piperidina–1– carboxamina 77
1H RMN 1.29–1.33 (m, 1H), 1.41–1.47 (m, 2H), 1.51–1.61 (m, 1H), 1.62 (d, 1H, J = 12.7 Hz), 1.83 (d, 1H, J = 12.4 Hz), 1.91 (d, 2H, J = 12.4 Hz), 2.07–2.26 (m, 2H), 2.73 (t, 2H, J = 12.2 Hz), 3.46 (t, 2H, J = 10.8 Hz), 3.73–3.78 (m, 1H), 3.81–3.89 (m, 1H), 3.93–4.05 (m, 4H), 4.40 (d, 1H, J = 7.5 Hz), 4.61 (br s, 2H), 5.41 (t, 1H, J = 5.9 Hz), 7.18 (s, 1H), 7.24–7.30 (m, 1H, condensado con cloroformo), 7.39 (t, 1H, J = 7.5 Hz), 7.44 (d, 1H, J = 7.6 Hz), 7.56 (d, 1H, J = 7.6 Hz), 7.92 (s, 1H)
1504
N–ciclohexil–4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a] isoindol–5–il)etil)piperidina– 1–carboxamina 77
1H RMN 0.97–1.23 (m, 3H), 1.26–1.36 (m, 4H), 1.48–1.70 (m, 5H), 1.82 (d, J = 13.1 Hz, 1H), 1.93 (d, J = 10.3 Hz, 2H), 2.07 (ddd, J = 14.3, 6.8, 2.7 Hz, 1H), 2.14 – 2.27 (m, 1H), 2.70 (td, J = 12.8, 2.5 Hz, 2H), 3.57– 3.65 (m, 1H), 3.71 – 3.81 (m, 1H), 3.97 (t, J = 13.2 Hz, 2H), 4.31 (d, J = 7.6 Hz, 1H), 5.39 (t, J = 6.0 Hz, 1H), 7.16 (s, 1H), 7.24 (dd, J = 7.6, 1.0 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.80 (s, 1H)
1507
N–ciclopentil–4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a] isoindol–5–il)etil)piperidina– 1–carboxamina 87
1H RMN
1511
1–(4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)–2–(4–(trifluorometil)fenil)etanona 69
1H RMN 1.03 – 1.26 (m, 2H), 1.28 – 1.39 (m, 2H), 1.56 (q, J = 13.9, 13.1 Hz, 2H), 1.75 (d, J = 13.0 Hz, 1H), 1.91 – 2.10 (m, 2H), 2.45 (t, J = 13.4 Hz, 1H), 2.90 (t, J = 13.0 Hz, 1H), 3.68 (d, J = 6.5 Hz, 2H), 3.83 (t, J = 13.9 Hz, 1H), 4.59 (t, J = 11.5 Hz, 1H), 4.94 (br s, 1H), 5.35 (q, J = 6.6 Hz, 1H), 7.06 (d, J = 7.6 Hz, 1H), 7.21 – 7.40 (m, 5H), 7.42 – 7.56 (m, 3H), 8.16 (d, J = 17.3 Hz, 1H).
1512
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5– il)etil)–N–(4–(trifluorometil)fenil) piperidina–1– carboxamina 78
1H RMN 1.15–1.61 (m, 6 H), 1.86 (d, 1H,J = 12.8 Hz), 2.17–2.22 (t, 1H, J = 11.2 Hz), 2.66–2.75 (m, 2H), 3.68–3.76 (m, 1H), 4.04–4.08 (m, 2H), 4.60 (br,2H), 5.47 (d, 1H, J = 8.8 Hz), 6.86–6.90 (t, 1H, J = 11.2 Hz), 6.94 (s, 1H), 7.09–7.31 (m, 7H), 7.45 (d, 1H,J = 7.2 Hz), 8.24 (s, 1H)
1513
(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)(1H– imidazol–1–il)metanona 50
1H RMN 1.44–1.54 (m, 2H), 1.65–1.68 (m, 1H), 1.73 (d, 1H, J = 12.8 Hz), 1.98 (d, 1H, J = 13.0 Hz), 2.05– 2.14 (m, 1H), 2.18–2.25 (m, 1H), 2.99 (t, 2H, J = 12.0 Hz), 3.82–3.87 (m, 1H), 4.16 (t, 2H, J = 10.7 Hz), 4.80 (br s, 1H), 5.41 (t, 1H, J = 5.9 Hz), 7.07 (s, 1H), 7.14 (s, 1H), 7.18 (s, 1H), 7.24–7.28 (m, 1H, condensado con cloroformo), 7.38 (t, 1H, J= 7.5 Hz), 7.43 (d, 1H, J = 7.6 Hz), 7.55 (d, 1H, J = 7.6 Hz), 7.84 (s, 1H), 7.86 (s, 1H).

Ejemplo 31 1–(1–(bencilsulfonil)piperidin–4–il)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol
imagen99
5 A un vial que contiene 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(piperidin–4–il)etanol diclorhidrato (0.12 g, 0.34 mmol) en CH2Cl2 (3 mL) se le adicionó etil diisopropilamina (0.35 mL, 2.0 mmol) y bencil sulfonil cloruro (67 mg, 0.35 mmol). La mezcla de reacción se agitó a rt, durante 18 h y se concentró. El residuo se disolvió en diclorometano (30 mL) y se lavó con agua (3 x 10 mL). La capa orgánica se secó sobre Na2SO4 y se concentró. El producto en bruto se purificó por cromatografía en columna instantánea para proporcionar 1442 como un sólido de color blanco (85 mg, 58%).:1H RMN
10 (una mezcla de diastereómeros) 1.21–1.29 (m, 2H), 1.34–1.36 (m, 1H), 1.57–1.60 (m, 1H), 1.79–1.90 (m, 2H), 2.03–2.10 (m, 1H), 2.52–2.66 (m, 2H), 3.55–3.63 (m, 2H), 3.67–3.71(m, 1H), 4.38 (s, 2H), 5.03 y 5.14 (dos d, 1H, J = 6.0 Hz, OH),
5.39 (t, 1H, J = 6.8 Hz), 7.13 y 7.16 (dos s, 1H), 7.29 (t, 1H, J = 7.2 Hz), 7.37–7.42 (m, 6H), 7.60 (dd, 2H, J = 7.8, 14.2 Hz), 7.92 y 7.95 (dos s, 1H).
Ejemplo 32 ácido 2–(5H–imidazo[5,1–a]isoindol–5–il)acético
imagen100
imagen101
imagen102
imagen103
imagen104
A una solución de 86 (160 mg, 0.57 mmol) en EtOH (3 mL) a rt se le adicionó NH2OH acuoso al 50% (1.71 mmol) y la solución se agitó a 50 °C, durante la noche. Después de enfriar a rt, el solvente se eliminó a presión reducida y el producto en bruto se purificó por cromatografía en columna instantánea para proporcionar 1360 (120 mg, 71%). 1H RMN 0.99–1.15 (m, 5 H), 1.45–1.72 (m, 6 H), 2.43 y 2.58 (dos m, 1H), 2.70 y 2.91 (m, 1H), 4.69 (m, 1H), 7.23–7.29 (m, 3H),
7.40 y 7.46 (dos m, 1H), 7.53 y 7.58 (dos m, 1H), 7.75 y 7.76 (dos s, 1H), 10.34 y 10.41 (dos s, 1H).
imagen105
10 A una solución de 1360 (100 mg, 0.34 mmol) en EtOH/AcOH 1:1 (4 mL) se le adicionó polvo de zinc (67 mg, 1.0 mmol) y la mezcla se agitó durante la noche a rt. El solvente se eliminó a presión reducida y la mezcla se suspendió en MeOH/DCM 1:1 (10 mL) y se filtró. El filtrado se recolectó y se concentró a presión reducida. El producto en bruto se purificó por cromatografía de intercambio iónico utilizando agua y NH4OH como el eluyente para proporcionar 1364 (25 mg, 26%). 1H RMN (mezcla de diastereómeros) 0.89–1.75 (m, 11H), 2.24 y 2.42 (dos m, 1H), 2.62 (m, 1H), 4.52 (m,
15 1H), 7.09 (t, 1H, J = 9.2 Hz), 7.29 (m, 2H), 7.38 (m, 1H), 7.47 (m, 1H), 7.60 (d, 1H, J = 9.2 Hz).
Ejemplo 45 Procedimiento general para la eliminación del grupo protector BOC a partir de anilinas y aminas sustituidas
imagen106
A una solución de 17, 1300, 1328 o 1363 (66.0 mmol) en diclorometano (2 mL) se le adicionó ácido trifluoroacético (0.2 mL, 2.66 mmol) y la mezcla se agitó a rt, durante 2 h. Los solventes se separaron por destilación a presión reducida y la
20 solución se basificó con NaHCO3 saturado. La capa acuosa se extrajo con EtOAc (3 x 15 mL). Las capas orgánicas combinadas se lavaron con agua, salmuera y se secaron (Na2SO4). La solución se filtró y el solvente se eliminó a presión reducida. El residuo en bruto se purificó por cromatografía en columna para proporcionar los siguientes compuestos.
imagen107
1330
1–(2–aminofenil)–2–(5H imidazo[5,1– a]isoindol–5– il)etanona 76
1H RMN 3.40 (dd, 1H, J = 18.0 Hz, 9.6 Hz), 3.70 (dd, 1H, J = 18.0 Hz, 3.3 Hz), 5.81 (dd, 1H, J = 6.3 Hz, J = 3.3 Hz), 6.43 (br s, 2H), 6.60 (t, 1H, J = 7.5 Hz), 6.68 (d, 1H, J = 8.4 Hz), 7.18 (s, 1H), 7.29 (m, 2H), 7.36 (d, 2H, J = 7.8 Hz), 7.55 (d, 2H, J = 7.5 Hz), 7.74 (s, 1H)
1370
2–(5H–imidazo[5,1–a]isoindol–5–il)– 1– (piperidin–4–il)etanol 15
1H RMN (La mezcla de diastereómeros) 1.66–1.87 (m, 6 H), 2.20 (s, 1H), 2.75 (m, 2H), 3.40 (m, 2H), 3.84 (m, 2H), 5.27 y 5.34 (dos m, 1H), 7.05 (s, 1H), 7.19 (t, 1H, J = 4.0 Hz), 7.30 (t, 1H, J = 8.0 Hz), 7.38 (d, 1H, J = 8.0 Hz), 7.46 (d, 1H, J = 8.0 Hz), 8.06 y 8.12 (dos s, 1H)
1301
1–(4–aminofenil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanona 87
1H RMN 3.35 (dd, 1H, J =18.6 Hz, 9.6 Hz), 3.61 (dd, 1H, J = 18.6 Hz, 9.6 Hz), 4.13 (br s, 2H), 5.84 (dd, 1H, J =18.6 Hz, 9.6 Hz), 6.65 (d, 2H, J = 8.7 Hz), 7.18 (s, 1H), 7.24–7.29 (m, 1H), 7.37–7.58 (m, 3H), 7.74–7.82 (m, 3H)
1369
1–(3–aminofenil)–2–(5Himidazo[5,1– a]isoindol–5–il)etanol 58
(MeOH–d4) 2.32 (t, 2H, J = 6.3 Hz), 4.89–4.94 (m, 1H), 5.30 y 5.38 (dos m, 1H), 6.64 (d, 1H, J = 7.8 Hz), 6.71–6.77 (m, 2H), 7.05–7.10 (m, 1H), 7.28–7.41 (m, 2H), 7.51–7.58 (m, 2H), 7.66 (s, 1H)

Ejemplo 46 5–(2–Ciclohexil–2–hidroxietil)–5H–imidazo[5,1–a]isoindol–9–ol
imagen108
imagen109
imagen110
imagen111
imagen112
imagen113
imagen114
imagen115
imagen116
imagen117
imagen118
A una solución de 1304 (40 mg, 0.14 mmol) en THF (5 mL) se le adicionó trietilamina (43 µL, 0.31 mmol) seguido por fenilisocianato (17 µL, 0.16 mmol). La mezcla de reacción se agitó a rt, durante 18 h y se concentró. El producto en bruto se purificó utilizando cromatografía en columna instantánea (EtOAc:MeOH 4:1) para proporcionar 1427 como gel
5 incoloro (19 mg, 34%). 1H RMN (una mezcla de diastereómeros): 1.02–1.04 (m, 5H), 1.56–1.70 (m, 6H), 2.10–2.14 (m, 1H), 2.31–2.40 (m, 1H), 5.02–5.10 (m, 1H), 5.18–5.24 (m, 1H), 7.04–7.08 (m, 1H), 7.18–7.35 (m, 6H), 7.39–7.41 (m, 2H), 7.50 (d, J = 4 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 7.74 (s, 1H).
Ejemplo 69 Procedimiento general para la síntesis de profármacos de 1304
A un vial que contiene 1304 (0.5 mmol) en diclorometano (5 mL) se le adicionó el apropiado ácido carboxílico (1.1
10 mmol), diisopropiletil amina (3.0 mmol) y HATU (1.3 mmol). La mezcla de reacción se agitó a rt, durante 48 h y se vertió en NaHCO3 saturado acuoso (10 mL) y la capa acuosa se extrajo con diclorometano (2 x 20 mL). Las capas orgánicas combinadas se secaron sobre Na2SO4, y se concentró. El producto en bruto se disolvió en diclorometano (6 mL) y TFA (2 mL) se le adicionó. La mezcla de reacción se agitó a temperatura ambiente durante 2 h y se concentró. El residuo se disolvió en agua y se le adicionó K2CO3 sólido hasta que la solución fue básica. La solución acuosa se extrajo con
15 diclorometano (2 x 20 mL). Las capas orgánicas combinadas se secaron sobre Na2SO4, se filtraron y concentraron para proporcionar 1433, 1440, 1442 y 1443.
#
Compuesto Nombre Rendimiento (%)
1440
(2S)–1–ciclohexil– 2–(5H–imidazo[5,1– a]isoindol1–5– il)etil 2–aminopropanoato 87
1H RMN (una mezcla de diastereómeros) 0.96–1.06 (m, 2H), 1.09–1.19 (m, 3H), 1.27 y 1.30 (dos d, 3H, J = 7.0 Hz), 1.41–1.53 (m, 3H), 1.63–1.77 (m, 5H), 2.10–2.16 y 2.23–2.26 (dos m, 1H), 2.37–2.45 (m, 1H), 3.21 y 3.50 (dos q, 1H, J = 7.0 Hz), 4.86–4.90, 5.06–5.09 y 5.15–5.17 (tres m, 2H), 7.19 (d, 1H, J = 3.2 Hz), 7.24– 7.27 (m, 1H, condensado con cloroformo), 7.37 (dt, 1H, J = 2.8, 7.6 Hz), 7.49–7.55 (m, 2H), 7.69 (s, 1H)
1442
(2S)–1–ciclohexil– 2–(5H–imidazo[5,1– a]isoindol–5– il)etil pirrolidina–2–carboxilato diclorhidrato 77
1H RMN (una mezcla de diastereómeros) (CD3OD) 0.90–1.17 (m, 5H), 1.4–1.75 (m, 10H), 2.11–2.18 (m, 2H), 2.36–2.42 (m, 1H), 2.82 (br s, 1H), 2.89–3.0 (m, 2H), 3.54–3.60 y 3.72–3.75 y 3.81–3.83 (tres m, 1H), 4.93–5.25 (cuatro m, 2H), 7.16 (s, 1H, J = 3.6 Hz), 7.22–7.16 (m, 1H), 7.35 (t, 1H, J = 7.40 Hz), 7.48–7.52 (m, 2H), 7.69 (d, 1H, J = 8.40 Hz)
1443
(2S)–5–(1–ciclohexil– 2–(5H–imidazo[5,1– a]isoindol–5–il)etil) 1–metil 2– aminopentanodioato diclorhidrato 73
1H RMN (una mezcla de diastereómeros) (DMOS–d6) 0.85–0.88 (m, 2H), 1.02–1.12 (m, 3H), 1.34–1.38 (m, 1H), 1.53–1.67 (m, 5H), 2.14–2.20 (m, 2H), 2.60–2.73 (m, 2H), 3.41–3.53 (m, 2H), 3.74 y 3.87 (dos s, 3H), 4.44–4.52 (m, 1H), 5.81–5.3 (m, 1H), 7.50–7.53 (m, 2H), 7.69–7.70 (m, 1H), 7.81–7.72 (m, 1H), 7.95 (d, 1H, J = 6.4 Hz), 8.66 (br s, 3H), 9.52 (s, 1H)
1433
(2S)–1–(1–ciclohexil–2–(5H–imidazo[5,1–a] isoindol–5– il)etoxi)–3–metil–1–oxobutan–2– aminio cloruro clorhidrato 40
1H RMN (una mezcla de diastereómeros) (DMOS–d6) 0.86–0.98 (m, 6H), 1.01–1.12 (m, 4H), 1.42 y 1.44 (dos s, 9H), 1.58–1.87 (m, 6H), 2.0–2.16 (m, 2H), 2.33–2.43 (m, 1H), 4.04–4.07 y 4.08–4.15 (dos m, 1H), 4.91–5.29 (tres m, 3H), 7.17 (s, 1H), 7.21–7.28 (m, 2H), 7.31–7.40 (m, 2H), 7.70 (s, 1H)
Ejemplo biológico 1 clonación, expresión y purificación de proteína IDO humana
Los vectores de expresión para la proteína humana indolamina–2,3–dioxigenasa (IDO) se prepararon por amplificación
5 de un fragmento de 1219 pb de la secuencia presente en el vector phID06His ADNc con los cebadores 5’– ggagcatgctaATGGCACACGCTATGGAAAAC– 3’ y 5’–gagagatctACCTTCCTTCAAAAGGGATTTC–3’ y clonación del fragmento BglII–SphI de 1213 pb en pQE70 (Qiagen), para producir vector pQE70–hIDO. Esta construcción adiciona 2 aminoácidos adicionales y una etiqueta de 6–histidina en el extremo C–terminal de la proteína IDO humana natural mientras se conserva intacto el codón de iniciación natural y la secuencia de aminoácidos N–terminal. El alelo
10 amplificado de IDO humana muestra dos polimorfismos con respecto a la secuencia depositada en el catálogo inventario P14902 de base de datos SwissProt. Estos polimorfismos resultan en un cambio de aminoácidos de P110S y E119G.
El plásmido pQE70–hIDO se transformó en células M15 (pREP4) (Qiagen) y los clones se seleccionaron en placas de agar LB suplementado con 50 g/mL de carbenicilina y 30 g/mL de kanamicina. La expresión de proteínas se llevó a 15 cabo por el crecimiento de un cultivo durante la noche del clon/pQE70–hIDO M15pRep4 en 100 µL de LB suplementado con 100 g/mL de carbenicilina, 50 g/mL de kanamicina y 50 g/mL de (medio LBCKT) de L–triptófano. 40 mL de este cultivo se inocularon en 750 mL de LBCKT durante 4 horas a 37 °C. Este cultivo se diluyó 1:10 en medio LBCKT y se cultivaron durante otras 2 horas a 37 °C hasta que OD600 fue mayor que 0.8. En este punto, se inocularon los cultivos con hemina a 7 M y L–triptófano a 75 g/mL y se incubaron a 37 ºC, durante 2 h. La inducción de la expresión de la
20 proteína se llevó a cabo complementando los cultivos con IPTG a 1 mM, PMSF a 200 M, EDTA a 1 mM y L–triptófano a 50 g/mL. La incubación se continuó durante otras 16 h a 25 ºC. Las células se recogieron por centrifugación y los sedimentos celulares se lavaron con solución reguladora de PBS suplementada con PMSF 200 M y EDTA 1 mM y se almacenaron a –80 ºC hasta la purificación de proteínas.
imagen119
control negativo del ensayo. Las células incubadas en medio de inducción y sin inhibidor sirven como el control positivo del ensayo. La incubación se lleva a cabo durante 16 horas a 37 ºC en una incubadora de cultivo celular. 200 L de medio se transfieren a placas de polipropileno de 96 pozos de fondo en U que contienen 25 L de TCA al 30%, se incubaron 30 minutos a 60 ºC y se centrifugaron a 3400 g durante 5 minutos. 150 L del sobrenadante claro se transfiere a un placa de poliestireno de 96 pozos que contenía 50 L de 4% (p/v) de p–dimetilaminobenzaldehído en ácido acético, se incubaron durante 10 min. La concentración de quinurenina se determina midiendo la absorbancia a 480 nm.
Para medir la toxicidad de cada compuesto después de 16 h de incubación con las células, la viabilidad celular se mide mediante un ensayo de WST– 1 (Roche) de acuerdo con las instrucciones del fabricante. En resumen, después de la incubación con cada compuesto, el medio se aspiró y se reemplazó con 100 mL de reactivo WST–1, y se incubó 30 min a 37 ºC. La absorbancia a 540 nm se correlaciona con el número de células viables. La determinación de IC50 (ensayo quinurenina) o LD50 (ensayo WST–1) se lleva a cabo a través de análisis de regresión no lineal utilizando el software GraphPad Prism.
Ejemplo biológico 4 Inversión de la represión mediada por IDO de la proliferación de células T por inhibidores de IDO.
Los monocitos humanos fueron recogidos a partir de células mononucleares periféricas de leucoaféresis y cultivadas durante la noche a 106 células/pozo en una placa de 96 pozos en medio RPMI 1640 suplementado con suero de ternera fetal al 10% y L–glutamina 2 mM. Las células adherentes se conservan y se cultivaron durante 7 días con 200 ng/mL de IL–4, 100 ng/mL de GM–CSF. Las células se maduraron durante 2 días con un cóctel de citoquinas que contiene TNF– , IL–1, IL–6 y PGE2 durante 2 días adicionales para inducir la maduración de células dendríticas. Al final de la maduración, las células débilmente adherentes se separaron por aspiración suave y se sembraron en placas de 96 pozos de fondo en V, a 5000 células/pozo. Estas células son > 80% de IDO + células dendríticas. Las células humanas alogénicas T (3x105) de donantes normales se resuspendieron en RPMI 1640 suplementado con 100 a 200 U/mL de IL– 2 y 100 ng/mL de anticuerpo anti–CD3 y se adicionaron a los pozos. Se adicionaron diluciones en serie de compuestos IDO disueltos en RPMI libre de rojo de fenol para producir una concentración final de inhibidores de IDO entre 500 nM y 1 M. Después de la incubación durante 2–4 días, la proliferación de células T se midió por ensayo de incorporación de BrdU después de un pulso durante la noche con mezcla de marcación BrdU (Roche Molecular Biochemicals). Al final del pulso, las células se fijaron y se incubaron con anticuerpo anti–BrdU–POD 100 L/pozo siguiendo las instrucciones del fabricante. Las placas se leyeron en un lector de microplacas.
Alternativamente, el ensayo de los inhibidores de IDO en un modelo de ratón in vitro en la supresión mediada por IDO de proliferación de células T se realiza mediante el siguiente procedimiento. Los ratones C57B16 se inoculan con 1x106 células tumorales B78H1–GMCSF en el flanco derecho. Después de 10–12 días, el drenaje del tumor de ganglios linfáticos se recogen y las células se tiñeron con anticuerpos monoclonales anti–CD11c y anti–B220. Las células están ordenadas por clasificación de células activadas por fluorescencia de alta velocidad y las células dendríticas plasmacitoides el CD11c +/B220 se recogen y se sembraron a 2000 células/pozo en placas de 96 pozos de fondo en V. Los esplenocitos se recogen de los ratones transgénicos BM3 (en el fondo CBA) y se recogieron por enriquecimiento de lana de nylon. Las células BM3 T (105 células/pozo) se adicionan a cada pozo en 200 L de RPMI, 10% de FCS, – mercaptoetanol 50 M. Alternativamente, las células T se obtienen a partir de bazos de ratones transgénicos OT–I y se adicionan al cultivo en combinación con el péptido OVA. Los inhibidores de IDO se adicionan disueltos en RPMI a concentraciones finales que van desde 1 mM a 10 nM. Después de 3 días de estimulación, las células se sometieron a un pulso por 16 h con BrdU o 3H–timidina. Las células se recogieron, se fijaron y se ensayaron para la incorporación de BrdU siguiendo las instrucciones del fabricante del kit de la marcación de BrdU (Roche Diagnostics). Si se utiliza 3H– timidina para medir la proliferación de células T, las células se recogen y el recuento de dpm se mide en un contador de centelleo siguiendo procedimientos ampliamente conocidos en la técnica. Las células CD11c+ de control tomadas desde el nodo linfático contralateral o células CD11c +/ B220– (población de IDO) de la TDLN se utilizan como control positivo de proliferación.
Ejemplo biológico 5 Valor farmacológico
Los valores farmacológicos probados en los compuestos ensayados de acuerdo con uno o más de los ejemplos anteriores en la siguiente tabla, incluyendo,
IC50 de IDO humana: esta es la concentración del compuesto a la que se observa el 50% de la actividad enzimática utilizando IDO humana recombinante en las condiciones de ensayo descritas en uno de los ejemplos;
Se reportan los valores de IC50 en rangos: A: <1 M, B: 1 –10 M, C: 10 –100 M; D: > 100 M.
imagen120
1254
2–(5H–imidazo[5,1–a]isoindol–5–il)etanol B
1256
etil 2–(5H–imidazo[5,1–a]isoindol–5–il)acetato B
1258
ácido 2–(5H–imidazo[5,1–a]isoindol–5– il)acético D
1259
2–(5H–imidazo[5,1–a]isoindol–5–il)–N– metilacetamida D
1273
imagen121 (E)–5–(2–bromostiril)–5H–imidazo[5,1– a]isoindol C
1286
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol A
1287
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanona B
1288
2–(5H–imidazo[5,1–a]isoindol–5–il)etil 2– (((1R,2R,5S)–2–isopropil–5–metilciclohexil) oxi)acetato B
1299
2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol A
1300
tert–butil (4–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)fenil)carbamato B
1301
imagen122 1–(4–aminofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanona C
1302
tert–butil (4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)fenil)carbamato A
1303
1–(4–aminofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol C
1304
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etanol A
1306
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3– nitrofenil)etanona B
1307
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3– nitrofenil)etanol A
1326
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2– nitrofenil)etanona B
1327
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2– nitrofenil)etanol A
1328
tert–butil (2–(2–(5H–imidazo[5,1–a]isoindol–5– il)acetil)fenil)carbamato B
1329
tert–butil (2–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)fenil)carbamato B
1330
1–(2–aminofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanona B
1331
imagen123 1–(2–aminofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol A
1334
1–(2–clorofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanona B
1335
1–(5H–imidazo[5,1–a]isoindol–5–il)–2– metilpropan–2–ol B
1336
1–(2–clorofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol A
1343
1–(3–clorofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol A
1348
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– feniletanona B
1349
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– feniletanol A
1352
1–(2,4–dimetilfuran–3–il)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanol; B
1353
1–(3–clorofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanona B
1356
1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanona B
1357
1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanol A
1358
imagen124 2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (tetrahidro–2H–piran–4–il)etanol A
1359
2–(7–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol A
1360
(Z)–1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etanona oxima B
1362
1–ciclopentil–2–(5H–imidazo[5,1–a]isoindol– 5–il)etanol A
1363
tert–butil 4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidina–1–carboxilato A
1364
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etanamina B
1367
tert–butil (3–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)fenil)carbamato B
1369
imagen125 1–(3–aminofenil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol B
1370
imagen126 2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piperidin–4–il)etanol D
1371
4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–hidroxietil)ciclohexanol; A
1372
1–ciclohexil–2–(9–metoxi–5H–imidazo[5,1– a]isoindol–5–il)etanol C
1373
5–(2–ciclohexil–2–hidroxietil)–5H– imidazo[5,1–a]isoindol–9–ol C
1374
2–(8–cloro–5H–imidazo[5,1–a]isoindol–5–il)– 1–ciclohexiletanol; B
1375
1–(ciclohex–1–en–1–il)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol; B
1376
1–ciclohexil–2–(8–fluoro–5H–imidazo[5,1– a]isoindol–5–il)etanol; B
1378
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(1,4–dioxaspiro[4.5]decan–8–il)etanol; B
1379
4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5– il)–1–hidroxietil)ciclohexanona; A
1381
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–metilenociclohexil)etanol; A
1382
1–(ciclohex–3–en–1–il)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol; A
1383
1–(4–(hidroximatil)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol; A
1384
(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)piperidin–1–il)(tiofen–2–il)metanona; A
1385
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)etanona; B
1386
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– metilenociclohexil)etanol; A
1387
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–metilciclohexil)etanol; A
1388
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etanamina B
1389
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– metil–1H–imidazol–4–il)etanol; D
1390
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol– 4–il)etanol; C
1391
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol– 5–il)etanol; B
1392
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2,2– dimetilpropan–1–ona; B
1393
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(furan–2–il)etanol; B
1394
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(1–metil–1H–imidazol–2–il)etanol; C
1398
imagen127 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–(yodometileno)ciclohexil)etanol; A
1400
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)propan–1–ol; B
1402
2–(5H–imidazo[5,1–a]isoindol–5–il)acetonitrilo; C
1403
1–ciclohexil–3–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)propan–2–ol; A
1404
1–ciclohexil–3–(5H–imidazo[5,1–a]isoindol–5– il)propan–2–ol; A
1405
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– feniletanona; A
1406
1–(4,4–difluorociclohexil)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanol; A
1407
1–(4,4–difluorociclohexil)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol; A
1409
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(1–metil–1H–imidazol–5–il)etanol; C
1410
1–(4–(ciclopropilmetileno)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol; A
1411
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–(propan–2–ilideno)ciclohexil)etanol; A
1412
(E)–5–(2–ciclohexilvinil)–5H–imidazo[5,1– a]isoindol; A
1413
2–(9–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–metilciclohexil)etanol; A
1414
1–(ciclohex–3–en–1–il)–2–(6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)etanol; A
1415
(R)–1–ciclohexil–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etanol B
1416
(S)–1–ciclohexil–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etanol B
1417
(S)–1–ciclohexil–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etanol A
1418
(R)–1–ciclohexil–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etanol A
1419
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– ilideno)etanol B
1420
imagen128 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)acetato de etilo C
1421
1–(4–(2–(benciloxi)etilideno)ciclohexil)–2– (5H–imidazo[5,1–a]isoindol–5–il)etanol A
1422
1–(1–(bencilsulfonil)piperidin–4–il)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol A
1423
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– (pirimidin–5–il)etanona A
1424
2–(3,4–difluorofenil)–1–(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)etanona A
1425
ciclohexil(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)metanona A
1426
metil 4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil) ciclohexanocarboxilato A
1427
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etil fenilcarbamato B
1428
ácido 4–(1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etoxi)–4–oxobutanoico B
1429
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)ciclohexanol A
1430
1–(4–(hidroximatil)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol A
1431
1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5– il)etil benzoato C
1432
imagen129 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)–N–(2– (metilsulfonamido)etil)ciclohexanocarboxamina B
1433
(2S)–1–(–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etoxi)–3–metil–1–oxobutan–2– aminio cloruro C
1434
sodio 1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etil fosfato A
1436
4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)ciclohexanoácido carboxílico B
1437
1–(4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2–(piridin– 4–il)etanona A
1438
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (espiro[2.5]octan–6–il)etanol C
1439
2–(4–fluorofenil)–1–(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)etanona A
1440
(2S)–1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etil 2–aminopropanoato C
1441
1–(4–(2–hidroxietilideno)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol A
1442
(2S)–1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etil pirrolidina–2–carboxilato B
1443
(2S)–5–(1–ciclohexil–2–(5H–imidazo[5,1– a]isoindol–5–il)etil) 1–metil 2– aminopentanodioato C
1447
1–(4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– feniletanona A
1448
imagen130 (3–fluoro–2–hidroxifenil)(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)metanona A
1449
imagen131 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)–N–fenilpiperidina–1–carboxamina A
1450
imagen132 (4–fluorofenil)(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1– il)metanona B
1451
(2S)–2–amino–1–(4–(1–hidroxi–2–(5H– imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)– 3–fenilpropan–1–ona B
1454
(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)piperidin–1–il)((S)–pirrolidin–2– il)metanona D
1455
(1R,4s)–4–(2–((S)–6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)–1–hidroxietil)ciclohexil benzoato A
1456
(1R,4s)–4–(2–((S)–6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)–1–hidroxietil)ciclohexanol A
1458
1–(3–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)azetidin–1–il)–2– feniletanona A
1459
3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol– 5–il)etil)–N–fenilazetidina–1–carboxamina A
1460
tert–butil 3–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)azetidina–1–carboxilato A
1461
1–(azetidin–3–il)–2–(5H–imidazo[5,1– a]isoindol–5–il)etanol C
1469
tert–butil 4–((S)–1–hidroxi–2–((R)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxilato B
1470
tert–butil 4–((R)–1–hidroxi–2–((R)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxilato B
1471
tert–butil 4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxilato A
1472
tert–butil 4–((S)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxilato A
1473
imagen133 1–((1s,4s)–4–(benciloxi)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol A
1474
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–3–il)etanol B
1475
(1r,4r)–4–(2–(6–fluoro–5H–imidazo[5,1– a]isoindol–5–il)–1–hidroxietil)ciclohexanol A
1476
4–((S)–1–hidroxi–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina B
1477
4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina B
1478
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina A
1479
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–fenilpiperidina–1– carboxamina A
1480
1–(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– feniletanona A
1481
1–(4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– feniletanona A
1482
(1R,4s)–4–((S)–2–((R)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol B
1483
(1S,4s)–4–((R)–2–((R)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol B
1484
(1S,4s)–4–((R)–2–((S)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol A
1485
(1R,4s)–4–((S)–2–((S)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol A
1486
(1S,4r)–4–((S)–2–((S)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol A
1487
(1S,4r)–4–((S)–2–((R)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol B
1488
(1R,4r)–4–((R)–2–((S)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol A
1489
imagen134 (1R,4r)–4–((R)–2–((R)–6–fluoro–5H– imidazo[5,1–a]isoindol–5–il)–1– hidroxietil)ciclohexanol B
1490
1–(4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– (tetrahidro–2H–piran–4–il)etanona A
1491
1–(4–((R)–1–hidroxi–2–((R)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– feniletanona B
1492
N–((1s,4s)–4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)ciclohexil)benzamida A
1493
imagen135 1–(4–((S)–1–hidroxi–2–((R)–5H– imidazo[5,11–a]isoindol–5–il)etil)piperidin–1– il)–2–feniletanona B
1494
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1– (fenilcarbamoil)piperidin–4–il)etil fenilcarbamato C
1495
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–((1r,4R)–4– hidroxiciclohexil)piperidina–1–carboxamina A
1496
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–(tetrahidro–2H–piran– 4–il)piperidina–1–carboxamina A
1497
4–((S)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–((1r,4S)–4– hidroxiciclohexil)piperidina–1–carboxamina A
1498
1–((1r,4r)–4–(benciloxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol A
1499
imagen136 1–((1r,4r)–4–(benciloxi)ciclohexil)–2–(6– fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol A
1500
1–(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2– (tetrahidro–2H–piran–4–il)etanona A
1501
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–4–il)etanol A
1502
2–(5H–imidazo[5,1–a]isoindol–5–il)–1– (piridin–2–il)etanol B
1503
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–(tetrahidro–2H–piran– 4–il)piperidina–1–carboxamina A
1504
N–ciclohexil–4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxamina A
1505
N–((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1– a]isoindol–5–il)etil)ciclohexil)benzamida A
1506
1–((1r,4r)–4–(benciloxi)ciclohexil)–2–(5H– imidazo[5,1–a]isoindol–5–il)etanol A
1507
N–ciclopentil–4–((R)–1–hidroxi–2–((S)–5H– imidazo[5,1–a]isoindol–5–il)etil)piperidina–1– carboxamina A
1508
2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)– 1–(4–(trifluorometil)ciclohexil)etanol A
1509
2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4– (trifluorometil)ciclohexil)etanol A
1511
1–(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)–2–(4– (trifluorometil)fenil)etanona A
1512
4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)–N–(4– (trifluorometil)fenil)piperidina–1–carboxamina A
1513
(4–((R)–1–hidroxi–2–((S)–5H–imidazo[5,1– a]isoindol–5–il)etil)piperidin–1–il)(1H– imidazol–1–il)metanona
Ejemplo biológico 6 Ensayo in vivo de los inhibidores de IDO para la actividad antitumoral en combinación con agentes quimioterapéuticos
5 La eficacia antitumoral in vivo se puede probar usando protocolos de aloinjertos tumorales modificadas. Por ejemplo, se ha descrito en la literatura que la inhibición de IDO puede actuar en sinergia con quimioterapia citotóxica en ratones inmunocompetentes. Debido a las diferentes susceptibilidades de diferentes líneas de células tumorales a fármacos quimioterapéuticos y a rechazo inmune mediado, cada inhibidor de IDO se prueba solo y en combinación con 2 fármacos quimioterapéuticos diferentes en 4 modelos en animales de tumores diferentes, representado por 4 líneas de
10 células tumorales de ratón diferentes, de diferente origen tisular (carcinoma colorrectal, de vejiga, de mama y de pulmón), implantado por vía subcutánea en cepas de ratones singénicos. Estas líneas celulares han sido seleccionadas en base a su susceptibilidad conocida a fármacos quimioterapéuticos, su respuesta parcial a los inhibidores de IDO como agentes individuales, su presunto patrón de expresión de IDO de acuerdo a su tejido de origen, y su capacidad para provocar una reacción inmune.
imagen137

Claims (2)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    2–(6–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1–ciclohexiletanona;
    2–(5H–imidazo[5,1–a]isoindol–5–il)etil2–(((1R,2R,5S)–2–isopropil–5–metilciclohexil)oxi)acetato; tert–butil (4–(2–(5H–imidazo[5,1–a]isoindol–5–il)acetil)fenil)carbamato; 1–(4–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona; tert–butil (4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)fenil)carbamato; 1–(4–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3–nitrofenil)etanona; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(3–nitrofenil)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2–nitrofenil)etanona; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(2–nitrofenil)etanol; tert–butil (2–(2–(5H–imidazo[5,1–a]isoindol–5–il)acetil)fenil)carbamato; tert–butil (2–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)fenil)carbamato; 1–(2–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona; 1–(2–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–(2–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona; 1–(5H–imidazo[5,1–a]isoindol–5–il)–2–metilpropan–2–ol; 1–(2–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–(3–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–feniletanona; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–feniletanol; 1–(2,4–dimetilfuran–3–il)–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–(3–clorofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona; 1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanona; 1–ciclohexil–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tetrahidro–2H–piran4–il)etanol; 2–(7–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1–ciclohexiletanol; (Z)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanona oxima; 1–ciclopentil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; tert–butil 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxilato; 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanamina; tert–butil (3–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)fenil)carbamato;
    177
    1–(3–aminofenil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol;
    4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–hidroxietil)ciclohexanol; 1–ciclohexil–2–(9–metoxi–5H–imidazo[5,1–a]isoindol–5–il)etanol; 5–(2–ciclohexil–2–hidroxietil)–5H–imidazo[5,1–a]isoindol–9–ol; 2–(8–cloro–5H–imidazo[5,1–a]isoindol–5–il)–1–ciclohexiletanol; 1–(ciclohex–1–en–1–il)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–ciclohexil–2–(8–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1,4–dioxaspiro[4.5]decan–8–il)etanol; 4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–hidroxietil)ciclohexanona; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4–metilenociclohexil)etanol; 1–(ciclohex–3–en–1–il)–2–(5H–imidazo [5,1–a]isoindol–5–il)etanol; 1–(4–(hidroximatil)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; (4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)(tiofen–2–il)metanona; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)etanona; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–metilenociclohexil)etanol; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4–metilciclohexil)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol–4–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(tiazol–5–il)etanol; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2,2–dimetilpropan–1–ona; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(furan–2–il)etanol; (1S)–1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; (1R)–1–ciclohexi)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(yodometileno)ciclohexil)etanol; 1–ciclohexil–2–(5H–imidazo[5,1–a]isoindol–5–il)propan–1–ol; 2–(5H–imidazo[5,1–a]isoindol–5–il)acetonitrilo; 1–ciclohexil–3–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)propan–2–ol; 1–ciclohexil–3–(5H–imidazo[5,1–a]isoindol–5–il)propan–2–ol; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–feniletanona; 1–(4,4–difluorociclohexil)–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–(4,4–difluorociclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–(1–metil–1H–imidazol–5–il)etanol; 1–(4–(ciclopropilmetileno)ciclohexil)–2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)etanol;
    178
    imagen7
    imagen8
    imagen9
    imagen10
    2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexil)oxi)metil)benzamida;
    metil 4–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato; metil 3–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato; metil 2–((((1r,4r)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexil)oxi)metil)benzoato; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–metoxiciclohexil)etanol; 1–((1 r,4r)–4–etoxiciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–isopropoxiciclohexil)etanol; 1–((1r,4r)–4–(ciclopropilmetoxi)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–((1r,4r)–4–(ciclopentilmetoxi)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–((1r,4r)–4–(tiofen–2–ilmetoxi)ciclohexil)etanol; 1–((1r,4r)–4–((1H–indol–3–il)oxi)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–((1r,4r)–4–((1H–indol–5–il)oxi)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–((tetrahidro–2H–piran–4–il)metoxi)ciclohexil)etanol; 4–(((4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexil)oxi)metil)bencenosulfonamida; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(oxazol–2–ilmetoxi)ciclohexil)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(tiazol–2–ilmetoxi)ciclohoxil)etanol; 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(1–(1–imino–2–feniletil)piperidin–4–il)etanol; 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–fenilpiperidina–1–carboximidamida; 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–(piridin–4–il)piperidina–1–carboximidamida; 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–(tetrahidro–2H–piran–4–il)piperidina–1–carboximidamida; N–(4–cianofenil)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxamina; N–(tert–butil)–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxamina; N–(tert–butil)4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–sulfonamida; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–(3–hidroxifenil)etanona; 2–(1–(azetidina–1–carbonil)piperidin–4–il)–2–hidroxi–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5– il)etil)piperidin–
    1–il)etanona; 2–ciclopentil–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidhe–1–il)etanona; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–(2–metiltiazol–5–il)etanona; N–ciclohexil–N–hidroxi–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxamina; N–(4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–oxoetil)fenil)metanosulfonamida; N–ciclopropil–N–hidroxi–4–(1–hidroxi–2–(3H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxamina; 3,3–difluoro–1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)butan–1–ona; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindot–5–il)etil)pipendin–1–il)–2–(p–tolil)etanona;
    183
    1–(1–(4–aminopirimidin–2–il)piperidin4–il)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; 1–(1–(2–aminopirimidin–4–il)piperidin–4–il)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol; N–ciclopropil–4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidina–1–carboxamina; 2–ciclopropil–1–(4–(1–hidroxi–2–(5H–imidazo [5,1–a]isoindol–5–il)etil)piperidin–1–il)etanona;
    5 2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)ciclohexilideno)acetonitrilo; 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–(4–(trifluorometil)tiazol–2–il)piperidina–1–carboxamina; 4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–oxoetil)benzamida; 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isomdol–5–il)etil)pipendin–1–il)–2–(4–(metilsulfonil)fenil)etanona; 4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)–N–((1r,4r)–4–metilciclohexil)piperidina–1–carboxamina;
    10 1–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–3,3–dimetilbutan–1–ona; 4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–oxoetil)bencenosulfonamida ; N–(tert–butil)–4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–oxoetil)bencenosulfonamida; ácido 4–(2–(4–(1–hidroxi–2–(5H–imidazo[5,1–a]isoindol–5–il)etil)piperidin–1–il)–2–oxoetil)benzoico; 1–(4–(difluorometileno)ciclohexil)–2–(5H–imidazo[5,1–a]isoindol–5–il)etanol;
    15 2–(5H–imidazo[5,1–a]isoindol–5–il)–1–(4–(2,2,2–trifluoroetilideno)ciclohexil)etanol; N–bencil–4–(2–(6–fiuoro–5H–imidazo[5,1–a]isoindol–5–il)–1–hidroxietil)ciclohexanocarboxamina; 4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il–1–hidroxietil)–N–fenilciclohexanocarboxamina; N–(4–(2–(6–fluoro–5H–imidazo[5,1,a]isoindol–5–il)–1–hidroxietil)ciclohexil)benzamida; 1–(4–(2–(6–fluoro–5H–imidazo[5,1–a]isoindol–5–il)–1–hidroxietil)ciclohexil)–3–fenilurea;
    20 N–(4(2–6–fluoro–5H–imidazo[5,1–a]–isoindol–5–il)–1–hidroxietil)ciclohexil)–2–fenilacetamida;
    o una sal farmacéuticamente aceptable del mismo.
  2. 21. Una composición farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 – 19 y un diluyente, excipiente, o portador farmacéuticamente aceptable.
    184
ES12715295.7T 2011-04-15 2012-04-12 Derivados de imidazol condensados útiles como inhibidores de IDO Active ES2569665T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
US201161475788P 2011-04-15
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
ES2569665T3 true ES2569665T3 (es) 2016-05-12

Family

ID=45976556

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15197593.5T Active ES2660831T3 (es) 2011-04-15 2012-04-12 Derivados de imidazol condensados útiles como inhibidores de IDO
ES12715295.7T Active ES2569665T3 (es) 2011-04-15 2012-04-12 Derivados de imidazol condensados útiles como inhibidores de IDO

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15197593.5T Active ES2660831T3 (es) 2011-04-15 2012-04-12 Derivados de imidazol condensados útiles como inhibidores de IDO

Country Status (30)

Country Link
US (5) US9260434B2 (es)
EP (3) EP3018132B1 (es)
JP (4) JP2014511876A (es)
KR (1) KR102164443B1 (es)
CN (2) CN103547579B (es)
AU (4) AU2012242871C1 (es)
BR (1) BR112013026494A2 (es)
CA (1) CA2833296C (es)
CL (1) CL2013002990A1 (es)
CO (1) CO6862146A2 (es)
CY (1) CY1117440T1 (es)
DK (2) DK2697227T3 (es)
ES (2) ES2660831T3 (es)
HK (1) HK1256355A1 (es)
HR (2) HRP20160369T1 (es)
HU (2) HUE038586T2 (es)
IL (3) IL228862A (es)
LT (1) LT3018132T (es)
ME (1) ME02417B (es)
MX (1) MX340442B (es)
NO (1) NO2694640T3 (es)
NZ (2) NZ723271A (es)
PE (2) PE20141124A1 (es)
PL (2) PL3018132T3 (es)
PT (1) PT3018132T (es)
RS (2) RS56992B1 (es)
RU (2) RU2017107026A (es)
SI (2) SI3018132T1 (es)
SM (1) SMT201600130B (es)
WO (1) WO2012142237A1 (es)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (es) 2011-04-15 2018-03-17
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
RU2667509C2 (ru) 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN103382187B (zh) * 2013-08-06 2015-06-03 信实生物医药（上海）有限公司 一种3-氯-7(5)-溴苯并异恶唑的合成方法
DK3466949T3 (da) 2013-12-24 2021-03-15 Bristol Myers Squibb Co Tricyklisk forbindelse som anticancermidler
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6449338B2 (ja) 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
WO2016037026A1 (en) 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
EA037112B1 (ru) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Ингибиторы tgf-
AU2016242978A1 (en) 2015-04-03 2017-11-23 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
CN107531693B (zh) * 2015-04-10 2021-07-06 百济神州有限公司 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
WO2016165613A1 (en) 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
AU2016250976B2 (en) * 2015-04-21 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 成都海创药业有限公司 一种氘代的ido抑制剂及其制备方法和用途
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
CA3132620C (en) 2015-07-24 2024-03-05 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
KR20180034548A (ko) 2015-07-28 2018-04-04 브리스톨-마이어스 스큅 컴퍼니 Tgf 베타 수용체 길항제
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20180250303A1 (en) 2015-08-25 2018-09-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106478634B (zh) * 2015-09-01 2020-05-22 尚华医药科技(江西)有限公司 稠合咪唑化合物、其制备方法、药物组合物和用途
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108026565A (zh) * 2015-11-09 2018-05-11 豪夫迈·罗氏有限公司 用于鉴定ido1和/或tdo调节剂的筛选测定法
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｘｃｒ４受容体アンタゴニスト
US10800780B2 (en) * 2015-12-24 2020-10-13 Genentech, Inc. TDO2 Inhibitors
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
WO2017134555A1 (en) 2016-02-02 2017-08-10 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3418282A4 (en) * 2016-02-19 2019-01-09 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC CONNECTION AS IMMUNOMODULATOR
CN108884104B (zh) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
JP7066186B2 (ja) 2016-02-19 2022-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満の処置のための方法及び医薬組成物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CN105732643A (zh) * 2016-04-18 2016-07-06 苏州大学 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
CN107312005B (zh) * 2016-04-27 2021-12-17 上海翰森生物医药科技有限公司 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004742A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
JP2019522627A (ja) 2016-05-04 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
EP3452452A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN105902542A (zh) * 2016-05-16 2016-08-31 张阳 一种偶联物在制备治疗心血管疾病药物中的应用
CN107556316B (zh) * 2016-06-30 2021-11-12 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN106957318B (zh) * 2016-05-19 2019-12-10 中国科学院上海有机化学研究所 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
CN107488179B (zh) * 2016-06-11 2024-06-07 鲁南制药集团股份有限公司 含桥环的咪唑醇衍生物
CN107556315B (zh) * 2016-06-30 2021-08-31 鲁南制药集团股份有限公司 含四元环的咪唑衍生物
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN107698594A (zh) * 2016-08-09 2018-02-16 苏州国匡医药科技有限公司 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途
EP3503916A1 (en) 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 含咪唑稠合三环类化合物及其应用
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018072743A1 (zh) * 2016-10-21 2018-04-26 苏州盛迪亚生物医药有限公司 Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
EP3535243B1 (en) 2016-11-04 2021-12-15 Auckland Uniservices Limited Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
CN106474468B (zh) * 2016-11-23 2020-03-27 中国医学科学院医学生物学研究所 一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
CN108203438B (zh) * 2016-12-20 2021-09-28 深圳微芯生物科技股份有限公司 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
CN108239091B (zh) * 2016-12-26 2021-08-13 中国医学科学院药物研究所 1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI778050B (zh) 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
CA3057866A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 成都海博锐药业有限公司 一种ido抑制剂化合物、药用组合物、用途
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
EP3645533B1 (en) 2017-06-28 2025-03-26 Genentech, Inc. Tdo2 and ido1 inhibitors
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
TW201910336A (zh) * 2017-08-08 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種咪唑并異吲哚類衍生物的製備方法
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
CN110997682A (zh) 2017-08-17 2020-04-10 爱杜西亚药品有限公司 吲哚胺2,3-二氧酶及/或色氨酸2,3-二氧酶的抑制剂
MX2020001793A (es) 2017-08-17 2020-07-22 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
US11236107B2 (en) 2017-08-18 2022-02-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of tricyclic compound
JP6934562B2 (ja) * 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
ES2935729T3 (es) 2017-09-14 2023-03-09 Lankenau Inst Medical Res Métodos y composiciones para el tratamiento del cáncer
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
KR102747388B1 (ko) 2017-10-16 2024-12-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
US12209079B2 (en) 2017-10-19 2025-01-28 General Incorporated Association Pharma Valley Project Supporting Organization IDO/TDO inhibitor
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
KR102808367B1 (ko) 2017-11-06 2025-05-14 브리스톨-마이어스 스큅 컴퍼니 Hpk1 억제제로서 유용한 이소푸라논 화합물
WO2019101188A1 (en) 2017-11-25 2019-05-31 Beigene, Ltd. Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
KR20250078626A (ko) 2018-01-12 2025-06-02 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20200405696A1 (en) 2018-01-15 2020-12-31 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 脒类和胍类衍生物、其制备方法及其在医药上的应用
JP7229257B2 (ja) 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
KR20200115620A (ko) 2018-01-29 2020-10-07 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR20200128518A (ko) 2018-02-23 2020-11-13 바이사이클티엑스 리미티드 다량체성 비사이클릭 펩타이드 리간드
WO2019173587A1 (en) 2018-03-08 2019-09-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP2021518367A (ja) 2018-03-20 2021-08-02 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Ｉｄｏおよびｔｄｏ調節のための化合物および方法、ならびにそれらのための兆候
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
MX2020010604A (es) 2018-04-12 2020-10-20 Bristol Myers Squibb Co Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
HRP20231253T1 (hr) 2018-06-27 2024-02-02 Bristol-Myers Squibb Company Supstituirani spojevi naftiridina korisni kao aktivatori t stanica
ES2950007T3 (es) 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona útiles como activadores de células T
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
US12551478B2 (en) 2018-09-27 2026-02-17 Shenzhen Chipscreen Biosciences Co., Ltd. Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
EP3941503A1 (en) 2019-03-19 2022-01-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
AU2020253990A1 (en) 2019-04-02 2021-10-28 Bicycletx Limited Bicycle toxin conjugates and uses thereof
JP2022527114A (ja) 2019-04-05 2022-05-30 カイメラ セラピューティクス， インコーポレイテッド 分解剤およびそれらの使用
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
MX2021015995A (es) 2019-06-28 2022-03-11 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
WO2021005222A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CN119874700A (zh) 2019-09-13 2025-04-25 林伯士萨顿公司 Hpk1拮抗剂和其用途
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
AR120481A1 (es) 2019-11-19 2022-02-16 Bristol Myers Squibb Co Compuestos útiles como inhibidores de la proteína helios
CN115151306A (zh) 2019-11-26 2022-10-04 百时美施贵宝公司 (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
PL4065582T3 (pl) 2019-11-26 2025-08-18 Ikena Oncology, Inc. Polimorficzne pochodne karbazolu i ich zastosowania
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN111333653A (zh) * 2019-12-16 2020-06-26 山东大学 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
CN115175907B (zh) 2019-12-23 2024-08-02 百时美施贵宝公司 可用作t细胞激活剂的经取代的哌嗪衍生物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114846015B (zh) 2019-12-23 2024-07-30 百时美施贵宝公司 用作t细胞激活剂的经取代的杂芳基化合物
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
WO2021141907A1 (en) 2020-01-06 2021-07-15 Hifibio (Hong Kong) Limited Anti-tnfr2 antibody and uses thereof
JP7719799B2 (ja) 2020-01-07 2025-08-06 ハイファイバイオ， インコーポレイテッド 抗ガレクチン－９抗体およびその使用
CN115279771B (zh) 2020-01-15 2025-03-21 缆图药品公司 Map4k1抑制剂
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
EP4188374A4 (en) 2020-07-30 2024-08-14 Kymera Therapeutics, Inc. METHODS FOR TREATING LYMPHO MUTANTS
KR20230074119A (ko) 2020-08-03 2023-05-26 바이사이클티엑스 리미티드 펩타이드 기반 링커
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
EP4196792A1 (en) 2020-08-17 2023-06-21 BicycleTX Limited Bicycle conjugates specific for nectin-4 and uses thereof
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN117015531A (zh) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 Tead抑制剂及其用途
CN116964050A (zh) 2020-12-16 2023-10-27 戈萨默生物服务公司 可用作t细胞激活剂的化合物
CA3202360A1 (en) 2020-12-30 2022-07-07 Nello Mainolfi Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
PE20231505A1 (es) 2021-02-12 2023-09-26 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
EP4301358A2 (en) 2021-03-05 2024-01-10 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
KR20230167067A (ko) 2021-04-05 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
SI4320112T1 (sl) 2021-04-06 2025-09-30 Bristol-Myers Squibb Company Oksoizoindolin spojine, substituirane s piridinilom
US12325697B2 (en) 2021-04-09 2025-06-10 Nimbus Clio, Inc. CBL-B modulators and uses thereof
KR20230172548A (ko) 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
KR20240083168A (ko) 2021-07-14 2024-06-11 블루프린트 메디신즈 코포레이션 Map4k1 저해제로서의 헤테로사이클 화합물
WO2023288264A1 (en) 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN118946556A (zh) 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
KR20250056924A (ko) 2022-08-02 2025-04-28 리미널 바이오사이언시스 리미티드 치환된 피리돈 gpr84 길항제 및 이의 용도
EP4565568A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
CN119894873A (zh) 2022-08-02 2025-04-25 里米诺生物科学有限公司 芳基三唑基和相关gpr84拮抗剂及其用途
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
CN119677740A (zh) 2022-08-09 2025-03-21 百时美施贵宝公司 用作t细胞活化剂的叔胺取代的双环化合物
CN119677732A (zh) 2022-08-11 2025-03-21 豪夫迈·罗氏有限公司 双环四氢氮杂䓬衍生物
CR20250043A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados bicíclicos de tetrahidrotiazepina
PE20251399A1 (es) 2022-08-11 2025-05-22 Hoffmann La Roche Derivados de tetrahidrotiazepina biciclicos
JP2025526683A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 广州市联瑞制药有限公司 一种环磷腺苷杂质的制备方法
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
PE20260451A1 (es) 2023-05-08 2026-02-25 Bristol Myers Squibb Company Compuestos de feniloxazolona sustituida
WO2024233900A1 (en) 2023-05-10 2024-11-14 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
KR20260020409A (ko) 2023-05-31 2026-02-11 브리스톨-마이어스 스큅 컴퍼니 Ikzf1-4 단백질의 수준을 감소시키기 위한 치환된 옥사졸론 화합물
KR20260022374A (ko) 2023-06-07 2026-02-19 브리스톨-마이어스 스큅 컴퍼니 스피로시클릭 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
CN120379669A (zh) 2023-06-23 2025-07-25 凯麦拉医疗公司 Irak降解剂及其用途
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
JP7789280B1 (ja) 2023-09-02 2025-12-19 ブリストル－マイヤーズ スクイブ カンパニー 置換フェニルオキソオキサゾリルピペリジンジオン化合物
EP4587429B1 (en) 2023-09-13 2026-02-18 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096539A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126713B1 (de) 1983-05-18 1989-01-18 Ciba-Geigy Ag Cyclohexandion-carbonsäurederivate mit herbizider und das Pflanzenwachstum regulierender Wirkung
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
RS52711B (sr) * 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008115804A1 (en) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
EP2227233B1 (en) * 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP2011518841A (ja) * 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
NO2694640T3 (es) * 2011-04-15 2018-03-17
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
RU2667509C2 (ru) 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
MA38483A1 (fr) 2013-03-15 2018-02-28 Bristol Myers Squibb Co Inhibiteurs de l'ido
WO2014150677A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
WO2015002918A1 (en) 2013-07-01 2015-01-08 Bristol-Myers Squibb Company Ido inhibitors
US9895330B2 (en) 2013-07-11 2018-02-20 Bristol-Myers Squibb Company IDO inhibitors

Also Published As

Publication number Publication date
RU2613579C2 (ru) 2017-03-17
CN105111210A (zh) 2015-12-02
IL228862A (en) 2015-10-29
EP2697227A1 (en) 2014-02-19
LT3018132T (lt) 2018-03-26
AU2012242871A8 (en) 2013-11-21
SI2697227T1 (sl) 2016-06-30
AU2018202706A1 (en) 2018-05-10
IL241846A0 (en) 2015-11-30
IL246515B (en) 2018-08-30
AU2014274564B2 (en) 2016-10-06
JP5837673B2 (ja) 2015-12-24
CA2833296A1 (en) 2012-10-18
RU2017107026A3 (es) 2019-01-23
US9260434B2 (en) 2016-02-16
US10233190B2 (en) 2019-03-19
BR112013026494A2 (pt) 2016-12-27
MX340442B (es) 2016-07-08
ES2660831T3 (es) 2018-03-26
JP2017149769A (ja) 2017-08-31
MX2013012021A (es) 2014-07-10
HK1256355A1 (en) 2019-09-20
HUE027316T2 (en) 2016-10-28
CY1117440T1 (el) 2017-04-26
AU2012242871B2 (en) 2014-09-11
US9850248B2 (en) 2017-12-26
KR20140059167A (ko) 2014-05-15
US20160362412A1 (en) 2016-12-15
AU2012242871A1 (en) 2013-10-31
IL241846A (en) 2016-06-30
RS56992B1 (sr) 2018-05-31
JP2014511876A (ja) 2014-05-19
HK1193822A1 (zh) 2014-10-03
US20190225618A1 (en) 2019-07-25
CA2833296C (en) 2020-12-08
RS54723B1 (sr) 2016-08-31
EP3018132B1 (en) 2017-12-13
KR102164443B1 (ko) 2020-10-12
AU2016277574A1 (en) 2017-01-12
ME02417B (me) 2016-09-20
AU2012242871C1 (en) 2017-02-02
US9388191B2 (en) 2016-07-12
US20140066625A1 (en) 2014-03-06
CO6862146A2 (es) 2014-02-10
JP2016029092A (ja) 2016-03-03
CL2013002990A1 (es) 2014-07-04
PL2697227T3 (pl) 2016-09-30
NZ708090A (en) 2016-12-23
HUE038586T2 (hu) 2018-10-29
HRP20180335T1 (hr) 2018-04-20
NO2694640T3 (es) 2018-03-17
AU2014274564A1 (en) 2015-01-22
WO2012142237A1 (en) 2012-10-18
CN103547579A (zh) 2014-01-29
PE20141124A1 (es) 2014-09-06
DK2697227T3 (en) 2016-04-25
WO2012142237A8 (en) 2012-11-22
CN105111210B (zh) 2018-10-09
EP3018132A1 (en) 2016-05-11
SI3018132T1 (en) 2018-04-30
IL228862A0 (en) 2013-12-31
PE20181023A1 (es) 2018-06-27
EP2697227B1 (en) 2016-02-03
NZ723271A (en) 2018-03-23
RU2017107026A (ru) 2019-01-23
HRP20160369T1 (hr) 2016-06-03
RU2013150811A (ru) 2015-05-20
DK3018132T3 (en) 2018-03-12
US20160002249A1 (en) 2016-01-07
PL3018132T3 (pl) 2018-05-30
JP2015061877A (ja) 2015-04-02
EP3348558A1 (en) 2018-07-18
AU2016277574B2 (en) 2018-04-19
CN103547579B (zh) 2017-02-15
US20180118753A1 (en) 2018-05-03
SMT201600130B (it) 2016-07-01
NZ616457A (en) 2015-05-29
HK1223371A1 (en) 2017-07-28
PT3018132T (pt) 2018-03-09
JP6145491B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
ES2569665T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
ES2963417T3 (es) Derivados de imidazol condensados como moduladores de IL-17
AU2018391675B2 (en) Sulphonyl urea derivatives as NLRP3 inflammasome modulators
JP5612661B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5615352B2 (ja) Ｃ型肝炎ウイルス阻害剤
KR102098122B1 (ko) 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
ES2281565T3 (es) Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
TWI792158B (zh) 嘧啶酪氨酸激酶抑制劑
AU2015327411B2 (en) Boronic acid derivatives
ES2550312T3 (es) Antagonistas ciclohexil-azetidinilo de CCR2
JP2021531257A (ja) Ｉｌ−１７モジュレーターとしてのスピロ環状インダン類似体
AU2015327412B2 (en) Boronic acid derivatives
EA020777B1 (ru) 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
ES2576555T3 (es) Derivados de piperidina como antagonistas de NK1
JP2010527373A (ja) Ｃ型肝炎ウイルス阻害剤
JP2004512323A (ja) Ｃｃｒ５ケモカイン受容体活性のピロリジンモジュレーター
EA035998B1 (ru) Способ получения замещенных производных тиазола
IL301055A (en) Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
JP6333826B2 (ja) アザインドリン
PT96138A (pt) Processo para a preparacao de compostos ciclo-heptimidazolona,uteis como antagonistas de angiotensina ii, para o controlo da hipertensao
CN115210237B (zh) 一种二氢嘧啶类化合物、其制备方法及其应用
TW201713622A (zh) 含氮雜環化合物
JP2023527792A (ja) Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用
JP2025521353A (ja) Ｍａｇｌ用蛍光プローブ
KR20150068464A (ko) 매크로사이클릭 케토아미드 면역프로테아좀 억제제